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Abstract: 
Abstract 
Mutations in actin, the major protein that forms the backbone of the thin 
filaments in all muscles, cause a variety of muscle diseases including 
nemaline myopathy (NIVI), congenital fibre type disproportion (CFTD), 
hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). 
Actin is a multi-functional protein, any of its functions could be altered due to 
the mutation. Two assays were developed, the total internal reflectance 
microscopy (TIRF) polymerisation assay for visualising actin polymerisation 
in real time and the binding competition assay for measuring the relative 
binding affinity of actin for a Z-line protein j-actinin. The in vitro motility assay 
was applied to investigate the motor and regulatory properties of actin. Six 
disease-causing actin mutations: V163M, E205D, D286G, D292V, P332S, 
and K336E with different clinical phenotypes were functionally characterised 
at the molecular level. All the mutant actins were isolated from patients ' 
biopsies except D286G actin, which was extracted from transgenic mouse 
muscle. It has been demonstrated that actin mutations with the same clinical 
phenotype do not cause one common defect but rather affect various 
functions of actin, and there is no apparent correlations between genotype 
and phenotype of actin mutations. 
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1.1 Introduction 
Actin was first identified as part of the protein complex actin-myosin 
responsible for producing the contractile force in skeletal muscle (Straub 
1942). Actin is a highly conserved protein of the contractile apparatus and it 
is one of the most abundant proteins in human tissues. It is present in nearly 
all types of eukaryotic cells. In the human genome there are six actin genes 
which encode for different isoforms with 90% similarity in their sequence. In 
vivo, different isoforms can coexist in the same cell, but are differentially 
regulated, and normally irreplaceable by each other functionally (Kumar et al. 
1997). By far the most well studied actin isoform is f-skeletal muscle actin 
encoded by ACTA1. This isoform is the predominant isoform in skeletal 
muscle cells, and accounts for 20% of total actin in adult hearts, while 
cardiac actin, encoded by ACTC, constitutes 80%. These two sarcomeric 
actins differ by only 4 residues, j - and f-smooth muscle actin are 
coexpressed in both visceral and vascular smooth muscle with variable 
relative expression level in different tissues (McHugh et al. 1988). The 
remaining two isoforms f- and f-cytoplasmic actin are predominantly found in 
non-muscle cells (Vandekerckhove & Weber 1978), Mutations in three of the 
actin isoforms have been reported to be disease-causing. Mutations in the 
ACTA1 gene lead to a variety of muscle diseases including nemaline 
myopathy (NM), intranuclear rod myopathy (IRM), actin myopathy (AM) and 
congenital fibre type disproportion (CFTD); whereas hypertrophic 
cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) can be 
consequent upon mutations in the ACTC gene, and missense mutations in j-
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cytoplasmic actin gene have been associated with autosomal dominant 
deafness (Zhu et al. 2003). Since actin is a multi-functional and highly 
conserved protein whose structure-function relationships are not well 
understood, study of function in actin mutations could provide valuable 
mechanistic insights. 
1.2 Structure 
Actin is a single chain peptide of a relative molecular mass of 41,816.7 with 
375 residues. The sequence of mature actin encoded by the ACTA1 gene is 
shown in Figure 1.1. 
10 20 @EDgTTALVC DNGSj^ VKAC 
70 80 
KSCgrj^KlfP |lEBGl|lplNWD 
130 140 QIMFETFJQP Apji#i|lQAVLl 
190 200 flj^DLTDgLM 
250 260 gLPOgviTI 
310 320 GCTTgYPCIA DgMQKEITAL 
370 
30 40 50 60 
FAGD[DjAEj|AV FPSI^HjPRBl |QCV*(t#lGQK DSyvgDEAQS 
90 100 110 120 DWgKIWBQTF v§iQrvae§e tSPTLLTgAPL I^ PKjAN E^KMgl 
150 160 ISO SLYtASGRTlTC IVlgSCDCVT r-, rnrn [gN^lgECYg LPBAIMR^^ 
210 220 2 30 240 
VTI^EjsglVR DIKEKLCYVA gOFgNEgAlg ASSSSLEKSY 
270 280 290 300 
LUlpsgll^E sgGIBETig SlgKCglDgR KgLY^NNV^ 
330 „ „ 340 350 360 APSTMglKlI ggggYSVW i§gsila1s|ls TgQQM-wgTKQ 
Figure 1.1: Sequence of the ACTA1 gene encoding mature 
actin 
Mature actin has pi of 5.23 and Mw of 41,816.7. Residues which are mutated 
in patients with congenital myopathies are highlighted in blue, while those are 
linked with cardiomyopathies are marked in pink. 
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The actin monomer is a globular protein (G-actin). It is a slow ATPase and 
nearly all actins are modified at His73 by methylation (Hennessey etal. 
1993). The crystal structure of G-actin has been determined using X-ray 
crystallography, most recently by Otterbein et al. (2001). The molecule 
(Figure 1.2) is divided into two domains of roughly equivalent size (inner 
domain 3+4 and outer domain 1+2) by a cleft containing the bound 
nucleotide and cation (Sparrow et al. 2003). 
Subdomain 2 
Subdomain 4 
^/i 
Subdomain 1 
N 
Figure 1.2: Molecular model ofactin monomer 
The four subdomains ofactin are represented in different colours: subdomain 
1 (cyan), 2 (pink), 3 (yellow) and 4 (green). The two termini are also labelled. 
Produced with Chimera software using Actin UdZ.pdb file. 
Those two domains are covalently connected by only two strands of the 
polypeptide chain (the 'hinge ' region 137-150 and 333-338) (Kabsch et al. 
1990), allowing potential intramolecular movement of the two domains. The 
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core of each domain consists of a five-stranded f-slieet at the bottom plus 
additional two subdomains (subdomain 1 and 2) above. 
The fibrous actin (F-actin) (Figure 1.3) is composed of two twisting strands 
of actin monomers with a crossover repeat of the strands about 36nm 
(Egelman 1985). 
(A) (B) 
Figure 1.3: Molecular model of actin filament 
The figure i/i/as produced with Chimera software using Actin_IVIodel.pdb file 
(Holmes et al. 2003) with individual actin monomers differently coloured (A). 
The central part of the structure is magnified in (B). 
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The structure of actin filaments has been characterised by taking the G-actin 
crystal structure and refining it to fit the X-ray fibre diffraction pattern (Holmes 
et al. 2003). The diameter of the filament is 9-1 Onm (Holmes et al. 1990). 
Subdomain 1 and 2 of each strand are on the outside of the filament whilst 
subdomain 3 and 4 associate at the centre of the filament holding the two 
strands together (Rayment et al. 1993). The interactions between molecules 
along and across the filament are extensive. These interactions described by 
Holmes et al. (1990) involve contacts between subdomain 2 and 4 in one 
monomer and subdomain 3 in the next one along the same strand including 
residues 41-45 and 166-169 and 375, 202-204 and 286-289 and 243-245 
and 322-325. The contacts across the filament are made by residues 110-
112 in subdomain 1 of one monomer and 195-197 in subdomain 4 of 
another, and also by a 'plug ' 266-269 pointing into a hydrophobic 
' pocket ' formed by residues 166, 169, 171, 173, 285, 289 and 40-45, 63 
and 64 of two adjacent monomers. Supporting evidence come from an EM-
reconstruction of F-actin by Bremer et al. (1991) showing strong interactions 
between monomers across the filament where the 'plug ' is situated. 
Refinement of the F-actin model against X-ray fibre diffraction data using a 
directed mutation algorithm by Lorenz et al. (1993) additionally revealed 
several regions in actin which potentially form intermolecular bonds between 
actin monomers along the filament including 34-68, 162-176, 197-209, 280-
295 and 318-328. They proposed possible hydrogen bonds between the 
DNase-loop (38-52) in monomer 1 and 162-176 and 280-295 located in 
subdomain 3 of the adjacent monomer 2. 197-209 in subdomain 4 of 
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monomer 1 is also capable of interacting with 280-295 of monomer 2. Figure 
1.4 illustrates the residues that are involved in intermolecular contacts. 
^ 
Figure 1.4: Intermolecular contacts along and across the 
filament 
Residues that are involved in intermolecular contacts are shown as spheres 
and are colour coded for different monomers. Produced with Chimera 
software using Actin_Model.pdb file. 
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1.3 Functions 
1.3.1 M o d i f i c a t i o n s 
1.3.1.1 N-Termtnal Processing 
Actin undergoes several co-translational and post-translational covalent 
modifications. Modification of the N-terminus by removal of one or two 
residues is the most universal one. Actins in mammalian cardiac, skeletal 
muscle and Drosophila are encoded by genes initially with Met-X-Asp, where 
X is usually Cys, but sometimes is Gly or Ala (Pollard & Cooper 1986). By 
investigating the synthesis of Drosophila actin in Schneider L-2 cells, a 
cultured Drosophila embryonic cell line, and in a mRNA-dependent rabbit 
reticulocyte lysate primed with Drosophila mRNA, Rubenstein & Martin 
(1983) demonstrated that the actin is first translated as a nascent polypeptide 
containing Met-Cys-Asp. The initiator residue Met is presumably cleaved 
either early on or soon after translation yielding an actin precursor which 
terminates in NH2-Cys-Asp. It is then quickly acetylated followed by a post-
translational removal of Ac-Cys, and finally acetylation of the new exposed 
N-terminal Asp generating the mature actin sequence. Actin is not active until 
it reaches its cellular destination. The work by Sutoh (1982) indicated that 
one of the major interactions site between actin and myosin is within the first 
three residues at actin N-terminus. Failure to remove the two extra amino 
acids Met-X might therefore seriously disrupt the binding between these two 
proteins. Furthermore, inhibition of N-terminal processing in vitro can alter 
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actin polymerisation (Hennessey et al. 1991). However, complete blocking of 
the N-terminal processing does not affect the stability of actins expressed in 
yeast (Cook ef a/. 1991). 
1.3.1.2 Post-Translational Methylation at His73 
As mentioned earlier, almost all actins are methylated at His73 (Hennessey 
et al. 1993), The residue sits in the cleft between subdomain 2 and 4 (Figure 
1.5), and forms a salt bridge across the cleft that stabilises the structure (Yao 
etal. 1999). 
His73 
Figure 1.5: Location of His73 in actin monomer 
Produced with Chimera software using Actin USZ.pdb file. 
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Yao et al. (1999) studied the effect of His73 on actin function by mutating this 
residue to Lys, Arg, Ala, Gin and Glu in S.cerevisiae actin. Substitution at 
His73 produces a gradient of effects on actin structure and function 
depending upon the acidity of the amino acids introduced. Basic residues Lys 
and Arg resulted in an actin monomer with a greater resistance to 
proteolysis, a slower rate of nucleotide exchange, a tighter and more 
compact structure and increased stability, whilst Glu mutation leads to 
extensive retardation in polymerisation, greatly increased susceptibility to 
proteolysis, accelerated nucleotide exchange rate, a looser and more flexible 
monomeric structure and significantly reduced stability, whereas neutral 
residues Ala and Gin caused a middle extent of effects. Despite the fact that 
His73 is on the exterior of the protein, it appears to play an important role in 
stability and conformational flexibility of the actin monomer, but it is still not 
clear about the functions of the methyl group. 
1.3.1.3 Other Modifications 
In addition, monomeric mammalian actin has been reported to undergo 
post-translational phosphorylation in vivo (Steinberg 1980), which has been 
implicated in a number of actin functions. Eichinger et al. (1996) 
demonstrated that extensive actin phosphorylation on tyrosine residue in 
Dictyostelium discoideum occurred under chemical stress. Similar results 
was also published by Furuhashi et al. (1998) that Physarum actin was 
phosphorylated on Thr203 in response to stress and the phosphorylated 
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actin did not polymerise. ADP-ribosylation on Arg177 is another possible 
post-translational modification (Wegner & Aktories 1988). Consequently one 
of actin 's binding sites for other filament subunits was demolished by this 
toxic process and thereby filament elongation was prevented. The functional 
significance of such ribosylation is not yet known. 
1.3.2 Post-Translational Folding 
Proper folding is the initial requirement for functions of actin. The folding of 
actin is facilitated by chaperone proteins, which assist folding and prevent 
aggregation of proteins in the cell. The eukaryotic cytosol contains several 
chaperones including cytosolic chaperonin containing TCP-1 (CCT) and 
prefoldin (Gao etal. 1992; Vainberg etal. 1998). Prior to interactions with 
CCT, the nascent actin is captured during translation by prefoldin (also called 
GimC) (Hansen et al. 1999). Recently Neirynck et al. (2006) identified two 
major binding sites in human f-actin for prefoldin (Figure 1.6), between 
residues 60-89 (site I), 170-183 and 194-199 (site II). Both sites are required 
for efficient and stable formation of the actin-prefoldin complex, but site I 
seems to be more important for prefoldin recognition. After completion of the 
synthesis, actin-prefoldin complex forms a transient ternary complex with 
CCT, thereby transferring the non-native actin to CCT. At that stage, the 
domains of actin are separated and the C-terminus is unstructured (Vainberg 
et al. 1998). Actin associates with CCT at discreet sites (Figure 1,6), 30-34, 
135-139, 170-174, 240-254, 265-274 and 340-349 in an ATP-dependent 
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manner. 245-254 acts as an initial contact for CCT. The interaction between 
30-34 and CCT, sequential binding of ATP to CCT and hydrolysis of ATP 
trigger the subsequent folding, rearrangement of the domains, and finally the 
release of the folded actin molecule (Neirynck et al. 2006). 
Figure 1.6: Discreet binding sites of prefoidin and CCT on 
actin 
Prefoidin binds to actin on two discreet sites: 60-89 (site I, purple), 170-183 
and 194-199 (site II, brown); whereas residues 30-34, 135-139, 170-174, 
240-254, 265-274 and 340-349 (yellow) are involved in actin binding to CCT. 
Produced with Chimera software using Actin 1J6Z.pdb file. 
Costa et al. (2004) investigated two ACTA1 mutations that had impaired 
folding; L94P and E259V. L94P and E259V are both recessive missense 
mutations and cause severe nemaline myopathy. It was predicted that when 
mixing with wild-type actin in heterozygotes, these two non-functional mutant 
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actins were benign (Sparrow et al 2003), indicating that the folding machinery 
is fully functional with one copy of folding-defective actin. 
1.3.3 Polymer isat ion 
The functional form of actin in cells appears to be the filaments (F-actin). 
Actin monomers form polymers by the process of polymerisation. It involves 
two steps; slow formation of nuclei, followed by rapid elongation of actin 
filaments (Figure 1.7). For actin, elongation is highly favoured over 
nucleation, so that before many more nuclei form, the few nuclei formed in 
the early stage of polymerisation process quickly elongate. Measurements of 
initial polymerisation rate against G-actin concentration show a dependence 
of rate to the 4^ ^ power of G-actin concentration, implying that the rate-
determining nucleation step involves the formation of an actin tetramer 
(Tobacman & Korn 1983). 
Nucleation 
A , ^ 
Adin 
Elongation 
Barted Pointed 
Figure 1.7: Two-step mechanism of actin polymerisation 
Adapted from www.cooperlab.wustl.edu/Reviews/ReviewARCB Ms.html 
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The turnover of actin filaments in cells is rapid. The assembly and 
disassembly of actin filaments is a steady-state system, and the chemical 
switch required is the hydrolysis of ATP. One ATP molecule is hydrolysed 
during each assembly and disassembly cycle of an actin monomer. The 
interaction of G-actin with nucleotide is complicated by the association of a 
cation (normally is Mg2+) at the high-affinity site. ATP is hydrolysed within 
the polymer to yield an ADP-actin filament with the release of Pi. The rate 
constant for hydrolysis has been measured at about 0.02 s'"" (Pollard & 
Weeds 1984). The immediate product of hydrolysis is a monomer carrying 
ADP.Pi in the filament. It has been found that the rate of hydrolysis is slower 
than the rate of actin assembly (Korn et al. 1987). The actin filament is thus 
predominantly actin-ADP. 
The different rates of monomer exchange at the pointed and barbed end of 
a single actin filament result in a difference between the critical 
concentrations at the two opposite ends of the same filament. The critical 
concentration is the concentration at which polymerisation and 
depolymerisation rates are equal and is the equivalent of the dissociation 
constant in a conventional bi-molecular reaction. The rate is about 20-fold 
faster at the barbed end than at the pointed end (Pollard 1986). The critical 
concentration at the barbed end is about 0.12^iM and that at the pointed end 
is around 0.6^M under physiological conditions (Pollard 1986). Both ends of 
the same filament must share the same monomer pool and attain equilibrium 
at different concentrations of monomer, thus there is net loss of monomers at 
the pointed end and net gain at the barbed end. In a process called head-to-
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tail polymerisation or treadmilling, ATP-actin monomer binds to the barbed 
end, and the ATP is hydrolysed to ADP.Pi bound to the actin, followed by 
release of the phosphate to form ADP-actin, which is freed at the pointed end 
(Nakajima et al. 1997). Its rate-determining step is the release of ADP-actin 
at the pointed end (Pollard 1986). ATP hydrolysis is not tightly coupled to 
monomer addition, therefore the balance between the amounts of ATP, 
ADP.Pi and ADP bound to actin depends on the rate at which the actin 
polymerises and the rate of ATP hydrolysis (Carlier 1989). 
Asakura et at. (1963) studied the temperature-dependency of rabbit skeletal 
muscle actin polymerisation, and found that polymerisation was enhanced at 
increasing temperature. The spontaneous polymerisation of actin is 
endothermic and driven by a large positive entropy change. While under 
physiological conditions, actin polymerisation is accompanied by irreversible 
ATP hydrolysis, a similar temperature-dependency has also been found for 
polymerisation of actin bound to ADP or non-polymerisable ATP analogs 
(Janmey et at. 2001). In vivo, formins nucleate formation of actin filaments 
and remain processively attached to the barbed end of the filament as actin 
monomers are added at the barbed end. This prevents binding of capping 
proteins at the barbed end that would inhibit filament growth (Vavylonis et al. 
2006). 
The nucleation and growth of actin filaments can be studied at the single 
filament level if the actin filaments are visualised by fluorescent microscopy. 
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The polymerisation process could be observed in real time by using total 
internal reflectance microscopy (TIRF) (Amann & Pollard 2001). 
By using TIRF (provided by Prof. Mike Ferenczi and Dr. Dmitry Ushakov, 
Biophysical Science, Imperial College London), we were able to visualise the 
polymerisation process of single actin filaments labelled by TRITC-phalloidin, 
which inhibits the depolymerisation of actin, therefore only net elongation rate 
was measured. A range of concentrations of actin was tested, our results 
showed that the elongation rate increased linearly with G-actin concentration. 
1.3.4 Interactions with the Z-Line Protein f -Actinin 
During muscle contraction, the interactions between actin and myosin 
generate tension, which is then transmitted by the Z-line along the myofibril 
to the end of the muscle. The Z-line delineates the extent of the sarcomeres. 
In vertebrate striated muscles, the Z-line is composed of predominantly actin 
filaments, f-actinin and titin. Recent 3-D reconstruction studies reveal that 
the actin filaments from two adjacent sarcomeres enter each side of the Z-
line and overlap by about 22-25nm across the Z-line (Luther 2000). An 
electron micrograph of the Z-line is shown in Figure 1.8. f-actinin is the 
major F-actin cross-linking protein and belongs to the spectrin family which 
consists of two consecutive calponin homology (CH) domains. The two CH 
domains are interlinked, and CHI accounts for most of the F-actin binding 
affinity. 
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Figure 1.8: Electron micrograph of the Z-line in plaice fin 
muscle 
The electron-dense Z-line is in the middle with actin filaments attached at 
both ends. Adapted from (Luther 2000). 
t-actinin is a rod-shaped anti-parallel homodimer, each monomer has an N-
terminal actin-binding region thus it can cross-link two actin filaments. Data 
from several groups (Lebart et al. 1993; Liu etal. 2004; McGough et al. 
1994) shows that it binds to two adjacent actin monomers at residues 112-
125 and 360-372 of actin molecule, both sites are located on the same side 
of subdomain 1 (Figure 1.9). The crystal structure of actin binding domains 
(ABD) of several members of the spectrin family including f-actinin has been 
determined. All the ABD structures in the actin-free state display a similar 
compact conformation with extensive interactions between the two CH 
domains (Franzot et al. 2005). 
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Figure 1.9: Location of two (f>-actinin binding sites on actin 
Ribbon representation of actin monomer showing the location of two <p-
actinin binding sites (pink) within residue 112-125 and 360-372 on 
subdomain 1. Produced with Chimera software using Actin UdZ.pdb file. 
1.3.5 Interactions with Nebulin 
Another important protein of the thin filament is nebulin, a filamentous 
protein extending along the entire length of the thin filament. It contains about 
185 t-helical 35-residue repeats, each of which has a potential actin binding 
motif (Wang et al. 1996). EM reconstructions of F-actin decorated wih a 
nebulin C-terminal fragment indicates three separate nebulin binding sites on 
each actin subunit (Figure 1.10), raising the possibility that nebulin 
undergoes positional movements between different locations on the F-actin 
helix (Lukoyanova et al. 2002). Nebulin acts as a molecular ruler of the thin 
filament determining filament length in contact with capping proteins 
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tropomodulin at the pointed end and CapZ at the barbed end (Witt et al. 
2006). 
Figure 1.10: Location of nebulin binding sites on actin 
Nebulin binds to actin possibly at three separates sites: residue 96-101, 125-
130, 359-366 (purple), 226-236 (brown) and 2-6, 348-356 (yellow). Produced 
with Chimera software using Actin 1J6Z.pdb file. 
1.3.6 Contractility 
1.3.6.1 Structure of the Contractile Apparatus 
The basic contractile apparatus of all striated muscles consists of 
sarcomeres (Figure 1.11), each containing an interdigitating lattice of thick 
filaments (myosin-containing) in the middle and thin filaments at both ends of 
the sarcomere, which slide past each other during contraction and relaxation. 
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(B) 
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Figure 1.11: Structure of the sarcomere 
(A) Thin section electron micrograph! displaying the structure of the 
sarcomere, adapted from http-J/www. sarcomere, org 
(B) Schematic representation of the arrangement of the thick and thin 
filaments in relation to the striated pattern shown in (A). 
The thick filaments are predominantly made up of the protein myosin, which 
is composed of two heavy chains and two pairs of light chains. The myosin 
heavy chains dimerises with a long tail and two globular heads. The myosin 
tails are packed side-to-side to form the centre of the thick filament whilst 
heads protrude from the filament and are close to the actin filaments. Myosin 
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filaments are bipolar; myosin heads in the two halves of the thick filament 
have opposite polarities. The myosin heads are the motor proteins of muscle; 
they hydrolyse ATP to ADP. The free energy of hydrolysis drives mechnical 
work in the muscle through interaction with actin in the thin filaments. 
The thin filaments arise from Z-lines and extend from both ends towards the 
centre of the sarcomere. Thin filaments are made of F-actin, a polarised 
filamentous polymer of identical actin molecules, interacting with regulatory 
proteins including tropomyosin (Tm) and the troponin (Tn) complex (made up 
of troponins C, I and T). Tropomyosin forms two continuous strands along F-
actin and cooperatively propagates regulatory signals along the actin 
filaments. One troponin complex which is positioned at intervals along the 
actin filaments binds to each tropomyosin molecule. The relative position of 
each component in the thick and the thin filaments is schematically 
presented in Figure 1.12. 
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Figure 1.12: Schematic diagram of thick and thin filament 
The structure of myosin is also illustrated at the bottom. Taken from 
httpy/www.embl-
heidelberQ.de/CellBioDhvs/LocalProbes/motorproteins/mvosin.html 
1.3.6.2 Contractile Mechanism (the Cross-Bridge Cycle) 
Sarcomere shortening is caused by the interaction between myosin and 
actin (the cross-bridge cycle), which form the major motor protein complexes 
in all eukaryotic cells. A complete cross-bridge cycle is illustrated in detail in 
Figure 1.13. 
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Figure 1.13: Schematic representation of the myosin cross-
bridge cycle 
Kindly provided by Weiss & Geeves (www.kent.ac. uk/bio/Qeeves/Research) 
Myosin heads either under load (Figure 1.13b) or in a resting state (Figure 
1.13c), bind to ATP. Such binding induces a conformational change in the 
myosin head, which dissociates the myosin head from actin almost 
irreversibly (Figure 1.13d). ATP is then hydrolysed to ADP and Pi, both of 
which remain very tightly bound to the myosin head (Figure 1.13e) and the 
free energy of hydrolysis is retained within the myosin molecule. Hydrolysis is 
a rapid and reversible process taking about 10msec, and is accompanied by 
a major conformational change that represents the reversal of the power 
stroke. If an actin is close enough to the myosin head, it will attach to the 
actin quickly and reversibly (Figure 1.13a). The association of myosin.ADP.Pi 
complex with actin releases the stored energy via another conformational 
change (the power stroke), which moves the actin filament by up to lOnm 
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relative to the thick filament with detachment of Pi. A cross-bridge cycle is 
completed while a new cycle begins. Different actin-myosin confirmations in 
pre- and post-power stroke state are shown in Figure 1.14. 
(A) Pre-power stroke state (B) Post-power stroke state 
F-actin 
a Actin binding domain upper 50K 
domain % 
^ - Converter domain 
Essential light chain 
Regulatory light chain 
Myosin SI 
Figure 1.14: A conformational change of actin-myosin 
complex during the power stroke 
Reconstructions from the crystallographic data on the Dictyostelium myosin 
motor domain truncated at residue 759 (A) complexed with ADP. vanadate in 
the 'pre-power strol<e' state (B) complexed with ADP.BeFs in the 'post-power 
stroke' state. The end of the lever arm moves up to 10nm between the two 
states. Adapted from (Geeves & Holmes 1999). 
The summation of many cross-bridge cycles results in the sliding of the thin 
filament over the thick filament and sarcomere shortening. The cross-bridge 
cycle generates force when the muscle is under load; thermal efficiency is up 
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to 40% in intact muscle. Maximum force is produced under isometric 
conditions whilst maximum shortening speed is observed in unloaded 
muscle. The isometric force produced by a muscle depends on the 
sarcomere length. In the optimal condition, thick and thin filaments overlap at 
2.0-2.25^m, so that all the myosin cross-bridges can interact with actin. 
Each myosin head interacts with two actin monomers at binding sites that 
span two actin subdomains. Based on the crystal structure of myosin 
subfragment 1 (S1), three potential myosin-binding sites on actin has been 
revealed by Payment etai. (1993) as shown in Figure 1.15. 
Figure 1.15: Location of myosin binding sites on actin 
Myosin binds to actin on three sites: 1-4, 24-25, 99-100 (purple), 144, 341, 
345, 349, 352 (brown), and 332, 333 (yellow). Produced with Chimera 
software using Actin 1J6Z.pdb file. 
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The first site involves the N-terminus and the acidic residues 1-4, 24-25 and 
99-100 which interact with a lysine-rich loop on myosin. The results of actin 
mutation studies indicate that N-terminal acidic group is essential for the 
ATP-dependent actin-myosin interaction and the development of movement. 
The second site contains hydrophobic residues 144, 341, 345, 349 and 352 
on the surface of actin; while the third site includes 332 and 333 in the 
' hinge ' region of the actin molecule. It is proposed that the initial 'weak 
binding ' complex involves the acidic N-terminal residues, whilst the 'strong 
binding ' complex involves all the contacts. 
1.3.7 Regu la t i on 
2+ 1.3.7.1 Regulation by Tropomyosin, Troponin and Ca 
The thin filament is fully regulated by via interactions of tropomyosin 
and troponin with actin thin filaments. The functional unit of the thin filament 
consists of seven actin monomers, one molecule of tropomyosin and one 
troponin. Muscle contraction is initiated by an increase in sarcoplamic Ca^^ 
concentration which binds to the troponin complex of the thin filament. 
Troponin has three subunits; troponin C is the binding protein; troponin 
is the inhibitory subunit and troponin T, which binds to troponin C, troponin I 
and also to tropomyosin, independently of the Ca '^" concentration, thereby 
anchoring the regulatory complex on the thin filament. At the high Ca^^ 
concentration the C-terminus of troponin I is bound to the N-terminus of 
troponin C. Ca "^" and does not interact with other proteins (Figure 1.16A). 
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This shifts tropomyosin to its activated state, so that myosin attachment and 
force generation could proceed. In contrast, in relaxed muscle with the low 
Ca^^ concentration the C-terminus of troponin I is released from troponin C 
and binds to actin (Figure 1.16B), which blocks the binding of myosin, thus 
preventing the cross-bridge cycling. The inhibitory effect troponin I binding to 
actin is propagated along the actin filament by a concerted cooperative 
conformational change that involves all thin filament proteins. Consequently 
tropomyosin moves to a position that prevents myosin binding to all actins, 
thus switching off contraction. 
(A) High state 
(A) Low state 
Figure 1.16: -regulation of the ttiln filament 
The thin filament undergoes a conformational change in response to 
Ca^^binding. (A) In the high Ca^^state (contracting), troponin I (magenta) is 
bound to troponin C (blue), which shifts tropomyosin (green) to its activated 
state allowing myosin to attach to actin (orange). (B) In the low Ca^'^state 
(relaxing), the C-terminus of troponin I Is bound to actin moving tropomyosin 
(red) to a position that blocks the access of myosin heads. Adapted from (Xu 
et al. 1999), based on the model of Lorenz et al (1993). 
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The thin filament shows cooperativity in its interaction with myosin. This is 
seen both in F-actin + tropomyosin and F-actin + tropomyosin + troponin, but 
not in actin alone. It now has been observed that there are distinct structural 
changes induced by Ca "^" binding to thin filaments. 
(A) High State (B) Low State 
Figure 1.17: Position of tropomyosin relative to actin in 
different Ca^^states 
Relative position of actin (cyan), tropomyosin (yellow) and troponin (pink) in 
the (A) high Ca^^ state and (B) low state. Produced with MacPyMOL 
software using files: Actin_Model.pdb, TmJowCa.pdb, and Tn_Mg.pdb for 
(A); Actin_Model.pdb, Tm_Ca.pdb, and Tn_Ca.pdb for(B), (Pirani etai. 
2006/ 
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Those changes are consistent with X-ray diffraction modelling; In the low 
(Ca^^ -free) state (Figure 1.17B), tropomyosin is close to the myosin 
binding site in a cleft between subdomain 1 and 3 of actin monomers; whilst 
in the high Ca "^" (Ca^'^-activated) state (Figure 1.17A), this mass is shifted 
across the surface of subdomain 3 by around 1 to 2nm (Al-Khayat et a/. 
1995). The position of tropomyosin with Ca "^" bound to troponin is still close 
enough to myosin S1 binding site to modify the SI-actin interaction. 
1.3.7.2 Regulation by Structural Changes on Actin Itself 
The structure of the double helical F-actin filament is stabilised by many 
interactions between actin monomers in the single filaments and between 
monomers in different filaments of the duplex. Egelman (2001) found that the 
structural changes of actin monomers could be cooperatively propagated 
along the filament to the neighbouring monomers, if that is the case, changes 
will occur in the distribution of residues on its surface. Some of these 
residues would be involved in tropomyosin binding and the filament will have 
to adjust its position along its whole length on the surface for energetic 
purposes. Such large cooperative effects within the actin filament potentially 
enable actin filaments to convey information over large distances in the cell. 
It has been proposed by Perry (2003) that the transmission of the structural 
changes along the actin duplex is probably induced by troponin I molecules 
as they are located opposite each other on the adjacent actin filaments of the 
duplex. Tropomyosin would stabilise the filament structure and thus facilitate 
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the transmission of those structural changes along the actin filament. This 
process has been experimentally demonstrated for the homologous actin 
inhibitory protein, caldesmon (Ansari et al. 2003). 
1.4 Muscle Disease Caused by Actin Mutations 
Mutations in the actin gene have been associated with various myopathies, 
including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy 
(DCM), caused by mutations in ACTC, whereas mutations in ACTA1 gene 
can give rise in nemaline myopathy (NM), intranuclear rod myopathy (IRM), 
actin myopathy (AM) and congenital fibre type disproportion (CFTD), 
1.4.1 Card iac Myopa t i i i e s 
1.4.1.1 Hypertrophic Cardiomyopathy 
Hypertrophic cardiomyopathy (HCM) is an autosomal dominantly inherited 
disease of cardiac muscle defined by a non-dilated left ventricle hypertrophy. 
It is a common cardiac disorder affecting 1:500 of the population and is the 
leading cause of sudden cardiac death in the young. Genetic studies have 
shown that HCM is a disease of the sarcomere with mutations being found in 
nearly all the sarcomeric proteins. Around 50% of the HCM-causing 
mutations are in the f-myosin heavy chain (f-MyHC) encoding gene (Richard 
57 
Introduction 
et al. 2003). A few ACTC mutations have been identified to result in HCM; 
E99K, P164A, Y166C. A230V, A295S, M305L and A331P (Mogensen et al. 
2004), The location of these mutations is illustrated in Figure 1.18. 
A230 
A295 
Figure 1.18: Location of HCIVI-causing actin mutations 
Mutated residues are marked as brown spheres. Produced with Chimera 
software using Actin UdZ.pdb file. 
On-going structure-functional investigations on E99K and Y166C by Emma 
Dyer in our laboratory Implied altered muscle thin filament motility and 
contractility. E99K actin purified from transgenic mouse hearts had a lower 
sliding speed than non-transgenic (NTG) actin. Thin filaments reconstituted 
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with E99K actin had a sliding speed not significantly different from NTG 
whilst Ca^^'-sensitivity was 2-fold greater in common with other HCM thin 
filament mutations. 
1.4.1.2 Dilated Cardiomyopathy 
Dilated cardiomyopathy (DCM) is characterised by dilatation and impaired 
contraction of the left or both ventricles (Richardson 1996). 56% of familial 
DCM is autosomal dominant, while autosomal recessive and X-linked 
inheritance have also been described. Mutations in t-MyHC, myosin binding 
protein C (MyBPC), troponin T (TnT), troponin I (Tnl), troponin C (TnC), 
actin, f-tropomyoisn, desmin, tin in and vinculin have all been linked to the 
DCM phenotype (Kamisago etal. 2000). Many of these proteins are the 
same as those involved in the pathogenesis of HCM. Mutations in the gene 
encoding t-MyHC and MyBPC account for the most familial DCM cases. So 
far only two actin muations have been associated with DCM, R312H in 
subdomain 3 and E361G in subdomaini (Figure 1.19) of the actin molecule 
(Olson et at. 1998). No functional studies have been carried out on R312H 
mutations yet, but mutation-induced structural changes may affect actin-
actin, actin-Tm or actin-myosin interactions. A project on effects of E361G 
using transgenic mouse hearts has been carried out by Emma Dyer in our 
laboratory. The main difference between thin filaments containing mutant and 
NTG actin was that the Ca^^-sensitivity of E361G actin thin filaments was not 
responsive to the level of Tnl phosphorylation. 
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R312 
E361 
Figure 1.19: Location of DCM-causing actin mutations 
R312H and E361G are marked as brown spheres. Produced with Chinnera 
software using Actin USZ.pdb file. 
1.4.2 Skeletal Myopathies 
1.4.2.1 Nemaline Myopathy 
Nemaline myopathy (NM) is a slowly- or non-progressive neuromuscular 
disorder characterised by muscle weakness and the presence of rod-like 
structure ( 'nemaline rod ' or 'nemaline body ') in affected muscle fibres 
(Sanoudou & Beggs 2001). Other non-specific pathological features 
frequently found in NM include fibre size variation, fibre type disproportion 
and type 1 (slow-twitch) fibre predominance. In more rare cases, degrading 
and regenerating fibres, internal nuclei and increased connective tissue may 
also be observed (Ryan etai. 2003). It was first described in 1963 almost 
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simultaneously by two groups (Conen et al. 1963) and (Shy etal. 1963). 
Although a relatively rare disease, NM is the most common of several 
congenital myopathies and is heterogeneous genetically as well as 
phenotypically. Many cases are sporadic, but some exhibit autosomal 
recessive or dominant inheritance pattern. 
1.4.2.1.1 Clinical Phenotype 
Due to a wide range of clinical representations, NM has been divided into 
seven different categories based on the severity of the disease, age of onset 
and additional features (Sanoudou & Beggs 2001): typical, severe, 
intermediate, mild, adult onset, amish NM and other forms of NM. 
1.4.2.1.2 Pathophysiology 
The presence of nemaline rods (or nemaline bodies) in muscle fibres is the 
hallmark in the diagnosis of NM. These Z-line originating structures can be 
seen using Gomori trichrome staining under a light microscope (Figure 
1.20A) or electron microscopy (Figure 1.206). The rods vary from 1 to 7<m in 
length and from 0.3 to 2<m in width. Type 1 fibre is often predominant in NM 
muscle biopsies, and may be the only fibre type. Nemaline rods can have 
even distribution in all fibre types, or preferentially in either type 1 or type 2 
fibres. In many cases, those fibres containing rods are hypotrophic. The 
sarcomeric structure is greatly disrupted and disorganised in the most 
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affected fibres, which may explain the correlated muscle weakness in some 
degree. The rods might be found in from less than 1% to nearly all fibres 
(Sanoudou & Beggs 2001). The population of fibres containing rods does not 
correspond to the severity of the disorder. The majority of the rods are 
formed around nuclei, but intranuclear rods are rarely present. Although rods 
are the defining feature of NM or IRM, they have also been observed in other 
neuromuscular disorders and normal muscles. 
(A) (B) 
mmm 
Figure 1.20: Light and electron microscopy of muscle 
biopsies from NM patients 
(A) Gomori trichrome treatment results in deep-purple staining ofnemaline 
bodies (arrow). Adapted from (llkovski et al 2001). (B) Electron micrograph 
illustrating an area of relatively normal muscle structure with normal Z lines 
(small arrows, bottom right) next to a structurally disrupted region with 
multiple nemaline rods (large arrows) and disorganized thin filaments (top 
left) in a patient with nemaline myopathy. Adapted from (Sanoudou & Beggs 
200?;. 
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The mechanism of nemaline rods formation is still unknown. Adjacent actin 
filaments of opposite polarity cross-linked by j-actinin dimers revealed in a 3-
dimensional reconstruction of rods imply possible involvement of an inability 
to terminate or cap the thin filament ends at Z-lines in rod formation as 
shown in Figure 1.21 (Morris et al. 1990). 
(A) 
h i * 41 M • 
(B) Figure 1.21: Longitudinal 
view of the nemaline Z-line 
(A) Micrograph of a longitudinal 
section seeing actin filaments 
running through of the enlarged Z-
line and emerging from one or the 
other end. (B) Fourier-filtered image 
of (A). Dark areas represent 
protein. The a and c axes of the 3D 
unit cell are marked. Adjacent 
filaments running vertically have 
opposite orientations and are linked 
together with increased intensity. 
Adapted from (Morris et al. 1990). 
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Nemaline rods may form as accumulations of damaged protein when mutant 
actin in incapable of incorporating properly into the sarcomere. 
1.4.2.1.3 NM Mutations 
NM is a disorder of sarcomeric thin filaments, mutations that have been 
described causing NM are located in five genes encoding different skeletal 
muscle thin filament proteins. 50% of mutations were found in the nebulin 
gene, all are autosomal recessive and 20% of patients have actin mutations. 
Mutations in t- , ^-tropomyosin and troponin T are also identified, probably 
accounting for 5-10% of cases (Clarkson et at. 2004). 
ACTA1 was screened as a candidate gene for NM by Nowak et al. (1999). 
In total, they identified 15 mutations in 14 families, 11 of which were NM 
affected. All but one of the mutations were autosomal dominantly inherited. 
Since then, 127 mutations in ACTA1 have been linked with NM on 89 out of 
375 amino acids in the ACTA1 sequence, most are heterozygous missense 
and exhibit autosomal dominant inheritance pattern. NM-associated ACTA1 
mutations span all six coding exons and spread all over the 3D structure of 
actin (Figure 1.22A). Interestingly, four f-sheets in subdomain 1 seem to be 
spared from NM mutations (Figure 1.22B). Despite 99% identical sequence, 
overlap between the residues mutated in skeletal myopathies and in 
cardiomyopathies has only been rarely discovered. 
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When Sparrow et al. (2003) explored the effects of functional null alleles of 
the ACTA1 gene, however, a severe NM phenotyoe was found to be 
generated by a recessive ACTA1 mutation R39X, due to a nonsence 
mutation of codon 39 producing a premature translation termination signal. 
(A) (B) 
Figure 1.22: NM ACTA1 mutations do not cluster on 3D 
structure of actin molecule 
(A) NM actin mutations spread all over the 3D structure of actin molecule 
with mutated residues marked as brown spheres. (B) Four ^-sheets (indigo) 
in subdomain 1 are spared from NM mutations (brown). Produced with 
Chimera software using Actin 1J6Z.pdb file. 
The recessive nature of R39X suggested that firstly, one copy of wild-type 
ACTA1 gene is sufficient enough for normal actin function; and secondly, the 
dominance of the vast majority of ACTA 1 mutations is a result of dominant 
negative effects rather than absence of all actin functions. In other words, the 
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activity of wild-type actin produced by the non-mutant gene copy is 
sabotaged by the mutant-containing toxic peptide. Investigation of another 
recessive ACTA1 mutation A144delG, a frame shift mutation caused by a 
base deletion in codon 144, supported this proposal. Further evidence came 
from ACTA1 knockout mice. Heterozygotes were generally normal, but the 
homozygous null mice died by 9 days (Crawford et al. 2002). Dominant 
negative actin mutations have also been described in Drosophila (Sparrow et 
al. 1992) and yeast (Wertman et al. 1992). This important property of ACTA1 
mutations is similar to that of NM-causing mutations in other thin filament 
protein genes: slow f-tropomyosin (TPM3) (Laing et al. 1995) and slow 
troponin (TNNT1) (Johnston et al. 2000). 
In order to predict molecular consequences of different ACTA 1 mutations, 
Sparrow et al. (2003) mapped 60 mutations onto the actin 3D structure. With 
no obvious clustering or tendency to sit on the surface of actin molecule, 
where actin binding proteins (ABP) bind, it is difficult to draw the functional 
patterns of the mutations. Nevertheless, they grouped the mutated residues 
by their likely impact. Residue change on the nucleotide binding site will 
interfere with nucleotide exchange. Some mutations lying within the 'hinge ' 
of actin monomer possibly affect the flexibility of the 'hinge '. Mutations on 
residues that are important in actin-actin interactions are thought to disrupt 
polymerisation hence to destablise F-actin structure. There is also a group of 
mutated residues sitting close or at actin surface, which presumably 
compromise interactions between actin and ABP. 
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Only a small number of NM actin mutations have been functionally 
characterised at the molecular level. Costa etai (2004) 's study provided the 
first experimental evidence of molecular defects in actin caused by ACTA1 
mutations that result in human muscle disease, mostly in NM. They 
examined 19 ACTA1 with 16 NM mutations in biochemical and in vitro cell 
assays, those mutations have various phenotypes and were categorised 
according to the degree of severity in defects. L94P and E259V caused the 
most severe phenotype as the two mutant actins did not fold properiy, thus 
were non-functional. The second category including G15, N115S, V163L and 
G182D resulted in unstable folding. I64N, 1136M, R183G, Q263L, G268C, 
G268R, N280K, I357L and V370F actin showed impaired polymerisation; 
while the remaining mutants H40Y, M132V, R183C and D286G behaved 
very similariy to wild-type actin. 
Ilkovski et al. (2004) expressed mutant actins in C2C12 myoblasts, which 
gave rise in significant alterations in the ability of mutant actins to polymerise 
and formation of actin accumulations. Another NM actin mutation M132V 
actin from a patient with NM was studied by Marston et al. (2004) using in 
vitro motility assays. The mutant actin extracted from a patient biopsy had 
partial polymerisibility with KCI/MgCIa, a higher sliding speed than wild-type 
actin in reconstituted thin filaments at the high Ca "^" concentration, and an 
increased relative force of the interaction between actin and myosin. So far 
no link between functional changes and the disease phenotype is apparent. 
In order to try to establish a link I characterised two NM mutations: D286G 
expressed in transgenic mice and K336E with a HCM complication in patient 
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biopsy samples. Results are elaborated in this thesis Chapter 3 and 5.1 
respectively. 
1.4.2.2 Intranuclear Rod Myopathy (IRM) 
The presence of intranuclear rods in NM was first reported by Jenis et al. in 
1969. A combination of intranuclear and sarcoplasmic rods were seen at 
autopsy. The term ' IRM ' was then introduced to describe the entity that is 
pathologically marked by the presence of rod-shaped inclusions within the 
nuclei of muscle cells (Goebel & Warlo 1997) (Figure 1.23). 
(A) (B) 
Figure 1.23: Light and electron microscopy of muscle 
biopsies from IRM patients 
(A) Gomori trichrome staining showing large rods in almost all the muscle 
fibre nuclei (arrowhead). (B) Electron micrograph revealing an intranuclear 
rod (white arrowhead), and smaller surrounding cytoplasmic rods (black 
arrowhead). Adapted from (Hutchinson et al. 2006). 
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IRM is however generally considered as a variant of NM in terms of clinical, 
pathological and genetic features. To date, 11 mutations have been linked 
with IRM and all of them are in the ACTA1 gene; H40Y, G55R, Q137H, 
A138P, T148S, D154N, H161D, V163L, V163M, K336L and I357L. Again, 
they do not cluster (Figure 1.24) and were predicted to affect nucleotide 
binding and 'h inge' flexibility by Sparrow ef a/. (2003). 
D154 
V163 
G55 
K336 
A138 
Figure 1.24: Location of IRI\^ actin mutations 
Mutated residues H40, D154, 1-1161, VI63 and 1357 are marked as brown 
sptieres. Q137, A138, T148 (yellow sphere) are part of the 'hinge' region 
(yellow). K336 (purple sphere) sits within the 'hinge' region also at the 
nucleotide binding site (purple). Produced with Chimera software using Actin 
1J6Z.pdb file. 
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Costa et al. (2004) demonstrated folding instability of V163L actin, altered 
polymerisation of I357L actio and comparable molecular phenotype of H40Y 
mutant to wild-type actin. Transfection studies in C2C12 myoblasts indicated 
abnormal polymerisation of V163L actin (ilkovski et al. 2004). In vitro motility 
experiments on V163M actin from a patient biopsy is discussed in detail in 
Chapter 5.2. 
1.4.2.3 Actin Myopathy (AM) 
The term 'actin myopathy ' was originally applied by Goebel et al. (1997) for 
a clinical phenotype distinguished by actin-containing filamentous inclusions 
(as illustrated in Figure 1.25) in areas where myofibrillar filament lattice would 
normally be located (Costa et al. 2004). 
y 
J 
Figure 1.25: Electron microscopy of a muscle biopsy from an 
AM patient 
The muscle fiber on the right is almost completely filled with bundles of actin 
filaments between some aggregates of glycogen granules and some other 
organelles; whereas the fiber on the left contains myofibrils showing only 
minor irregularities in their structure. Adpated from (Schroder et al. 2004). 
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All the AM ACTA1 mutations: G15R, T66i, G146D, G146S, R147K, D154N, 
V163L, S348L and a duplication of A144/S145 sit in subdomain 1 and 3 
(Figure 1.26), close to the nucleotide binding site and the 'h inge' region, 
these mutations hence may potentially change nucleotide binding and 
' hinge ' flexibility (Sparrow et al. 2003). 
D154 
V163 
I 
A144 
R147 G146 
S145 
Figure 1.26: Location of AM actin mutations 
Mutated residues T66, D154, V163 and S348 are marked as brown spheres. 
G15 (purple sphere) is part of the nucleotide binding sequence (purple). 
G146 and R147 (yellow sphere) are in the 'hinge' region (yellow). Produced 
with Chimera software using Actin USZ.pdb file. 
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1.4.2.4 Congenital Fibre Type Disproportion 
Congenital fibre type disproportion (CFTD) is the most newly discovered 
and a rare form of congenital myopathy in which the main pathological 
abnormality is hypotrophy of the type 1 (slow-twitch) muscle fibres compared 
to type 2 (fast-twitch) muscle fibres (Figure 1.27). However, this feature is 
non-specific with occurrence in many other neuromuscular conditions, 
especially in NM, it might as well be a variant of NM. 
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Figure 1.27: Electron microscopy of a muscle biopsy from a 
CFTD patient 
The muscle biopsy was stained with ATPase (plH 4.3). Type 1 fibers are 
black, type 2A and 2B fibers are pale, type 20 fibers are intermediate. 
Adapted from (Laing et al. 2004). 
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Three de novo missense mutations in the ACTA1 gene; L221P, D292V and 
P332S have been reported by Laing et al. (2004), E205D has been recently 
identified in a patient with CFTD by Professor Caroline Sewry, Hammersmith 
Hospital, London, and another unreported ACTA1 mutation G46D. Except for 
E205D, all mutations are situated on the surface of the actin monomer 
exposed in the filamentous polymer (Figure 1.28B), 
D292 
Figure 1.28: Location of CFTD mutations in actin molecule 
(A) Location of the mutations in actin monomer. (B) Except E205, all the 
residues mutated (G46-black, L221-grey, D292-orange, P332-navy) in CFTD 
patients are exposed in the actin polymer Interestingly, G46 is in contact 
with residue 0292 of the adjacent actin monomer Produced with Chimera 
software using Actin UdZ.pdb file for (A) and Actin_Model.pdb file for (B). 
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I utilised several in vitro techniques to explore the molecular properties of 
three of the mutations (E205D, D292V & P332S). There is no common 
pattern among them (see Chapter 4) (Clarke et al. 2007). 
TPM3 (encoding slow |-tropomyosin) mutation is the most frequent cause 
of CFTD, the identified six mutations in TPM3 accounted for 25% of patients 
in reported CFTD cases. In addition to the ACTA1 and the TPM3 gene, 
SEPN1 mutation has also been associated with CFTD (Clarke et al. 
submitted for publication). 
1.5 Actin Expression Systems 
Most of the functional studies on actin mutations have been done using 
purified actin from transgenic mice and patients ' biopsies. Two systems 
have been demonstrated to have the potential to express actin. Yeast has 
been used to express an increasing number of mutant actins by several 
groups (Bryan et al. 2006; Korman et al. 2000; Korman & Tobacman 1999; 
McKane et al. 2005; Miller ef a/. 1996; Wong et al. 2001), but despite 87% 
identical amino acid sequence in yeast and muscle actin, yeast can not 
survive with mammalian muscle actin as the sole actin in cell. Actin can also 
be expressed in Drosophila indirect flight muscle (encoded by the ACT88F 
gene), which in theory should be perfect for actin expression since a 
transgene can be inserted into an actin-null mutant, but has not produced a 
satisfactory outcome yet. Nevertheless, the effect of natural mutations, for 
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instance E93K, in Drosophila have been investigated at the molecular level 
(Bing et al. 1998; Cammarato et al. 2005; Razzaq et al. 1999). Actin 
extracted from baculovirus pellets has also been successfully used for 
mutant actin expression (Akkari et al. 2003; Joel et al. 2004), but functional 
studies are limited. 
1.6 Conclusion 
Mutations in actin cause various phenotypes. HCM and DCM can be 
caused by mutations in the gene encoding f-cardiac actin, ACTC; whilst 
mutations in t-skeletal muscle actin gene, ACTA1 resulted in a range of 
congenital myopathies. NM is the most common one. There is no apparent 
correlation between the clinical cause and muscle pathology of disease-
causing ACTA1 mutations. ACTA1 mutations responsible for each myopathy 
do not cluster on the 3D structure of actin molecule. An increasing number of 
functional studies have been carried out on these mutations, and although 
there is a certain degree of agreement with the predictions of their likely 
effects based on the location of mutated residues, significant differences are 
exhibited in some cases. Mutations with the same clinical phenotype affect 
not one common, but rather variable actin properties, and mutations 
generating distinct clinical phenotypes may behave similarly at the molecular 
level. Different actin mutations can give rise in a single myopathy, the same 
mutations may however be associated with more than one myopathy 
(Marston & Hodgkinson 2001). 
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The aim of my project is by using established as well as newly developed 
techniques to test the hypothesis of structure-function correlations of ACTA 1 
mutations that are related to various congenital myopathies, thereby 
providing valuable insights into the relationship between genotype and 
phenotype of actin mutations, which will subsequently lead to better 
understanding of the cause and devising potential treatments for actin 
muscle diseases. For this work I shall use muscle biopsies and transgenic 
mouse model as my source of mutant actin. Study of the effect of actin 
mutations on contractility is currently very limited; it is hoped that study of a 
range of mutations will allow us to better link genotype and phenotype. At the 
same time, the tissue samples with known disease-causing mutations are an 
experiment of nature, which we can exploit to gain knowledge of how the 
actin molecule works In a way that has not been possible by the traditional 
method of site-directed mutagenesis. 
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2. Materials and Methods 
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2.1 Collection of Skeletal Muscle Samples 
2.1.1 Collection of Skeletal Muscle Biopsies from 
Myopathy Patients 
We were supplied with muscle biopsies which were taken for diagnostic 
purposes under local anaesthesia from the quadriceps, frozen in liquid 
nitrogen and stored at -80°C. Biopsies were taken either using a needle 
technique or by an open surgical method (10-100mg). For comparison, age-
matched normal control muscle biopsies were also collected from different 
individuals. The functional studies performed used approximately 3mg piece 
of muscle, which was mounted with Tissue-Tek O.C.T.™ Compound 
(polyvinyl alcolhol <11%, carbowax <5% and nonreactive ingredients >85%, 
Sakura Kinetek) and then cut into 20x30^m cryosections for each 
preparation using a cryostat (CM 1850, Leica) at -25°C. Sections were stored 
and shipped at -80°C. The biopsy samples I studied are summarised in Table 
2.1. 
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K336E biopsy 
Enrico 
Bertini, 
Rome 
3 vials of 
20x30|a,m 
cryosections 
nemaline 
myopathy, 
hypertrophic 
cardiomyopathy 
D ' Amico et 
al. 2006 
D292V biopsy 
Nigel 
Clarke, 
Sydney 
12 vials of 
20x30p,m 
cryosections 
congenital 
fibre type 
disproportion 
Laing et al. 
2004 
P332S biopsy 
Nigel 
Clarke, 
Sydney 
6 vials of 
20x30nm 
cryosections 
congenital 
fibre type 
disproportion 
Laing et al. 
2004 
V163M biopsy 
Nigel 
Clarke, 
Sydney 
6 vials of 
20x30|im 
cryosections 
intranuclear rod 
myopathy 
Laing et al. 
2004 
E205D biopsy 
Caroline 
Sewry, 
London 
2 vials of 
20x30fxm 
cryosections 
congenital 
fibre type 
disproportion 
unpublished 
D286G transgenic 
mouse 
Kristen 
Nowak, 
Perth 
4 vials of 
600-800mg 
severe nemaline 
myopathy 
Agrawal et 
al. 2004 
Table 2.1: Summary of biopsy and transgenic mouse 
samples I studied 
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2.1.2 Collection of Skeletal Muscle from Transgenic 
Mouse Tissue 
The transgenic mouse leg muscle tissue which had been used in our study 
was provided by Dr. Kristen Nowak, University of Western Australia (see 
Table 2.1). The mice were housed in Dept. Anatomy, Oxford University. 
Excised leg muscle was stored in liquid nitrogen. 
Transgenic mouse hearts used in the actin polymerisation assay were 
provided by Prof. Dominic Wells, Charing Cross Hospital, London, and were 
stored in liquid nitrogen. 
2.2 Skeletal Muscle Protein Preparation from 
Rabbit 
Rabbit fast skeletal back muscle was used as a source of skeletal muscle. 
The muscle was excised immediately after sacrifice and kept on ice. Actin 
and myosin were then extracted from this muscle for use in in vitro studies. 
2.2.1 Myosin Preparation 
Skeletal muscle myosin was prepared using the method of Margossian and 
Lowry (Margossian & Lowey 1982) by O Neal Copeland in Prof. Steve 
Marston 's laboratory. The purified myosin was stored by dropping a 
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concentrated solution (20-40mg/ml) directly into liquid nitrogen in 50(il 
aliquots. 
2.2.2 Skeletal Muscle HMM Preparation 
Rabbit skeletal muscle HMM was used as the immobilised motor in the in 
vitro motility assay. HMM was prepared by a method based on that of 
Okamoto & Sekine (1985). An aliquot of rabbit skeletal myosin of 
approximately 120^1 was thawed from liquid nitrogen on ice and diluted 10-
fold with HMM buffer A (0.1 mM NaHCOs, 0.1 mM EGTA, 1mM DTT, pH7.4), 
pre-chilled on ice. After the homogenate was incubated on ice for 20 
minutes, the myosin was pelleted by centrifugation at 25,000xg (16,400rpm, 
eppendorf centrifuge 5417R, F-45-24-11 rotor) for 10 minutes at 4°C. The 
myosin was resuspended in 2 x HMM buffer B (20mM Imidazole-HCI, 1M 
KCl, 4mM MgCl2, 2mM DTT, pH7.0) and HMM buffer A to give a final 
concentration of 15mg/ml in HMM buffer B. The myosin was incubated for 10 
minutes on ice, then for a further 10 minutes at 25°C in a water bath, f -
chymotrypsin was added at 15<g/ml to digest the myosin, which was then 
incubated for exactly 8 minutes at 25°C. The digestion was stopped by 
diluting the mixture 10-fold with ice cold HMM buffer A containing 3mM MgCl2 
and 0.1 mM PMSF. After being incubated on ice for 1 hour, the mixture was 
centrifuged at 446,800xg (100,000rpm, Sorvall RC M120SE, S100-AT6 rotor) 
for 15 minutes at 4°C to remove any undigested myosin. The supernatant 
containing pure HMM at 0.3-0.7mg/ml was suitable for use in the motility 
assay for 3-4 days, 
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2.2.3 Skeletal Muscle F-actin Preparation 
Skeletal F-actin was prepared following Spudich 's method (Spudich & 
Watt 1971) with an additional step of a Sephacryl S300 gel filtration column 
for the purification of G-actin (Alahyan eta!. 2006). The preparation of 
skeletal F-actin was carried out by O 'Neai Copeland in Prof. Steve 
Marston 's laboratory. Normally 2ml 5-20mg/ml F-actin was obtained. This F-
actin was made for affinity precipitation of HMM (2.8.1) and used within 3 
weeks of preparation. 
2.2.4 Skeletal Tropomyosin and Troponin Preparation 
The method of Potter (Potter 1982) was applied to make skeletal ethanol-
ether powder which could then be used to extract skeletal tropomyosin and 
troponin. 
Skeletal muscle tropomyosin was prepared by the original method of Bailey 
(Bailey 1948; Eisenberg & Kielley 1974) with final purification using a hydroxy 
apatite column (HA Ultragel). 
Skeletal muscle troponin was prepared from the ethanol-ether powder by 
the method of Potter (Potter 1982) without the column chromatography. 
SDS-PAGE of the preparation is shown in Figure 2.1. All the above 
preparations were done by Dr. Mahmooda Mirza in Prof. Steve Marston 's 
laboratory. 
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•TroDonin T 
.Troponin I 
-Troponin C 
Figure 2.1: SDS-PAGE of extracted rabbit skeletai troponin 
Although this troponin contained impurities which were likely myosin light 
chains, it was demonstrated to function properly in in vitro motility assay at 
low concentrations. 
2.3 Actin Preparation from Patients' Biopsies 
and Transgenic IVIouse Tissue 
Very small quantities of tissue were available for actin preparation. Pure F-
actin was isolated from muscle biopsies and transgenic mouse tissue based 
on the technique of Razzaq et al. (1999) as adapted by Marston etal. (2004). 
Pairs of mutant and control muscle were treated simultaneously. Various 
fractions of samples were taken at different stages throughout the isolation 
process for SDS-PAGE (2.5) and Western blotting (2.6) to investigate 
properties of mutant actins. These stages and the amount of sample taken 
are highlighted in green. 
83 
Materials and Methods 
2.3.1 Isolation of F-actin from Muscle Biopsies 
Approximately 3mg muscle biopsy sample (normally 20x30(im 
cryosections) was homogenised in 0.5ml of 20mM KPO4 50% (v/v) glycerol, 
0.5% (v/v) Triton X-100, 2mM MgCb, 1mM dithiothreitol (DTT), ImM NaNs, 
pH7.0 in a 1.5ml eppendorf vial with an eppendorf micropestle <1> (10p,l 
taken). Samples were spun at 25,000xg (16,400rpm, eppendorf centrifuge 
5417R, F-45-24-11 rotor) for 2 minutes at 4°C, the supernantant was saved 
<2> and the pellet was extracted in 500^1 of high salt buffer (20mM KPO4, 
800mM KCI, pH7.0) at 25,000xg for 2 minutes at 4°C to remove myosin. The 
pellet was then washed twice with deionized water (1ml and then 0.5ml) to 
remove salt and dehydrated using 1ml 50% followed by 1ml 100% ice-cold 
acetone and dried under vacuum for 20 minutes. Actin was extracted from 
the acetone powder with two consecutive 40^1 aliquots of AC EX (2mM Tris-
HCI, 0.2mM CaClz, 0.2mM ATP, ImM DTT, pH8.0) for 45 minutes, with 5 
minutes sonication at the start of each extraction and 3 minutes spin at 
25,000xg (16,400rpm, eppendorf centrifuge 5417R, F-45-24-11 rotor) for 3 
minutes at 4°C at the end of each extraction (the pellet was saved <3> and 
1 }il supernatant of the second spin was taken <4>). The extract was 
centrifugated at 446,800xg (100,000rpm, Sorvall RCM120SE, S100-AT6 
rotor) for 20 minutes at 4°C. The supernatant containing monomeric actin 
(1^1 taken <6> and the pellet was saved <5>) half was polymerised with lOx 
polymerising buffer (250mM imidazole, 250mM KCI, 40ml\/l MgCb, 1mM 
CaClz, 10mM NagATP, lOmM DTT, pH7.4) alone for 90 minutes at room 
temperature. In the case of deficient polymerisation in mutant actins, 150nM 
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TRITC-phalloidin was added directly to the other half of the monomeric actin 
together with 10x polymerising buffer to induce full polymerisation to occur. 
After polymerisation, 3M KCl stock was added to the actin to a concentration 
of 1M, then the actin was spun at446,800xg (100,000rpm, Sorvall 
RCM120SE, S100-AT6 rotor) for 20 minutes at 4°C (supernatant saved 
<7&8>). The F-actin containing pellet was resuspended in 25^1 ACEX on 
blood wheel overnight at 4°C taken <9&10>). The actin concentration 
was 0.018-0.074mg/ml determined by Western blotting (2.6). The yield of 
actin was 0.15-0.6ng per Img of tissue. The F-actin was labelled with TRITC-
phalloidin (2.8.2), and then could be used in in vitro motility assay within a 
week (Figure 2.2). 
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1 2 3 4 5 6 7 8 9 10 11 12 
1 whole homogenate 
2 supernatant from first wash 
3 acetone powder extract pellet 
4 acetone powder extract supernatant (crude G-actin) 
5 sedimentation of crude G-actin pellet 
6 sedimentation of crude G-actin supernatant (G-actin) 
7 sedimentation of actin polymerised with KCl/MgCb, supernatant 
8 sedimentation of actin polymerised with KCI/MgCb/phalloidin, 
supernatant 
9 sedimentation of actin polymerised with KCl/MgCb, pellet (F-actin) 
10 sedimentation of actin polymerised with KCI/MgCb/phalloidin, pellet 
(F-actin) 
11 standard actin 0.02[xg 
12 standard actin O.OSfxg 
Figure 2.2: Isolation of K336E actin from a biopsy sample 
investigated by Western blotting 
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2.3.2 Isolation of F-actin from Transgenic Mouse 
Tissue (D286G) 
A different technique was used for mouse leg muscle tissue where greater 
quantities of muscle (up to 2g) was available. 
Approximately 150mg of transgenic mouse tissue was pulverized and then 
homogenised in 1.5ml of a wash buffer containing 1% Triton X-100, 50mM 
KCI, 5mM Tris-HCI pH 8.0 and 5mM DTT with 2<g/ml each of the protease 
inhibitors E-64, chymostatin, leupeptin and pepstatin A in a 2ml eppendorf 
vial with a homogeniser (Heidolph D1AX900, 6G with slate diameter of 
0.5mm) (50(xl taken). Samples were spun at 16,662xg (13,400rpm, 
eppendorf centrifuge 5417R, F-45-24-11 rotor) for 3 minutes at 4°C. This 
myofibril wash step was repeated 3 times (the supernantant of the first spin 
was saved) and the pellet was extracted in 500^1 of high salt buffer (20mM 
KPO4, 800mM KCI, pH7.0) and sedimented at 25,000xg for 2 minutes at 4°C 
to remove myosin. The pellet was then washed twice with 1.5ml deionized 
water to remove salt, dehydrated using 1.5ml 50% followed by 1.5ml 100% 
ice-cold acetone and dried under vacuum for 20 minutes. Actin was extracted 
from the acetone powder with two consecutive 1.5ml aliquots of ACEX (2mM 
Tris-HCI, 0.2mM CaClg, 0.2mM ATP, ImM DTT, pHB.O) for 25 minutes and 
then 10 minutes, with 5 minutes sonication at the start of each extraction and 
3 minutes spin at 25,000xg (16,400rpm, eppendorf centrifuge 5417R, F-45-
24-11 rotor) at 4°C at the end of each extraction (50^1 supernatant of the 
second spin was taken and the pellet was saved). The extract was 
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centrifugated at446,800xg (100,000rpm, Sorvall RCM120SE, S100-AT6 
rotor) for 20 minutes at 4°C. The supernatant containing monomeric actin 
(SOpil taken and the pellet was saved) half was polymerised with 10x 
polymerising buffer (250mM Imidazole, 250mM KCI, 40mM MgCIa, 1mM 
CaCIa, 10mM Na2ATP, 10mM DTT, pH7.4) alone for 90 minutes at room 
temperature. In the case of deficient polymerisation in mutant actins, 150nM 
TRITC-phalloidin was added directly to the other half of the monomeric actin 
together with 10x polymerising buffer to induce full polymerisation to occur. 
After polymerisation, SM KCI stock was added to the actin to a concentration 
of 1M, then the actin was spun at 446,800xg (100,000rpm, Sorvall 
RCM120SE, S100-AT6 rotor) for 20 minutes at4°C (supernatant saved). The 
F-actin containing pellet was resuspended in 200^1 ACEX overnight at 4°C 
(lOpJ taken). The actin concentration was 0.3-1 mg/ml determined by Lowry 
assay (2.4.1) and the yield of actin was 0.4-1.5|a,g per 1 mg of tissue. The F-
actin was labelled with TRITC-phalloidin (2.8,2), and then could be used in in 
vitro motility assay within a week (Figure 2.3). 
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whole muscle 1st wash s/n peMet after ACEX extract 
homogenate ACEX extract 
high speed s/n high speed 
+ phalioidin pellet + 
phalloidin 
m — 
homogenise 
tissue 
wash In 
low salt 
buffer 
make acetone 
powder, extract G-
actin with ACEX 
EGFP-
actin 
actin 
polymerise with 
KCI/MgCb and 
sediment actin 
Figure 2.3: Isolation of EGFP'D286G (Kermit) actin from 
transgenic mouse tissue 
SDS-PAGE stained with Coomassie Blue and Western blot probed with anti-actin 
5C5. 
2.3.3 Isolation of F-actin from Transgenic Mouse 
Hearts (E361G) 
The E361G actin was unstable and aggregated after acetone powder 
treatment, therefore it was isolated from a native thin filament preparation 
(Tobacman & Sawyer 1990). 
50-1 OOmg of transgenic mouse heart tissue was pulverized and then 
homogenised in lOx volume of a wash buffer containing 20mM Pi, 0.1 M 
NaCI, SmM MgCl2, 0.5 mM EGTA pH 7.0 and 5mM DTT with 2<g/ml each of 
the protease inhibitors E-64, chymostatin, leupeptin and pepstatin A in a 2ml 
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eppendorf vial with a homogeniser (Heidolph DIAX900, 6G with slate 
diameter of 0.5mm) <1> (10^J taken). Samples were spun at 16,662xg 
(13,400rpm, eppendorf centrifuge 5417R, F-45-24-11 rotor) for 3 minutes at 
4°C. This extraction step was repeated 4 times <2> (the supernantant of the 
first spin was saved) and the pellet was extracted twice in 1.5 volume of thin 
filament extraction buffer (5mM ATP/100ml wash buffer) at 16,662xg for 3 
minutes at 4°C. The two supernatant were combined (3 ,^1 was taken and the 
pellet was saved) and centrifugated at 111,700xg (50,000rpm, Sorvall 
RCM120SE, S100-AT6 rotor) for 5 minutes at 4°C. The supernatant was 
further spun at 446,800xg (100,000rpm, Sorvall RCM120SE, S100-AT6 
rotor) for 20 minutes at 4°C (supernatant was saved). The pellet containing 
thin filaments was dialysed in 1.5 volume of a buffer containing 20mM Pi, 
0.1M NaCI, 5mM MgCIa, and 1 mM ATP, pHG.O for 3 hours at 4°C, After 2 
minutes spin at 16,662xg (13,000rpm, eppendorf centrifuge 5417R, F-45-24-
11 rotor) at 4°C to remove remaining myosin, 3M KCI stock was added to the 
supernatant (3fxl was saved) to a concentration of 0.8M to dissociate actin 
from troponin-tropomyosin. In the case of deficient polymerisation in mutant 
actins, 150nM TRlTC-phalloidin was added directly to the actin together with 
KCI to induce full polymerisation to occur. Then the actin was spun at 
446,800xg (100,000rpm, Sorvall RCM120SE, S100-AT6 rotor) for 20 minutes 
at 4°C <3&4> (supernatant saved). The F-actin containing pellet was 
resuspended in 100^1 ACEX overnight at 4°C <5&6> (3|xl taken). The actin 
concentration was around 0.5mg/ml determined by Western blotting (2.6) 
and the yield of actin was approximately 1pig per 1mg of tissue. The F-actin 
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was labelled with TRITC-phalloidin (2.8.2), and then could be used in in vitro 
motility assay within a week (Figure 2.4). 
1 whole homogenate 
2 supernatant from first wash 
3 sedimentation of actin with KCI, supernatant 
4 sedimentation of actin with KCI/phalloidin, supernatant 
5 sedimentation of actin with KCI, pellet (F-actin) 
6 sedimentation of actin with KCI/phalloidin, pellet (F-actin) 
Figure 2.4: Isolation of E361G actin from transgenic mouse 
hearts investigated by Western blotting 
2.3.4 G-actin Preparation for Polymerisation Assays 
2.3.4.1 Depoiymerisation of Rabbit F-Actin 
Rabbit F-actin (2.2.3) was diluted to give 200^1 at 4mg/ml before being 
dialysed in depolymerising buffer (0.5mM ATP, 0.2mM CaCl2, 1mM DTT, 
10mM Trizma, pH8) for 48 hours at 4°C to depolymerise actin. Then the actin 
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was centrifugated at446,800xg (lOO.OOOrpm, Sorvall RCM120SE, S100-AT6 
rotor) for 20 minutes at4°C. The supernatant contained pure monomeric 
actin. 
2.3.4.2 Depolymerisation of Transgenic Mouse F-Actin 
For polymerisation assays, 400mg D286G transgenic mouse tissue and 
200mg E361G transgenic mouse heart tissue was used to isolate F-actin, 
which was polymerised without phalloidin (2.3.2 & 2.3.3). 400^^ undiluted 
mouse F-actin (0.3-1.0mg/ml) was depolymerised in depolymerising buffer 
(0.5mM ATP, 0.2mM CaCl2, 1mM DTT, lOmM Trizma, pHB) for 48 hours at 
4°C. Then the actin was centrifugated at 446,800xg (100,000rpm, Sorvall 
RCM120SE, S100-AT6 rotor) for 20 minutes at 4°C. The supernatant 
contained monomeric actin. 
2.3.4.3 Purification of G-actin from Transgenic IVIouse Tissue 
for Polymerisation Assays 
To further purify G-actin, it was loaded onto a 0.6x25 cm Sephacryl S300 
gel filtration column pre-equilibrated with 105ml of depolymerising buffer and 
run at a flow rate of lOml/hour. Fractions were collected every 12 minutes, 
checked on a SDS gel (2.5), the actin was eluted usually in fraction 6-8 at 
about 10-16ml, and the actin containing fractions were pooled (Figure 2.5). 
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standard S300 column fractions 
actin 
3 4 5 6 7 8 9 
4 1 
"I * : {f %-K 
actin 
Figure 2.5: Purification of G-actin using S300 gel filtration 
column detected by Coomassie Blue stained SOS gel 
The 3 column fractions (6-8) that contained the most concentrated actin were 
pooled. 
2.3.4.4 Concentration of Purified G-actin 
The concentration of G-actin that was eluted from S300 gel filtration column 
was 0.005-0.05mg/ml measured by dot blotting using a standard actin with a 
known concentration, and it was too dilute to be used in functional studies. 
Amicon Ultra-15 centrifugal filters were used to concentrate G-actins. BSA 
was added to purified G-actin to a final concentration of 0.2mg/ml in the 
centrifugal filters, which were then capped and placed into swinging buckets. 
After centrifugation at 2377xg (4300rpm, Journ BR4, S40 rotor) for 20 
minutes at 4°C, the concentrated G-actins were recovered by inserting a 
93 
Materials and Methods 
pipette into tine bottom of tine filter and the actin was withdrawn with a side-to-
side sweeping motion. Typically the volume was reduced at least 90%. and 
11.5-83% of the actin was recovered i.e. a 3-55 fold increase in actin 
concentration determined by dot blotting (2.4.3). 
2.4 Protein Concentration Determination 
2.4.1 Lowry Assay 
Protein concentration was determined by the method of Lowry et al. (1951). 
Aliquots of protein, typically 5, 10, and 15<l (2.5-240<g) were mixed with 
500<l of 1M NaOH and 5ml of freshly prepared Lowry solution (1part 0.5% 
CUSO4, 1 part 1% NaK tartrate, 48 parts 2% NagCOs), followed by a 10 
minutes incubation at room temperature. After adding 500<l of Folin solution 
(1 part Folin and Ciocalteu 's reagent, 1 part dH20), the solution was mixed 
thoroughly and incubated for 30 minutes at room temperature. The 
absorbance of the solution was measured at 700nm and the concentration of 
protein was determined using a calibration chart constructed by measuring 
the total nitrogen content of the actin and myosin. 
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2.4.2 Bradford Assay 
The Bradford Assay was used for rapid determination of HMM 
concentration. 100^1 of HMM or myosin was mixed thoroughly with 1ml of 
Bradford Reagent (Sigma B-6916), and incubated for 5 minutes at room 
temperature. The absorbance of the test and blank solution was measured at 
595nm and the protein concentration was worked out using a calibration 
curve of known HMM concentrations calibrated on Lowry assay (Figure 2.6). 
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Bradford assay of HMM: 
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Figure 2.6: Calibration graph for the Bradford assay. 
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2.4.3 Dot B l o t t i n g A c t i n A s s a y 
2.4.3.1 Preparation and Immunodetection 
Dot blotting was used to determine actin concentration when it was too low 
(as low as 0.06mg/ml) to be detected by Lowry assay or in the presence of 
BSA which would interfere with the absorbance measurement in Lowry 
assay. A grid was drawn by pencil on a nitrocellulose membrane to indicate 
the region to blot prior to loading the samples. 2^1 of sample was spotted 
onto the nitrocellulose membrane slowly at the centre of each grid to 
minimize the area that the solution penetrated (usually 3-4 nm) with narrow-
mouth pipette tip. Each membrane had serial two-fold dilutions of standard 
actin with a known concentration in a range of 0.06 to 0.64^g actin and test 
actin. After the membrane dried, it was immunodetected using 5C5 
monoclonal mouse anti-actin (Sigma), sheep anti-mouse horseradish 
peroxidase (Amersham Biosciences) and ECL detection (see 2.6.2). 
2.4.3.2 Densitometric Analysis of Dot Blots 
The blot was scanned with a HP Sanjet 4800 (HP Invent) desktop flatbed 
scanner and saved as Tiff files, then analysed using GeneTools 3.07 
software run on an IBM PC (Syngene) (Figure 2.7). The volume of each dot 
was measured, and a graph of dot volume vs. actin dilution factor was plotted 
for both standard and test actins. If the signal saturated at high 
concentration, the slope of the initial linear phase would be used to compare 
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that of standard actin, the slope ratio should be equal to the ratio of their 
concentrations (Figure 2.8). 
(A) 
Track 1 2 3 4 5 6 
(B) 
# # # 
• • t • • 
t • • • • 
Figure 2.7; Densitometric analysis of 
the dot blot 
(A) A sample dot blot. Standard actin is on track 
1, test actins are on track 2-6. Serial dilutions of 
each actin are shown in row 1-5. (B) Raw volume 
of each dot was used for concentration 
determination of test actins. 
Track 1 
Number Height Raw vol. 
1 
2 
3 
4 
5 
Track 2 
Number Height 
16.52046 345999.3 
29.44407 396467,3 
35.64613 462769.2 
103.507 1408780 
123.06271661498 
Raw vol. 
1 
2 
3 
4 
5 
Track 3 
Number Height 
1 
2 
10.46099 109608.2 
13.49354144669 
81.56218 696896.8 
122.504 1087660 
146.59761371958 
Raw vol. 
38.3152 497928 
47.78766 723258.1 
95.984731633523 
125.2892 2057209 
129.6224 2139034 
3 
4 
5 
Track 4 
Number Height Raw vol. 
1 23.1745 252892.9 
2 118.05431125728 
3 115.92581164623 
Track 5 
Number Height Raw vol. 
1 
2 
3 
4 
5 
Track 6 
Number Height Raw vol. 
1 44.69478 367328.7 
2 71.87935 635266.8 
11.10481 208885.5 
36.73896 585822.4 
73.855461365242 
108.1301 1776400 
126.6368 2376783 
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y = 72066 + 7.7525e+06x R= 0.949 
• y = -30628 + 1.4256e+06x R= 0.98484 
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- y = -6.1994e+05 + 2.1821 e+06x R= 1 
y = -1.80826+05 + 3.8606e+07x R:^99997 
y = 99391 + 6.6985e+0 
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0.6 
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Figure 2.8: A graph of serial dilutions ofactin against the 
volume ofactin dots 
The slope of test actins was compared to that of standard actin (1mg/ml 
shown in pink), the ratio should be equal to the ratio ofactin concentrations. 
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2.5 Sodium Dodecyl Sulphate-Polyacrylamide 
Gel Electrophoresis (SDS-PAGE) 
2.5.1 Sample Preparation 
Protein solutions were mixed 1:1 with 2x SDS sample buffer (20mM Tris-
HCI pH 8.0, 2.5% SDS, 5% 2-mercaptoethanol, Bromophenol Blue) and 
incubated for 3 minutes at 95-100°C. Dilute proteins were mixed 2:1 (voLvol) 
with 3xSDS sample buffer (20mM Tris-Hcl pH 8.0, 7.5% SDS, 15% 2-
mercaptoethanol, PAGE blue) so as to maximise the concentration of the 
sample loaded onto the electrophoresis system. 
2.5.2 Electrophoresis 
A precast gel on a plastic backing (Excelgel-SDS 8-18% gradient, 
Amersham) was orientated on the precooled horizontal plate of a Multiphor I 
electrophoresis system. Polyacrylamide anodic and cathodic buffer strips 
were placed at each end. 5mm x 10mm sized filter paper pieces were 
spaced approximately 5mm apart adjacent to the cathodic buffer strip. 
Prepared samples of up to 20<1 total volume, approximately 1-20<g protein, 
were loaded onto the filter papers and the gel was run at 50mA/600V/30W 
maximum for 80 minutes at 10°C. 
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Following electrophoresis, the gel was immersed in fixing solution (50% 
methanol, 10% acetic acid) for 20 minutes on a bench rocker. The protein 
bands were visualised by soaking the gel for 20 minutes in Coomassie Blue 
staining solution (0.5% PAGE blue in 50% methanol, 10% acetic acid), then 
in destain solution (25% methanol, 8% acetic acid), both steps with gentle 
agitation. 
The gel was preserved under cellophane by incubating in destain 
containing 10% glycerol together with a sheet of cellophane for 30 minutes. 
The gel was then removed, the cellophane cut to the size of the gel and 
allowed to dry overnight at room temperature. 
2.6 Western Blotting 
2.6.1 Protein Transfer 
Actin samples (< 0.05p,g) to be analysed by Western blotting were first 
separated by SDS-PAGE. A nitrocellulose membrane (0.45<m pore size, 
Amersham Biosciences, RPN 303D) and 2 pieces of BIO-RAD extra thick 
filter paper (Protean XL, 18.5x19cm) were cut to the same size as the gel 
(10x13cm) and pre-soaked in blotting buffer (20% methanol, 48mM Tris, 
39mlVI glycine, 1.3mlVl SDS) for 15 minutes. First a piece of filter paper was 
placed on the electrode of the semi-dry transblooter cell (BIO-RAD 221 BR), 
then the polyacrylamide get was placed on top of the nitrocellulose 
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membrane and sandwiched between the filter paper, with 1 piece either side. 
The proteins were electrophoretically transferred to the nitrocellulose 
membrane at 350mA and 25volts for 1 hour at room temperature. 
2.6.2 Immunodetection 
The nitrocellulose membrane was soaked in blocking buffer (phosphate 
buffered saline <PBS> with 1% dried milk powder, 0.1% Tween 20) overnight 
at 4°C with gentle rocking. Next, the membrane was incubated with primary 
antibody (Sigma, 5C5 monoclonal mouse anti-actin) in blocking buffer at 
1/1000 dilution for 1 hour at 4°C. The membrane was then subject to 3x5 
minute washes in a wash buffer (PBS with 0.1% Tween 20), before 
incubation with sheep anti-mouse IgG coupled with horseradish peroxidase 
(Amersham Biosciences) in blocking buffer at 1/1000 dilution for 1 hour at 
4°C. Following a further three 5 minute washes in the wash buffer, the 
membrane was then activated by soaking with enhanced chemiluminescence 
reagents (ECL, Amersham Biosciences, RPN2109) for exactly 1 minute and 
exposed to ECL Hyperfilm (Hyperfilm, Amersham Biosciences, RPN1674K) 
for a certain period of time (10 seconds-10 minutes) determined by band 
intensity. 
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2.7 2-Dimensional Electrophoresis 
Actin mutations that involve a charge change could be separated from wild-
type by 2-dimensional electrophoresis. 
2.7.1 Sample Preparation 
15^g tissue (wet weight) was homogenised in 150^il wash buffer (20mM 
KPO4, 2mM MgCIa, 1mM DTT, 1mM NaNs, 50% v/v glycerol, 0.5% v/v Triton 
X-100, pH7.0). Tissue homogenate or pure actin was diluted in lysis buffer 
(8M urea, 2% Triton X-100, 36mM DTT) to approximate 15p,g/ml tissue or 
4txg/ml actin, then made up to 340^1 with rehydration buffer (lysis buffer, 2% 
IPG buffer <Amersham Biosciences>, l^g/ml protease inhibitors E64, 
chymostatin, leupeptin and pepstatin which were added just prior to use) at 
0.15fxg/340^l tissue or 0.04fxg/340^l actin. The mixtures were loaded onto 
dehydrated 18cm pH4-7 IPG strips (Amersham Biosciences), each strip was 
covered with 2-3ml DryStrip Cover fluid to prevent evaporation and urea 
crystalisation overnight at room temperature. 
2.7.2 First Dimension Isoelectric Focusing (lEF) 
Rehydrated lEF strips were separated by lEF using first dimension lEF and 
following the manufacturer's protocols. 
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Isoelectric focusing was performed in 2 phases: 
Phase Voltage mA W Time (hrs) Vh 
1 500 1 5 4 2000 
2 3500 1 5 12.5 43750 
2.7.3 Second Dimension SDS-PAGE in ExcelGel 
Gradient Gels 
Prior to the second dimension SDS-PAGE, strips were incubated in 
equilibration buffer (375mM Tris-HCI pH8.0, 6M urea, 2% SDS, 20% 
glycerol) with additional 65mM DTT for 10 minutes and then with 243mM 
iodoacetamide in the same buffer without DTT for 10 minutes. The strip was 
then cut down to the 6cm central part which contained the focussed actin (Pi 
5.7), and placed onto an ExcelGel gradient 8-18% (2 strips for half gel), the 
gel was run in three steps; 
Step Voltage mA W Time (min) 
1 600 20 30 25-30 * 
2 600 50 30 3-5** 
3 600 50 30 70 
* Remove the strip and the filter paper pieces 
** Move the cathodic buffer strip forward by 1-2 mm. Adjust the position of 
the cathodic electrode. 
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2.7.4 Detection 
As described in Western blotting (2.6.2), the gel was electrophoreticaliy 
transferred to a nitrocellulose membrane for specific immunodetection with 
5C5 monoclonal mouse anti-actin (Sigma) (Figure 2.9). 
WT Mutant 
V 
Figure 2.9: 2-dimesional electrophoresis of purified D292V F-
actin 
Mutant actin vi/as shown to be expressed at 40% of total actin in the isolated 
F-actin. 
2.7.5 Densitometric Analysis of SDS-PAGE Gels, 
Western Blots and 2D Electrophoresis Gels 
Protein bands detected by SDS-PAGE gels, Western blots and 2D gels 
were measured by scanning densitometry. The gels and developed ECL 
films were digitised using a HP Scanjet 4800 (HP Invent) desktop flatbed 
scanner with transilluminator and saved as TIFF files, then analysed with 
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GeneTools 3.07 software run on an IBM PC (Syngene). The volume of each 
single protein band was measured, the volume of test actins was compared 
to that of standard actin, the ratio should be equal to the ratio of their 
concentrations. 
2.8 In Vitro Motility Assay 
The in vitro motility assay technique is applied to study fluorescently 
labelled actin filaments visualised moving over immobilised myosin. TRITC-
phalloidin (actin-1) was used to label the actin filaments. This method was 
originally devised by Kron & Spudich (1986). The method described is based 
on this original technique but has undergone several modifications (Bing et 
a/. 1997; Marston 2003). 
2.8.1 Affinity Precipitation of HMM 
In the in vitro motility assay, filament movement was prevented by the 
presence of a small proportion of HMM "rigor heads". These "rigor heads" 
bound to ATP irreversibly, therefore led to lower percentage motility of the 
actin filaments. To minimise this, HMM preparations were affinity precipitated 
with F-actin in the presence of ATP prior to use in the motility assay. Skeletal 
muscle HMM was mixed with F-actin and MgATP to final concentrations of 
200<g/ml, 150<g/ml and ImM respectively in buffer A (50mM KCI, 25mM 
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imidazole-HCI pH7.4, 4mM MgCl2, 1mM EDTA, SmM DTT), and incubated on 
ice for 10 minutes. The mixture was centrifugated at lOO.OOOrpm (Sorvall 
RCM120SE, S100-AT6 rotor) for 15 minutes at 4°C to pellet F-actin and 
associated myosin "rigor heads". The supernatant, which contained HMM 
suitable for use in in vitro motility assay, was stored on ice and could be used 
for up to three hours. 
2.8.2 F l u o r e s c e n t Labe l l i ng o f F - A c t i n 
2.8.2.1 Fluorescent Labelling of Rabbit F-Actin 
Normally rabbit F-actin was labelled with TRITC-phalloidin for visualisation 
under a fluorescent microscope. 219<l of buffer A was first thoroughly mixed 
with 18<l of 33<M TRITC-phalloidin. Then F-actin was added to give a 
concentration of 1<l\/l and gently mixed. The mixture was incubated for 16-18 
hours at 4°C, and was kept in an eppendorf covered by aluminium foil to 
prevent photo-degradation of the label. In some preparations TRITC-
phalloidin was added at the polymerisation stage. This labelled actin 
provided a stock of actin-1, which could be used for motility studies for 5-10 
days. 
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2.8.2.2 Fluorescent Labelling of F-Actin from Biopsy Samples 
207<l of buffer A was first thoroughly mixed with 18^1 of 33<M TRITC-
phalloidin. Then due to low concentrations, 22^1 F-actin (0.018-0.074mg/ml) 
that was isolated from biopsy samples was added and gently mixed. The 
mixture was incubated for 16-18 hours at 4°C, and was kept in an eppendorf 
covered by aluminium foil to prevent photo-degradation of the label. This 
labelled actin provided a stock of actin-j, which could be used for motility 
studies for 5-10 days. 
2.8.3 P repa ra t i on o f the Mot i l i t y A s s a y F low Cel l 
In order to visualise the actin-myosin system in the motility assay, a flow 
cell was constructed from a microscope slide and pre-washed 22x22mm 
superclean coverslip. The coverslip was silconised prior to use by washing 
the coverslip in a chloroform solution containing 0.2% dichloromethylsilane. It 
is important to maintain the solution very dry and dust free. Reagents were 
stored in a desiccated clean box and cells were constructed in a desiccated 
clean fume hood. This wash procedure involved the coverslip being stirred in 
the solution and then slowly drawn out of the liquid so that surface tension 
drew the liquid from the surface of the coverslip. The resulting coverslips 
provided a surface for binding of the myosin substrate. Any coverslip 
showing adherent liquid after immersion in the solution was discarded, as 
this indicated incomplete silconisation. The flow cell was divided into two 
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chambers by the application of a further longitudinal line of grease down the 
centre of the chamber. The coverslip was then mounted on two parallel 
longitudinal lines of grease, flanked by pieces of lacquered copper wire, 
diameter 100<m, to provide a flow cell with an internal volume of 
approximately 50^1. (Figure 2.10). This modification allows simultaneous 
comparisons of different samples and hence removing the variation that may 
arise by comparing different samples under the same conditions in different 
flow cells. 
I'lf 1 
grease 
2 Flow Chambers coverslip 
Figure 2.10 Construction of the flow cell 
2.8.4 Pre-Mixing and Incubation of Thin Filament 
Proteins 
For regulation studies in the in vitro motility assay, actin-f was pre-mixed 
with the appropriate regulatory proteins prior to infusion into the assay flow 
cell to reconstitute the myocardial thin filament. When making the 
reconstituted complex, firstly tropomyosin, troponin and buffer A were mixed 
thoroughly, then actin-f was added and the solution was mixed gently so as 
not to fragment the actin filaments. Thin filament proteins were mixed at 10x 
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final motility assay concentrations and incubated on ice for 15-20 minutes. 
The mixtures were subsequently diluted 10-fold in buffer A immediately prior 
to infusion. 
2.8.5 Infusion of Proteins into the IVIotility Assay Flow 
Cell 
The flow cell was set at an angle of approximately 30° to flat and protein 
components were infused at 30 second intervals. Figure 2.11 illustrates the 
sequence and constitution of the solutions passed through the flow cell. The 
first protein to be infused into the flow cell was skeletal muscle HMM diluted 
in buffer A at a concentration of 100<g/ml. Next, buffer B (buffer A + 0.5 
mg/ml BSA) was added to block any non-specific binding of the thin filaments 
to the coverslip. This was followed by the infusion of a solution containing 
10nM actin-t in buffer A with the appropriate thin filament proteins. The flow 
cell was then washed with 50<l buffer C (O.Smg/ml BSA, 0.1 mg/ml glucose 
oxidase, 0.02mg/ml catalase, 3mg/ml glucose and 0.5% methylcellulose), 
followed finally by 50<l buffer D (buffer C with additional ImM MgATP). The 
presence of catalase and glucose oxidase in buffers C and D is important as 
they act as free radical scavengers and reduce photo-bleaching of actin-f 
filaments. Methylcellulose minimises lateral diffusion of actin filaments. To 
compensate for the possibility of partial dissociation of troponin from the 
reconstituted thin filament complex, 5<l of troponin in buffer A was added to 
give the appropriate assay concentration of troponin in buffer C and D. When 
troponin was not required, 5SI of buffer A was used alone. 5<l of an 
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appropriate Ca^^ EGTA buffer solution was also added to buffer C and D to 
study the effect of different concentrations of on reconstituted thin 
filament regulation. Buffer C and D were then mixed thoroughly and infused 
into the flow cell. 
100<l aliquot of skeletal HMM at 
100<g/ml in Buffer A (50mM KCI, 25mM 
imidazole-HCI pH 7.4, 4mlVI MgCl2, ImM 
EDTA, SmM DTT) 
100<l of Buffer B 
(A + 0.5mg/ml BSA) 
Pre-incubate 
actin-Tm or 
actin-Tm-Tn 
mixtures at 
10 X 
concentration 
100<l of 10 nM actin-f 
±pssociated thin 
filament proteins (Tm 
Tn) in Buffer A. 
50<l of buffer C (dH20 + 0.1 mg/ml 
glucose oxidase, 0.02mg/ml catalase, 
3mg/mi glucose, 0.5% 
methylcellulose) or 40|il Buffer C + Sjil 
troponin at assay concentration and 
5111 buffer. 
50<l of Buffer D (C + 
1 mM ATP) or 40(xl Buffer" 
D + 5|il troponin at assay 
concentration and 5f,il 
Ca^* buffer. 
Cover glass coated with 
dichloromethyisilane 
15-30 seconds 
15-30 seconds 
15-30 seconds 
15-30 seconds 
Visualisation 
Figure 2.11: Infusion of proteins onto the pre-prepared 
microscope slide with the siliconised coverglass. 
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2.8.6 Preparations of Ca/EGTA Buffers 
Ca/EGTA buffers were prepared by a method adapted from McGuigan et 
al. (1991). Ca/EGTA buffers with different [Ca^""] ranging from pCa9 to 
pCa5.4 are shown in Table 2.2. 
A 47 0.5 94/1 9.00 
C 40 4 10/1 8 14 7 ^ 4 x 1 0 ^ 
D 40 10 4/1 7.74 t 8 2 x 1 0 ^ 
E 30 15 2/1 7.43 :&72x10^ 
F 25 17.5 1/0.7 7.24 5.75 X 10 " 
G 25 25 1/1 7.13 7.41 X 10" 
H 20 30 1/1.5 6.95 1.12 X 10'/ 
1 15 30 1/2 6.84 1.45x10"' 
J 10 30 1/3 6.64 :&29x10^ 
K 10 40 1/4 6.52 3.02 X 10"' 
L 8 40 1/5 6.42 3.80 X 10"' 
M 7 42 1/6 6.34 4.57 X 10"' 
N 6 42 1/7 (^28 5.25 X 10"' 
P 5 40 1/8 6.23 5.89 X 10"' 
Q 5 45 1/9 6.18 6.61 X 10"' 
R 2 40 1/20 5.88 1 ^ 2 x 1 0 ^ 
S 1.5 45 1/30 5.75 1 7 9 x 1 0 ^ 
T 0 50 -/I 5.43 :&72x10^ 
Table 2.2: Ca/EGTA buffers with different pCa values 
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2.8.7 Experimental Strategy for Screening Actin from 
Biopsies and Transgenic IVlouse Tissue 
The motility and regulation of thin filaments reconstituted from proteins from 
different origins was investigated by using the in vitro motility assay. To 
minimise the variability that may occur during protein preparation (wild-type 
or mutant), test proteins were prepared simultaneously. To mininise 
variations in the assay itself, test and control thin filaments were measured 
simultaneously in two-chambered motility cells. 
For every in vitro motility assay, an initial test of plain wild-type actin 
filament movement over a bed of immobilised HMM at 28°C was always run 
before experimenting on any test proteins. If the HMM is of sufficient quality, 
filaments should be able to achieve percentage motility of 70% and a sliding 
speed of 3<m/sec for rabbit actin and 2^m/sec for biopsy actin. An 
experiment was only continued when these parameters were obtained. First 
the appearance and motility of test actins was compared to that of wild-type 
actin at different temperatures (normally 20°C, 25°C, 28°C, 30°C and 35°C). 
The functional effect of tropomyosin was then measured by titrating 
tropomyosin against 10nM actin-f filaments. In order to continue the motility 
experiment, an increase in sliding speed (20-30%) with a high percentage 
motility at 28°C with 40-60nM cardiac or 5-1 OnM skeletal tropomyosin should 
be observed. If all these conditions had been met, the [Ca^'^j-dependent 
effect on regulation could be studied by first of all testing motility at high and 
low [Ca^""] with a range of troponin concentrations. The pre-requisite for these 
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experiments were that at low calcium concentration pCa9 (1<M Ca^""), thin 
filaments reduced the filaments percentage motility to lower than 10% and at 
high calcium concentration pCa5.4 (3.9nM the filaments percentage 
motility was above 80% with <50nM troponin. When the correct conditions for 
regulation were determined, the thin filaments could be compared 
simultaneously over a range of concentrations. 
2.8.8 Visualisation Apparatus 
To visualise the movement of the thin filaments in the motility assay, the 
actin filaments were labeled by the fluorescent TRITC-phalloidin. Figure 2.12 
shows the schematic set-up of the visualisation apparatus. Firstly the flow 
cell was placed into the metal temperature control chamber on the stage of a 
Zeiss Axiolab microscope, with a Zeiss 63x/1.40 NA PlanApochromat 
objective lens (44 07 60-03) fitted with an epifluorescence illuminator (Zeiss, 
39 26 42-9901) containing a SOW mercury high pressure arc lamp (Osram, 
HBO 50W/3), and a rhodamine compatible filter set (Chroma Technology, 
emission; HQ 595-50, excitation: 0539-25, dichroic: 565-DRLP special). The 
microscope was connected through a C-mount (45 61 05), to a 
HAMAMATSU C2400-80 silicon intensified video camera which in turn was 
linked to a monitor and to two computers, one of which was for visualising 
and recording, whilst the other one was for analysis. 
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H > 
Time base 
corrector 
Data Video 
TBC-1000 
- O Formac Studio DV 
converter 
Video camera 
HAMAMATSU 
C2400-80 
Lens (Zeiss 
63x71,40 
NA) 
Motility cell 
is placed 
here 
Filter set 
IVIicroscope 
(Zeiss:Axiolab) 
Mercury lamp 
_ Osram, 
HBO 50W/3 
Binomic 
temperature 
controller 
BC-100 
* A rhodamine compatible TRITC 
filter set (exciter: D539-25; emitter: 
HQ595-50; beamsplitter; 565-
DRLP 
Macintosh G4 computer 
showing the live image with 
IMovie software 
i 
Extract Velocities CEL] 
K II i 
Macintosh G3 computer 
showing analysis with 
Tracker software 
Figure 2.12: Schematic diagram of the visualisation and 
recording apparatus used for the analysis of the in vitro 
motility assay. 
A drop of Zeiss 518C immersion oil was placed onto the coverslip of the flow 
cell and finally the actin-cp filaments were brought into focus on the monitor 
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The movement of the thin filaments is temperature-dependent. The 
standard motility assay experiments were carried out at 28°C, the 
temperature was controlled using a Bionomic Controller BC-100 (20/20 
Technology Inc.). The controller was set at a given temperature 
corresponding to the temperature of the metal chamber into which the flow 
cell was placed. Temperature changes needed 5 minutes to reach 
equilibrium. 
2.8.9 Computer Hardware 
Analogue signals from the time base corrector (DataVideo TCB-1000) were 
digitized by a Formac Studio DV converter attached to a Macintosh G4 
computer. The live images were viewed and recorded using iMovie software. 
A Macintosh G3 computer was used with a built in PCI Neotech frame 
grabber to perform image digitisation and analysis of filament movement. 
2.8.10 Computer Analysis of Filament Movement 
Quantitative analysis of filament movement was made using specialised 
computer software provided by ME Electronics (Reading, UK) for use on a 
Macintosh computer running 0S9. The "Filament Tracker 2.0.3" 
programme was run using the LabVIEW*-3.1.1 Run-Time image analysis 
application (National Instruments Corp.). The software consisted of two 
115 
Materials and Methods 
functions; the image grabber function, which digitised a sequence of filament 
images; and the image analysis function, which analysed the movement of 
filaments between pairs of digitised images. 
2.8.10.1 Software Calibration 
Calibration was accomplished using a 1005m microscope graticule which 
was visualised in the same manner as described for a motility flow cell and 
recorded on videotape. The image shown in Figure 2.13 was provided by 
playing back the videotape. Using the mouse-controlled cursor, a line was 
drawn across the graticule image and the appropriate length entered to 
calibrate the software for subsequent motility analysis. 
Length in Units 
Figure 2.13: Diagram of the microscope graticule used to 
calibrate the in vitro motility assay image analysis software 
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2.8.10.2 Acquisition of A Sequence of Images 
Filament movements were analysed directly from the image viewed via the 
camera by using a Filament Tracker program. Figure 2.14 demonstrates the 
command sequence followed to acquire images from an in vitro motility 
assay. Live images of the in vitro motility assay were displayed in the image 
window where four parameters could be adjusted to optimise image analysis 
(Figure 2.14C). 
B 
I StuutRCB II Traclang j| Tracking | 
! Acquire Sequence 
I **#»««# 
CilbrdtiDiValues 
Sample step 
Image Acquisition oar * i S 
Video Standinl 
1 PAl 
& yiilnsiSsiinf 
5et-upCapture ' 
(willre Set-up 
Figure 2.14: Diagram of the sequence of commands followed 
to optimise the in vitro motility assay image for analysis and 
the acquisition characteristics prior to the final capture 
Normally 10-15 images were acquired to obtain 250-500 filament vectors 
recorded, which ensured minimum random errors (Marston et al. 1996). In 
order to give the maximum ratio between random filament oscillation, pixel 
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size and distance of filament movement between images, and at the same 
time to maintain accurate filament tracking, the timer interval was set to allow 
filament movement of approximately 1.6-1.8<m between captured images 
(Figure 2.15) (Marston et al. 1996). These timer intervals should be fixed for 
any single experiment. For any given experiment once the conditions were 
optimum for image acquisition images were captured randomly from three to 
four separate areas of the flow cell to obtain data that was representative of 
the whole flow cell, eliminating experimental bias. 
0 1 2 3 4 5 6 7 
Motile velocity / ^ (m/sec 
Figure 2.15: A graph of timer interval against sliding speed. 
2.8.10.3 Automatic Filament Tracking 
Automatic-tracking program was used to analyse image files of filament 
movement. The filaments detected by the computer were then displayed and 
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highlighted as green objects on the original black and white image. By 
selecting the "Change Settings" command the parameters were adjusted to 
optimise movement analysis. The maximum velocity cut-off was normally set 
to 8^m/sec to exclude incorrect tracking in the analysis and the minimum 
detected object area was changed in order to include all filaments but 
exclude camera noise as described by Marston et ai (1996). 
Following changing the settings, the "Extract Velocities" command was 
chosen (Figure 2,16A). During filament tracking, a sliding speed frequency 
histogram was created from individual vectors of filament movement shown 
on the on-line display of the tracking of the filaments. Two consecutive 
images which were superimposed were shown in Figure 2.16B. 
The first image was coloured green and the second was red. Vectors of 
filament movement were shown as blue lines connecting the centroids of the 
filament in its two locations. The frequency histogram of the vectors as 
shown in Figure 2.16C was displayed on the final panel. A threshold line was 
located by eye to divide motile and non-motile populations of filaments and 
remained constant for any series of tracks. In practice, the threshold was 
0.65 <m movement between consecutive images, thus when images were 
recorded every 0.65 seconds, the non-motile sliding speed was equivalent to 
1 <m/sec. With higher velocities, and therefore shorter recording intervals, 
the apparent movement of non-motile threshold was greater. Standard 
motility analytical parameters were as follows: acquisition timer interval of 0.4 
seconds which equated to a frame interval of 0.7 seconds (0.4s + computer 
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cycling time), maximum sliding speed cut off of 8<m/sec and a non-motility 
threshold of 1<m/sec, all of these parameters needed to be adjusted each 
day and held constant for any set of measurements. 
B 
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Figure 2.16: Diagram of the automatic tracking process. 
The percentage motility and sliding speed is displayed in the resulting 
frequency histogram data output window (C). 
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All the parameters on the left hand side should be kept constant during any 
single experiment. The calculated object (filament) density, the percentage 
motility of filaments, the mean sliding speed of moving filaments with 
standard deviation and the number of filament vectors measured were shown 
on the right hand side (Fraser & Mars ton 1995). 
2.8.11 Statistical Analysis 
Motility experiments were generally done in weekly cycles due to the 
requirement for fresh materials to produce optimal results. For unstable 
actins, motility experiments were performed within 2 days after the actin 
preparation. Each week's experiments used fresh HMM and the 
reconstituted thin filaments were made up on the day of the experiment. The 
experiments compared the control and experimental thin filaments in the 
same motility cell to give minimal errors, thus variation within an experiment 
was always less than variation between experiments performed at different 
times with different contractile protein preparations. The mean percentage 
motility and sliding speed with standard errors were calculated and recorded. 
Results were expressed as mean ± standard deviation unless otherwise 
indicated. Statistical significance of data sets was compared using the 
Student's ttest. P<0.05 was considered as significant. 
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2.9 Direct Visualisation and Kinetic Analysis of 
Actin Polymerisation Using Total Internal 
Reflectance Microscopy (TIRF) 
Actin polymerisation process could be observed in real time by using total 
internal reflectance microscopy (TIRF) (Amann & Pollard 2001). Fluorescent 
filaments could be seen in the presence of TRITC-phalloidin in the solution 
by using TIRF, because TIRF illumination excited only a few nm at the 
surface (Figure 2.17). 
U 'yJ j jy 
(f i = 
E x c i t a t i o n 
. > Gtass 
% Slide (n - 1.518) Reflection A n g l e 
Figure 2.17: Schematic illustration of the mechanism of total 
internal reflectance microscopy 
Adapted from 
httD://www. olvmpusmicro. com/primer/techniQues/fluorescence/tirf/tirfintro. htm 
I 
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TRITC-phalloidin was highly fluorescent and was incorporated into actin 
filaments as they polymerised on the cover glass surface. The polymerisation 
of actin was initiated by adding G-actin to pre-formed nuclei ("anchors") 
that were coated on a microscope cover glass. 
2.9.1 Cross-link HMM and Actin as Anchors 
To make anchors, equimolar (1.0-1.2nmol) F-actin and HMM were dialysed 
in 100ml of lOOmM MES pH6.0 for 2hrs at4°C, then cross-linked with 25mM 
EDAC (1-Ethyl-3-<3-DimethylAmino-Propyl>Carbodiimide) for 70 minutes at 
room temperature, and finally dialysed against motility buffer A overnight at 
4°C. Prior to polymerisation experiments, anchors were sonicated for 5 
minutes to provide nuclei for actin to grow on. 
2.9.2 Visualisation of Actin Polymerisation 
2.9.2.1 Preliminary Experiments by Conventional Fluorescent 
Microscopy 
Preliminary experiments were done by conventional fluorescent microscopy 
to determine the most suitable concentration for anchors, which appeared to 
vary for different actin preparations. 
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A modified method of Ishiwata et al. (2001) was applied to visualise actin 
polymerisation in preliminary experiments. First of all 100pJ of diluted anchors 
(1,000-10,000x dilution) in motility assay buffer B were infused to a motility 
flow cell to coat the cover glass, incubated for 4 minutes, followed by 2x250^1 
washes with buffer B to remove free anchors. G-actin (0.01-1 |iM) was then 
mixed with: lOOnM ATP, 0.5% methylcellulose, Img/ml BSA, and 50mM 
KCI/1mM MgCl2, 120nM TRITC-phalloidin to initiate polymerisation before 
being infused immediately into the flow cell. Since fluorescent filaments and 
TRITC-phalloidin in solution are not distinguished by conventional epi-
fluorescent microscopy, the process had to be halted at different times by 
washing out the G-actin and TRITC-phalloidin with 100^1 buffer B and 50^1 
motility assay buffer C. Concentration of anchors was adjusted to give the 
most reasonable actin density and polymerisation rate for analysis. Figure 
2.18 shows pictures of actin polymerisation with different anchor 
concentrations. 
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B 
A . ; 
Figure 2.18: Actin polymerisation visualised by conventional 
fluorescent microscopy 
O.SjuM G-actin from non-transgenic mouse heart tissue polymerised on (A) 
1,000x (B) 4,000x diluted anchors for 20 minutes. 
2.9.2.2 Experiments by TIRF 
In TIRF experiments, 100^1 of 4000x diluted anchors were infused to a 
motility flow cell first to coat the cover glass, followed by 2x250^1 washes with 
buffer B to remove free anchors. G-actin was mixed with: lOOnM ATP, 0.5% 
methylcellulose, 1mg/ml BSA, glucose oxidase, catalase, glucose, 50mM 
KCl/1mM MgCl2, 120nM TRITC-phalloidin to initiate polymerisation and 
infused into the flow cell. The cell was immediately put under a TIRF 
microscope (Figure 2.19). 
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Figure 2.19: Schematic representation of initiation of actin 
polymerisation on pre-formed anchors 
2.9.3 TIRF Apparatus 
A TILL Photonics TIRF system (provided by Prof. Mike Ferenczi and Dr. 
Dmitry Ushakov, Biophysical Science, Imperial College London) based on a 
Zeiss inverted microscope with a lOOxNA 1.45 lens and a 514nm laser was 
used to observe the polymerisation process. The surface of the cover glass 
was observed with a PCO SensiCam CCD camera (Figure 2.20). 
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Figure 2.20: Inverted microscope configuration for TIRF 
Adapted from 
http://www.olvmpusmicro.corri/primer/techniques/fluorescence/tirf/olvmpusap 
tirf.html 
2.9.4 Quantitative Analysis 
Digital images were acquired as a series of TIFF files every second for up 
to 1 hour and converted to Quicktime movie format with camera type for 
quantitative analysis with Dynamic Image Analysis Software (DIAS). Frames 
were selected at 0.5-3 minute intervals depending on the rate of actin 
polymerisation. To determine the length of individual filaments, a defined 
central field of view in each frame was selected, and the length of each 
filament in that field (even it grew out of the field) was measured manually 
using the "arbitrary length" function (Figure 2.21). Mean length at each time 
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point was calculated, histograms were drawn, and the rate of filament 
elongation and increase in filament number was calculated. 
Figure 2.21: l\flanual length analysis of a population of 
filaments in a selected field in a frame (0.1 M G-actin at 16min) 
2.10 Binding Competition Assay of Labelled & 
Unlabelled Actin for f-Actinin 
To measure the relative affinity of different actin filaments for the Z-line 
actin binding protein f-actinin, unlabelled actin was used to compete against 
TRITC-phalloidin labelled actin to bind to f-actinin, and the relative binding 
affinity of the two actins was compared. 100|xl of 5^ig/ml f-actinin was 
infused to a motility flow cell, followed by a wash with 100|il motility buffer B. 
Then a 100^1 mixture of labelled and unlabelled actin in a range of ratios at 
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fixed lOnM concentration (large excess over f-actinin) was infused and 
washed with SOjxl buffer C (nnethylcellulose was omitted as it caused non-
specific binding). Various fractions of labelled actin were studied. Up to 10 
filament fields were recorded per cell and the number of actin filaments was 
determined using the Tracker software. In each paired cell, since actin was in 
great excess over f-actinin, TRITC-phalloidin labelled actin competed with 
unlabelled actin for binding to f-actinin. The amount of labelled relative to 
unlabelled actin filaments that bind to f-actinin depends on the relative 
affinity of the two species, defined by the equation; 
y = filament number 
y = F.K / (FK+(1-F)) F = fraction of labelled actin filaments 
K = ratio of binding constant 
A theoretical curve of actin binding competition (Figure 2.22) provided the f -
actinin biniding equation, which was used to fit the experimental data 
producing K for each actin sample (see Chapter 3.4.6). 
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Figure 2.22: Theoretical curve of actin binding competition 
for ^-actinin 
Filament number varies with fraction of labelled actin for different K values 
(ratio of binding constant). 
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3. Functional Characterisation of A 
Nemaline Myopathy Mutation (D286G) 
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3.1 Introduction 
3.1.1 Phenotype of D286G 
The D286G ACTA1 mutation causes severe nemaline myopathy (Nowak et 
al. 1999). The patient with D286G mutation was reported to have hypotonia, 
joint contractures, femur fracture, no movement, no respiratory effect at birth, 
and died at 6 days. Pathological study showed marked fibre size variability, 
severe atrophy in both slow-twitch (type 1) and fast-twitch (type 2) fibres, 
numerous nemaline rods and severe myofibrial disruption (Agrawal et al. 
2004). 
3.1.2 Location of D286 
D286 is located in subdomain 3 of the actin monomer (shown in Figure 
3.1 A) and is at the long axis interface of the actin polymer (Figure 3.1 B). It 
forms a salt bridge with R39 and E270 of different actin monomers, but is 
completely buried in the polymer. It may affect actin-actin interaction, such as 
polymerisation and cooperativity. 
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(A) (B) 
# # 
D286 
Figure 3.1: Location of D286 in actin molecule 
(A) Secondary ribbon representation ofactin monomer showing location of 
D286 (brown sphere) in subdomain 3 of the molecule. (B) The residue (black 
sphere) is located at the long axis interface of the actin polymer and is in 
contact with residues of different monomers. Produced with Chimera 
software using Actin UdZ.pdb (A) and Actin__Model.pdb file (B). 
3.1.3 Source of Samples That We Studied 
The muscle we examined was provided by Dr. Kristen Nowak, University of 
Western Australia, who has produced several transgenic mouse lines 
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expressing D286G mutation in skeletal muscle. Studies were carried out on 
D286G actin isolated from leg muscle of three transgenic mouse lines: 
Kermit, is the D286G actin sequence modified by tagging green-fluorescent 
EGFP (28kDa) at the C terminus which enables identification of the mutant 
actin in fluorescent microscopy and also on SDS-PAGE and Western blots. 
D1 and D2 are two different lines expressing D286G mutant actin at different 
levels without any other modification. 
Because D286G was the first mutation 1 studied, several tests were carried 
out to establish the methodology for producing pure and fully functional 
actins from mouse tissue samples in cryosections as well as in larger 
sections. 
3.2 Isolation of F-Actin from Mouse Tissue 
3.2.1 Isolation of F-Actin from Mouse Tissue in 
Cryosections 
For isolating actin from very small, frozen muscle samples, the most 
economical method is to cut cryo-sections. Mouse muscle tissue samples 
(Kermit and non-transgenic) provided by Dr. Kristen Nowak were 
cryosectioned by Prof. Caroline Sewry at Hammersmith Hospital, London. 
Initially I attempted to isolate F-actin from approximately 3mg Kermit and 
paired non-transgenic (NTG) mouse tissue (in 20x30|im cryosections) using 
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the method of Razzaq et al. (1999) as applied to nemaline myopathy muscle 
by Marston et al. (2004). TRITC-phalloidin labelled F-actin was visualised in 
the fluorescent microscope in in vitro motility assay. Both actins had good 
motility with percentage motility over 80% and sliding speed of around 
3|xm/sec. However, the yield was low since actin filaments were only visible 
in 10x the concentrations of rabbit actin that had been used in standard 
motility assay. Compared to standard rabbit actin, both Kermit and NTG actin 
were less bright and had poorer contrast which made automatic tracking 
more difficult, suggesting that the species and the sample size rather than 
the mutation were likely to be the cause of the intensity differences. 
In order to produce more and better labelled F-actin from mouse tissue 
cryosections, 150nM TRITC-phalloidin was added directly to the monomeric 
actin together with 10x polymerising buffer. In addition, undiluted mouse F-
actin was labelled with TRITC-phalloidin. Samples at various stages of the 
isolation were studied by Western blotting assay. It showed that full 
polymerisation was induced in the presence of phalloidin and approximately 
2|ig actin per mg tissue was yielded. Tested in motility assay, both Kermit 
and NTG actin were bright with clear background allowing automatic tracking 
and analysis to be performed easily. This modified method (see Methods 
2.3.1 for full description) was then used for all the subsequent F-actin 
isolation from biopsy samples in cryosections including D292V, P332S, 
E205D, K336E and V163M. 
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3.2.2 Isolation of F-actin from Mouse Tissue in Larger 
Sections 
Since we were supplied with sufficient amount of D286G mouse tissue from 
Dr. Kristen Nowak, larger sections of muscle (approximately 150mg) were 
used to isolate F-actin following Spudich 's method (Spudich & Watt 1971). 
SDS-PAGE of actin isolated from EGFP-D286G (Kermit) actin showed that 
after polymerisation with KCI/MgCl2, most of the wild-type actin and all of the 
Kermit actin remained in the monomeric fraction (Figure 3.2). 
monomeric 
actin 
polymeric 
actin 
whole 1st wash pellet after ACEX highspeed highspeed 
homogenate s/n ACEX 
extract 
extract spin s/n 
4 
spin pellet 
F-actin 
6 
EGFP-
actin 
actin 
Figure 3.2 Isolation of F-actin from Kermit mouse tissue in 
larger sections 
There was no EGFP-mutant actin polymerised, and therefore no mutant F-
actin was yielded. Two concentrations of each sample were tested, with one 
concentration (right) being twice of the other (left). 
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In the next test. Kermit muscle tissue was homogenised and sedimented as 
before. On Western blots, about 50% of the mutant actin was in the 
supernatant, not the myofibrils. Addition of 150nM phalloidin at the 
polymerisation step (fraction 6 in Figure 3.3) indeed improved the proportion 
of polymerised Kermit F-actin. Probing a Western blot with 5C5 monoclonal 
mouse anti-actin (Sigma) revealed that 50% of the EGFP-mutant actin was 
lost when myofibrils sedimented and, when polymerising, there was only a 
very small proportion of EGFP-mutant actin present in Kermit F-actin (Figure 
3.3). By comparison with Coomassie Blue stained gel, 5C5 anti-actin was 
confirmed to specifically label all the actin that was present. 
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actin 
polymeric 
actin 
whole muscle 
homogenate 
1 St wash s/n pellet after 
ACEX extract 
ACEX extract high speed s/n 
+ phalloldin 
high speed 
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# - e # - w # -
EGFP-
actin 
actin 
wash in mal<e acetone polymerise with 
homogenise ^ low salt, powder, extract G- ^ KCI/MgCb and 
tissue buffer actin with ACEX sediment actin 
Figure 3.3: Isolation of EGFP'D286G actin from transgenic 
mouse tissue (Kermit) 
SDS-PAGE stained with Coomassie Blue (left) and Western blot (right) 
probed with anti-actin 5C5. 
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These experiments indicated that the EGFP-mutant actin was not 
incorporated properly into myofibrils and did not polymerise like wild-type G-
actin. To investigate if the difference was due to the D286 to G mutation or 
the presence of EGFP, 150mg Kermit, D1, D2 and NTG mouse tissue were 
isolated in parallel with the established method (full description in Methods 
2.3.2). Unlike Kermit, most of the D1 actin was in the myofibril fraction 
(Figure 3.4A). 
The extracted monomeric actin from the three mutant muscle samples and 
non-transgenic controls were polymerised by adding 25mM KCI, 20mM 
MgCb and 1mM Na2 ATP, pH7.4 from 10x polymerising buffer and incubating 
for 90 minutes at room temperature. Polymeric actin was then sedimented at 
high speed for 20 minutes at 4°C, both NTG and mutant actin produced a 
visible pellet of F-actin, which was resuspended in 200^1 ACEX. When 
polymerising monomeric actin without phalloidin, 30% of Kermit G-actin did 
not polymerise. In comparison, D1 was indistinguishable from NTG (7.9% 
and 8.3% respectively) (Figure 3.4B). Hence it seemed that the mutation did 
not affect filament formation but the EGFP addition did as previously found 
(Brault et al. 1999). In order to obtain as much co-polymerised wild-type and 
mutant actin as possible, I polymerised all actin with 150nM TRITC-phalloidin 
together with KCI/MgClain the subsequent preparation. Figure 3.5 shows full 
polymerisation was induced in Kermit actin in the presence of phalloidin. The 
yield of protein was about 2[ig/mg of tissue and equal quantities of F-actin 
were obtained from NTG and mutant sample D1. 
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Figure 3.4 Isolation of actin from Kermit and D1 from mouse 
muscle samples 
SDS-PAGE gel stained with Coonnassie Blue of (A) Whole homogenate and 
supernatant of the 1st myofibril wash. Proteins not incorporated into the 
myofibril fraction were in the supernatant fraction of low speed spin. (B) 
Polymerisation of G-actin with KCUMgCh- After high speed spin, F-actin was 
pelleted and supernatant contained G-actin. Kermit actin did not polymerise 
normally, whilst D1 mutant polymerised normally compared to NTG actin. 
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(A) 
EGFP-
actin 
actin 
Figure 3.5 Western blot of F-actin from Kermit polymerised 
with KCI/MgCl2 + TRITC-phalloidin 
(A) Supernatant (B) Pellet (F-actin). Phalloidin was required for Kermit actin 
to polymerise. 4% of the F-actin was EGFP-tagged mutant actin. 
3.3 Expression Level of Mutant Actin 
The Western blot showed there was only 4% mutant actin present in Kermit 
F-actin (Figure 3.5B). 2D electrophoresis of whole tissue (run by Biljana 
Ilkovski, Sydney.) revealed D1 mouse expressed mutant actin at 30% of total 
actin, whilst D2 mouse expressed a very small amount of the mutant actin in 
the whole homogenate (Figure 3.6A). I also investigated the expression level 
of the mutant actin in the F-actin that I isolated from D1 mouse using 2D 
electrophoresis, and 42% of the total actin is demonstrated to be the D286G 
mutant actin in Figure 3.68. 
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Figure 3.6 2D electrophresis of NTG and D286G mutant actins 
based on the charge change from negatively charged D to 
non-charged G 
(A) Whole homogenate (run by Biljana llkovski, Sydney) (B) F-actin. In the 
whole homogenate, D286G mutant actin constituted 30% of total actin in D1, 
and 10% In D2 mouse tissue. Whilst in D1 F-actin, D286G mutant actin i/i/as 
expressed at 42% of total actin. 
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3.4 In Vitro Motility Studies of D286G Actin 
Actin is a multi-functional protein; mutations in actin may affect any of its 
functions. In vitro motility assay was applied to functionaly characterise 
polymerised mutant actins. Various experiments were carried out to study 
different properties of the mutation and will be discussed in the following 
sections. 
All the actins were labelled with TRITC-phalloidin as strongly as we had 
seen with rabbit skeletal actin. The length distribution and density of 
filaments was similar for NTG and mutant actin (Figure 3.7) and shorter than 
rabbit actin. 
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Figure 3.7: Length distribution ofD286G and NTG actin 
The mean length of NTG, D1 and D2 actin filaments was 3.1+0.4, 2.5±0.2, 
and 2.4±0.2^m respectively. 
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3.4.1 Stability of D286G Actin 
During initial experiments, stability of proteins became a significant issue. 
As the actin filaments or HMM motor protein I used got older, I noticed that 
Kermit actin began to move slower, but the NTG did not change so that the 
difference between mutant and NTG actin diminished, eventually 
disappearing after 5 days, suggesting a progressive deterioration in 
performance relative to NTG (Figure 3.8). Therefore all experiments were 
done within 3 days of the start of the preparation of actin and HMM. 
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Figure 3.8: Effect of the age of actin and HIVIM on the sliding 
speed of Kermit actin relative to that of NTG (Sk/Sn). 
(A) Actin (B) HMM. Sliding speed was assayed over a period often days. 
The ratio of sliding speed for NTG and Kermit actin w/as plotted. 
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3.4.2 Sliding Speed of D286G Actins at 28° C 
Studies were done on several preparations at 28°C. All three mutant actins 
(Kermit, D1 and D2) had a consistent higher sliding speed than NTG actin (3-
4^m/sec). Results are summarised in Table 3.1. Rather surprisingly, Kermit 
seemed to move quite fast even with only 4% mutant as measured by 
Western blotting (Figure 3.5). D1, which had 42% mutant moved faster than 
D2, which had less mutant relative to NTG, correlating with results from 2D 
electrophoresis. The average % increase in sliding speed of Kermit, D1 and 
D2 compared to NTG actin was 12.5+4.0%, 10.0±2.6%, and 2.5+2.5% 
respectively, the difference between Kermit, D1 and NTG actins was 
significant (Table 3.1). The percentage motility of filaments was the same for 
NTG and the three mutants. It gave evidence that the presence of EGFP in 
Kermit actin did not affect the motility of the mutant F-actin. Because of the 
variations among different preparations of the proteins as well as motility flow 
cells, the increase in sliding speed of D286G actins compared to NTG actin 
was not significant when doing unpaired t test. On the basis of this, all the 
subsequent analysis was based on paired t test. 
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(A) Motility of Kermit Actin 
• I 
1 2.29±0.05 3.07+0.27 33 8 70.7±5.8 84.0+1.5 13.3 
2 3.15+0.02 3.99±0.50 26.7 71.0±1.6 80.5±6.0 9.5 
3 2.95±0.23 2.99±0.98 1.3 73.3±6.4 94.3±1.3 21.0 
2.10±0.19 2.31±0.50 10.0 70.3±2,6 63.5+5.3 -6.8 
2.56±0.48 2.81±0.16 9.8 73.4+4.0 74.6±1.7 1.2 
4 3.22±0,14 3.48±0.29 8.1 92.0+1.6 86.0±3.9 -6.0 
3.43+0.19 3.22±0.26 -6.1 86.8±2.0 78.0±3.9 -8.8 
5 2.18±0.06 2.49±0.03 14.2 73.5±2.9 94.5±1.2 21^ 
2.43±0.06 2.78±0.06 14.4 81.8+2.3 84.5±1.9 2.7 
Average 2.70±0.16 3.02±0.17 12.5+4.0 77.0+2.6 82.2+3.2 5.2+3.9 
TTest paired =0,02074 paired =0.2119 
P Value unpaired =0.2031 unpaired =0.2275 
(B) Motility of D1 Actin 
1 2.91±0.13 3.24±0.13 11.3 85.5±1.3 79.8±4.0 -5.7 
3.22±0.35 3.27±0.16 1.6 84.3±3.4 78.5±3.0 -5.8 
2 3.53+0.26 3.61±0.22 2.3 77.0±3.1 88.7+5.0 11.7 
3.27+0.17 3.74+0.07 14.4 82.3±6.8 95.0±3.7 12 7 
3.02+0.31 3.88±0.17 28 5 93.7+4.5 98.8±1.3 5.1 
3 3.41±0.17 3.79+0.16 11.1 93.3±2.8 95.3+3.9 2.0 
3.18+0.19 3.95±0.18 24.2 86.8±5.9 89.8+6.4 3.0 
3.23+0.13 3.51+0.08 8.7 91.3+2.3 93.7±2.3 2,4 
3.64+0.30 4.27±0.10 17.3 89.0±5.2 96.8±1.9 7.8 
4 1.43±0.04 1.65±0.05 15.4 73.3+4.3 78.3±2.1 5,0 
1.72±0.09 1.58±0.03 -8.1 77.0±1.5 73.8±4,1 -3.2 
1.98+0.03 2.10±0.03 12.2 71.8±2.3 84.3±1.4 12.5 
2.23+0.08 2.28+0.11 2.2 76.5±3.6 77.0±3,2 0.5 
1.68+0.02 1.73±0.06 3.0 79.0+2.3 78.8+2.1 -0,2 
5 2.80+0.18 2.69±0.16 -&9 90.3±1.2 86.3+4.1 -4,0 
Average 2.75+0.19 3.02±0.23 10.0±2.6 83.4+1.9 86.3±2,1 2.9±1.6 
TTest paired =0.004143 paired =0.09268 
P Value unpaired =0.3873 unpaired = =0.3156 
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(C) Motility of D2 Actin 
1 3.14+0.18 3.04+0.17 -3 3 89.8±2.6 84.3+6.2 -5.5 
3.59+0.50 3.44±0.27 -4.2 96.8±3.4 90.0+4.2 -6.8 
4.50+0.12 4.83+0.06 7,3 91.8+4.1 95.5±3.2 3.7 
4.28+0.01 4.45±0.03 4.0 97.0±0.8 96.3+1.7 -0.7 
2 3.51+0.10 3.51+0.16 0 94.0+0.4 93.3±2.2 -0.7 
2.91+0.24 3,23+0.18 10.9 87.8±4.8 90.5±1.7 2.7 
Average 3.66+0.25 3,75+0.29 2,5±2.5 92.9±1.5 91.7+1.8 -1.2+1.7 
T Test paired =0.3163 paired = 0.5128 
P Value unpaired =0.8119 unpaired = 0.6176 
Table 3.1: D286G mutation caused an increased filament 
sliding speed 
(A) Kermit (B) D1 (C) D2. Measurements were done over several protein 
preparations in paired cells with non-transgenic control. 
3.4.3 Temperature-Dependency 
The motility of Kermit and D1 was compared to that of NTG at three 
different temperatures (20°C, 28°C and 35°C). The percentage motility was 
similar between mutants and NTG at all temperatures. D1 had a higher 
sliding speed than NTG at all three temperatures whilst Kermit had an 
increased sliding speed at 28°C and 35°C (Figure 3.9). The difference in 
sliding speed between mutants and NTG at 28°C was statistically significant. 
Although the difference remained at 20°C and 35°C, t tests were not possible 
because the number of data was small. 
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Figure 3.9: Comparison of the effect of temperature on 
filament sliding speed for mutant D286G (Kermit and D1) and 
NTG actin 
D1 actin moved consistently faster than NTG actin at all temperatures we 
tested whilst Kermit had an Increased sliding speed at higher temperatures. 
The average sliding speed for NTG, Kermit and D1 actin at 20 °C was 
2.18±0.09, 2.15±0.15 and 2.34±0.07^im/sec: at 28°C was 2.88+0.16, 
3.02±0.17 and 3.14±0.24^m/sec; at 35°C was 4.23±0.43, 4.61 ±0.36 and 
5.18±0.22 jiim/sec respectively. 
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3.4.4 Regulation with Tropomyosin (Tm), Troponin 
(Tn) and Ca^^ 
I investigated tropomyosin, tropomyosin-troponin regulation and 
sensitivity of D286G actin (D1). Tropomyosin increased sliding speed of NTG 
(5.7%) and D1 (18.8%), skeletal tropomyosin tended to decrease percentage 
motility, there was no significant difference between NTG and D1 (Table 3.2). 
Addition of skeletal tropomyosin-troponin lowered filament sliding speed and 
percentage motility slightly at high Ca "^" concentration (pCa5); whilst at low 
Ca^^ concentration (pCa9), both sliding speed and percentage motility of 
actin filament were greatly reduced. Despite the slightly higher motility of 
reconstituted thin filaments containing D286G actin, it showed little difference 
in thin filament regulation and Ca^'^-sensitivity (Table 3.3) compared to that 
containing NTG actin. The effect of tropomyosin and tropomyosin-troponin is 
summarised in Figure 3.10. 
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(A) Filament Sliding Speed 
1 3.23±0.13 3.51±0.08 3.90+0.06 5.12+0.20 
2 1.43±0.04 
1.68+0.02 
1.65+0.05 
1.73±0.06 
* 1.47±0.08 
** 1.70±0.10 
***1.93±0.04 
** 1.90±0.03 
2.13±0.11 
2.12±0.07 
2.01±0.08 
1.92±0.11 
3 2.80±0.18 2.69±0.16 *2.92±0.04 
**3.09±0.09 
3.23±0.16 
3.43+0.14 
Average 2.29+0.43 2.40±0.44 2.42±0.34 2.85±0.44 
T test 
P value 
paired =0.3001 
unpaired =0.8646 
paired =0.02964 
unpaired =0.45 
(B) Filament Percentage Motility 
1 91.3±2.3 93.7±2.3 93.3+3.5 95.3+1.0 
2 73.3+4.3 78.3±2.1 * 53.5+4.9 75.8+3.8 
** 60.3±4.1 78.0+3.9 
***57.8±2.2 54.8+5.0 
79.0±2.3 78.8+2.1 ** 70.0+2.7 67.3+1.9 
3 90.3+1.2 86.3±4.1 * 87.3±2.8 87.0+3.9 
**84.0+3.0 89.8+2.3 
Average 83.5±4.4 84.3±3.6 72.3+6.0 78.3+5.3 
T test paired =0.7049 paired =0.1 679 
P value unpaired =0.893 1 unpaired =0.4701 | 
Prep 1: with 60nM cardiac tropomyosin 
Prep 2 & 3: * with SnM skeletal tropomyosin 
** with 10nM skeletal tropomyosin 
*** with 30nM skeletal tropomyosin 
Table 3.2: Effect of tropomyosin on motility ofD286G and 
NTG actin 
(A) Filament sliding speed (B) Filament percentage motility. D286G and NTG 
actin showed no significant difference due to tropomyosin. 
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(A) Filament Sliding Speed 
1 3.90±0.06 5.12±0.20 3.63±0.15 3.78+0.12 1.53+0.16 1.54±0.01 
2 1.70±0.10 
1.90+0.03 
2.12+0.07 
1.92+0.11 
2.31+0.07 
2.10+0.06 
2.16+0.02 
2.21+0.06 
1.77+0.11 
1.25+0.16 
1.65+0.11 
1.45±0.16 
3 3.09+0.09 3.43+0.14 2.92+0.10 
2.56+0.04 
2.99±0.08 
2.79+0.02 
2.72+0.21 
2.52±0.25 
3.25±0.06 
1.96±0.05 
Average 2.65+0.52 3.15±0.74 2.70±0.27 2.79±0.30 1.96±0.28 1.97±0.33 
T test 
P value 
paired =0.1448 
unpaired =0.5992 
paired =0.2667 
unpaired =0.8426 
paired =0.9501 
unpaired =0.9787 
(B) Filament Percentage Motilitv 
1 93.3+3.5 95.3±1.0 91.8±2.2 92.5+1.5 1.3+0.5 2.0+1.0 
2 60.3+4.1 
70.0±2.7 
78.0±3.9 
67.3±1.9 
64.5±3.2 
70.3±1.7 
72.8±1.6 
74.3±3,0 
42.3±6.8 
32.3+4.0 
45.0±8.3 
33.5+1.9 
3 84.0+3.0 89.8+2.3 65.3+5.4 
49.8+3.1 
58.9+6.5 
63.5±2.3 
15.8+0.6 
14,0±4.9 
34.0±1.8 
5.8+0.5 
Average 76.9±7.3 82.6±6.2 68.3+6.8 72.4+5.8 21.1+8.5 24.1+8.5 
Ttest 
P value 
paired =0.2824 
unpaired =0.5752 
paired =0.2988 
unpaired =0.6611 
paired =0.5319 
unpaired =0.8002 
Prep 1: with 60nM cardiac tropomyosin + 60nM cardiac troponin 
Prep 2 & 3; with 10nM skeletal tropomyosin + 10nM skeletal troponin 
Table 3.3: Effect of tropomyosin-troponin and Ca^* on motility 
of D286G and NTG actin 
(A) Filament sliding speed (B) Filament percentage motility. There u/as little 
difference in thin filament regulation and Ca^''-sensitivity between D286G and 
NTG actin. 
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(A) Filament Sliding Speed 
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CO 
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Figure 3.10: D286G mutation did not alter thin filament 
regulation. 
Average values in Table 3.2 and 3.3 were used to plot the effect of 
tropomyosin and tropomyosin-troponin on (A) sliding speed (B) percentage 
motility of D1 and NTG actin. 
3.4.5 Force Assay 
I determined the relative force of the interaction between actin and myosin 
by imposing an internal load using an immobilised actin binding protein, f -
actinin. The drag due to j-actinin cross-linking to the thin filaments reduced 
thin filament motility. The more force produced by actin-myosin interaction, 
the more t-actinin needed to stop the movement. Figure 3.11 illustrates the 
results from three experiments. 
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(A) 
100 
(B) 
o 60 
0 0.2 0.4 0.6 0.8 1 
[alpha-actinin] (jug/ml) 
0 0.2 0.4 0.6 0.8 1 
[alpha-actinin] (^g/ml) 
(C) 
100 
0 0.2 0.4 0.6 0.8 1 
[alpha-actinin] (/vg/ml) 
NTG 
D1 
Figure 3.11: Comparison of actin-myosin force generated by 
D286G and NTG actin 
This assay of force assumes affinity for (p-actinin does not change. Three 
experiments were performed, and D1 actin generated increased actin-myosin 
force in two of the three experiments (A&B), whereas in experiment C, D1 
and NTG actin generated comparable actin-myosin force. 
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In experiment A & B, D286G mutant appeared to generate greater actin-
myosin force than NTG actin, whereas in experiments C there was no 
apparent difference in the relative force between D286G and NTG actin. As 
the curve of both D286G and NTG actin never reaches 0, only the initial (0-
0.1[ig/ml) linear phase can be compared. In previous studies the plot 
extrapolated to zero motility at different f-actinin concentrations, e.g. actin 
and actin-tropomyosin differed by a factor of 2 (Bing et al. 2000), as 
observed in A & B. in contrast, the starting percentage motility in C was low 
(60%) and it remained at 25% with increasing concentration of f-actinin (0.1-
1<g/ml), in other words, there was only a small change in filament 
percentage motility, thus this experiment was unsatisfactory. If experiment C 
was excluded this basis, the mutation increased force. 
3.4.6 Actin Binding Competit ion Assay for t -Actinin 
The actin binding competition assay that I developed (see Methods 2.10) 
was applied to study the relative affinity of D286G actin for immobilised j -
actinin. In each paired cell, since actin was in great excess over f-actinin, 
TRITC-phalloidin labelled mouse actin (D286G or NTG) competed with 
unlabelled rabbit skeletal actin for binding to |-actinin at a constant total actin 
concentration. 0, 20%, 40%, 60%, 80% and 100% of unlabelled actin in the 
mixture with labelled mouse actin were examined. Data from two 
experiments is plotted in Figure 3.12 and 3.13. 
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(A) 
1200 
(C) 
NTG 
D1 
^ 800 
if 400 
2 0 0 -
120 
100 
0) 
3 C 
C 0) 
LL 
0 0.2 0.4 0.6 0.8 1 
Fraction of unlabelied actin 
(B) 
0 0.2 0.4 0.6 0.( 
Fraction of unlabelled actin 
(D) 
0 0.2 0.4 0.6 0.8 1 
Fraction of labelled actin 
0 0.2 0.4 0.6 0.8 
Fraction of labelled actin 
Figure 3.12: D286G mutant and NTG actin bound to (p-actinin 
with equal affinity 
(A) The actual numbers of labelled actin filaments were plotted. (B) The 
numbers for both mutant and NTG actin filaments were normalised to start at 
100, the remaining numbers were then plotted as a ratio to this number (C) 
Filament number as a ratio to 1 was plotted against fraction of labelled actin. 
(D) Data in (C) was fitted to the (p-actinin binding equation to produce K for 
each actin. 
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The amount of labelled relative to unlabelled actin filaments that bind to f -
actinin depends on the relative affinity of the two species, defined by the 
equation: 
y = filament number 
y = F.K / (FK + (1-F)) F = fraction of labelled actin filaments 
K = ratio of binding constant 
Figure 3.12 (A-D) explains how the experimental raw data was fitted to this 
t-actinin binding equation producing K for each actin. D286G actin had K of 
0.87+0.23, which was virtually equal to that of NTG actin (0.86+0.31). 
Labelled skeletal rabbit actin has a binding constant of 1. Both mutant and 
NTG actin fell below this value, indicating their binding affinity for j-actinin 
was slightly lower than rabbit actin. There were increases in filament number 
of both actins, which was theoretically impossible, likely a result of variations 
across motility cells as those points had generally higher standard error than 
others. 
Results from the 2nd experiment are illustrated in Figure 3.13. The starting 
filament number of the two actins was vastly different, and for D286G actin, 
the filament number remained unchanged when varying fraction of unlabelled 
actin (0-0.6), suggesting something abnormal about the mutant actin in this 
experiment that could invalidate the result. The K value for D286G and NTG 
actin was 4.42±1.85 and 0.25+0.05 respectively. The mutant bound to \ -
actinin with a 17-fold higher affinity than NTG actin, but the quality of the 
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mutant actin and therefore the accuracy of this data had to be taken into 
account. 
(A) 
600 
500 
(D 
.N 
E 3 
C 
C 
<D 
E 
CO 
400 -
= 200 
300 -
100'^ 
0.2 0.4 0.6 0.8 1 
Fraction of unlabeiled actin 
(B) 
(D 
n 
E 3 
C C 
(1) 
E 
(0 
0 0.2 0.4 0.6 0.( 
Fraction of labelled actin 
Figure 3.13: Comparison of relative affinity of D286G and 
NTG actin for ^-actinin 
(A) The actual numbers of labelled actin filaments were plotted. (B) Data n/as 
fitted to the (p-actinin binding equation to produce K for each actin. In this 
experiment, the mutant actin had a 17-fold higher ^-actinin binding affinity 
than NTG actin. 
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3.5 Discussion 
3.5.1 Establishment of Method for Isolating Actin from 
Cryosections 
Since D286G was the first actin mutaiton that I studied, the early stage of 
my research focussed on the establishment of method for isolating actin. 
When adapting method of Razzaq etal. (1999) to isolate actin from 3mg 
cryosectioned Kermit and NTG mouse tissue, the purified and TRITC-
phalloidin labelled F-actins although both were fully functional in motility 
assay, the yield was low. In addition, both Kermit and NTG actin had lower 
brightness and poorer contrast compared to standard rabbit actin. Such 
differences were more likely to be caused by the species and the small 
sample size rather than the mutation as NTG actin showed the same feature 
as Kermit actin. 
The addition of 150nM TRITC-phalloidin to monomeric actin with 
polymerising buffer induced full polymerisation to occur, therefore maximum 
quantity of F-actin was obtained. Moreover, double the amount of F-actin 
was labelled with TRITC-phalloidin. As a result, in motility assay both Kermit 
and NTG actin were bright with good contrast, which was desirable for 
automatic tracking and analysis. This modified method was then used for 
isolating actin from cryosectioned biopsy samples in all the subsequent 
experiments including those mutant actins that are discussed in chapter 4 
and 5. 
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3.5.2 Characterisation of EGFP-D286G (Kermit) Actin 
Before obtaining the unmodified D286G actins (D1 and D2), we were 
supplied with sufficient leg muscle of a transgenic mouse line Kermit whose 
native mutant actin sequence was tagged green fluorescent EGFP (28KDa) 
at the C terminus. The EGFP tag enabled the mutant actin to be detected on 
the SDS-PAGE gel and Western blots. It was shown by Western blotting that 
approximately half of the mutant actin was in the supernatant of the 
myofibrial wash. In the absence of phalloidin, 30% of the Kermit actin did not 
polymerise but it could be polymerised with additional phalloidin. When I 
examined Kermit actin in in vitro motility assay, it appeared unstable. Its 
sliding speed decreased as it got older, with the sliding speed of NTG actin 
unchanging, the difference between Kermit and NTG actins in sliding speed 
disappeared. These characteristics were not encountered with NTG, D1 or 
D2 actin, suggesting that rather than the mutation itself, the EGFP tag at the 
C terminus destablised actin as Brault etai. (1999) found. Brault 's group 
tested the impact of epitope tagging at C and N terminus of actin on the 
structure and function of indirect flight muscle-specific Act88F actin in 
transformed Drosophila. Their work indicated that certain modifications of 
actin C terminus possibly led to inability of actin to fold properly and/or to 
assemble into thin filaments. Fresh Kermit actin had a consistently higher 
sliding speed at 12.5% than NTG actin, this value was very similar to that of 
D1 (10.0%). EGFP did not seem to affect the motility of the mutant actin. 
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Histological studies were carried out by Dr. Kristen Nowak and Professor 
Caroline Sewry. Nemaline rods were seen in Kermit mouse (Figure 3.14), but 
so far there has been no evidence that they are formed in D1 mouse. The 
suspicion that the presence of nemaline rods and the other properties of 
Kermit are related to EGFP rather than the disease-causing D286G mutation 
remains. 
(A) (B) 
Figure 3.14: EM micrographs showing histology of Kermit 
transgenic mouse muscle 
Nemaline rods were clearly present in fibres from Kermit quadriceps 
muscle. These are the really dark "blobs" seen in (A) and look just like what 
was seen in the human patients. There were also a number of ring 
fibres which are fibres going longitudinal and some of them transverse. In the 
top left hand corner of (B) there is a ring of myofibrils running lenthwise 
around the edge of the fibre, whereas above these myofibrils they are 
coming out of the page and appear cross-sectional. On the very edge of this 
fibre (at the bottom) it gets darker - these are tubular aggregates that can be 
prevalent in NTG mice of certain background strains (especially in males). 
Kindly provided by Dr. Kristen Nowak. 
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3.5.3 Characterisation of Native D286G Actin (D1) 
Although D286 has been hypothesised to be involved in intermolecular 
interactions, native D286G actins (D1 and D2) showed no effect on isolation 
or extent of polymerisation. This is consistent with the observation of Costa 
et al. (2004) that, despite the abnormal incorporation into stress fibres or the 
formation of aggregates in the cytoplasm and the nucleus, polymerised 
D286G mutant actin behaved roughly like wild-type actin in all the in vitro 
assays they carried out. When I compared the motility of D1 and NTG actin 
one week after the initial experiment, unlike Kermit, the motility of D1 actin 
was stable, nevertheless all experiments were done with fresh actin within 3 
days of preparation. The average sliding speed of D1 at 28°C was 
10.0±2.6% higher than NTG actin. The difference was statistically significant 
(p=0.004) and still existed with tropomyosin present (17.8%) and with 
tropomyosin-troponin at high calcium concentration (3.3%). The mutation did 
not seem to alter the switch-off of the thin filaments at pCa9, and did not 
have any effect on the binding affinity for f-actinin. It might generate greater 
actin-myosin force than NTG actin. In the only previous research in our 
laboratory on a mild nemaline myopathy mutation Met132Val, it was found 
that the mutation impaired polymerisation and produced faster sliding thin 
filaments at activating Ca^*, but not with pure F-actin (Marston et al. 2004). 
Plenty of histology has been done on Kermit mice, but has not been carried 
out to a similar extent on D1 mice. Nemaline rods have not been seen in D1 
mice. Running wheel, strength grip, rotarod and locomotor tests were 
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performed on D1 mice by Integrated Neurosciences Facility in Melbourne, 
Australia, and no obvious phenotypic-functional difference has been 
observed in the whole mice. Isolated fibres from D1 mice showing a drop in 
maximun force performed by Gina Ravenscroft, University of Western 
Australia. On the other hand, this mutation might affect something that we did 
not measure. 
3.5.4 Conclusion 
I established the actin isolation techniques using minimal amounts of 
muscle, pure functional F-actin was obtained from biopsy-sized samples. 
This is particularly useful in my study of all the other actin mutations. It has 
been demonstrated that EGFP-actin is unstable both as monomer and as 
polymer. The expression level of mutant actin in D1 actin was detectable with 
2D electrophoresis. G286 mutant actin was expressed at 42% of the total F-
actin I isolated. D286G actin only and actin in constituted thin filaments had a 
consistently increased sliding speed than NTG actin. It generated similar 
relative force and binding affinity for f-actinin compared to NTG actin. 
Overall, D286G mutation did not appear to have any deleterious effects in 
muscle physiology and histology. What we want to ask now is why this 
mutation should cause severe myopathy? The most likely answer is that the 
D1 transgenic mouse did not recapitulate human disease as indicated by the 
lack of nemaline rods, another possibility is that the mutation affected actin 
functions in the range we did not determine, 
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Congenital Fibre Type Disproportion 
Mutations (D292V, P332S and E205D) 
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4.1 introduction 
ACTA1 encoding skeletal actin mutations have been associated with a 
variety of muscle disease, one of the most recently discovered 
histopathological pattern is congenital fibre type disproportion (CFTD). CFTD 
is a rare form of congenital myopathy in which the main pathological 
abnormality is that type 1 (slow-twitch) muscle fibres are uniformly smaller 
than type 2 (fast-twitch) muscle fibres and there are no nemaline rods. We 
were supplied with biopsies from three CFTD patients carrying novel 
heterozygous missense mutations in ACTA1: D292V, P332S from Dr. Nigel 
Clarke, University of Sydney, and E205D from Professor Caroline Sewry, 
Hammersmith Hospital, London. 
4.2 D292V 
4.2.1 Phenotype 
The male patient with D292V mutation was born in a family with no history 
of muscle weakness. He required nocturnal ventilation soon after birth. At 
age of 3, continuous ventilation was needed. He showed marked hypotonia 
and proximal weakness. He was unable to roll, sit, or flex his head or hips 
against gravity. There were no deep tendon reflexes present. Weakness of 
face, jaw muscles and tongue was observed. The electron microscopy (EM) 
revealed no abnormal protein aggregates or sarcomeric structures. The 
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patient died from respiratory complications at age of 3.5 years (Laing et al. 
2004). 
4.2.2 Histology 
We were provided with patient biopsies taken at age of 1 month from the 
tibialis anterior and triceps muscle and at age of 3.2 years from the 
quadriceps and deltoid muscles. Histochemical studies on these samples 
(Figure 4.1 A & B) showed that type 1 fibres were uniformly small and 
interspersed between large type 2 fibres with no other abnormalities on 
standard histochemical stains. Electron microscopy (EM) in biopsies taken at 
age of 3.2 years revealed loss of a few sarcomeres in some fibres, mainly in 
small (type 1) fibres. There were no rods orZ-line abnormalities (Laing et al. 
2004). 
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C 
Figure 4.1: IVIuscle biopsies from CFTD patients stained with 
ATPase (pH 4.3). 
Type 1 (slow-twitch) fibers are black, type 2A and 2B (fast-twitch) fibers are 
pale, type 2C fibers are intermediate. (A) Tibialis anterior muscle from patient 
with D292V at age of 1 month. (B) Quadriceps muscle from patient with 
D292V at age of 3.2 years, counterstained with hematoxylin. Type 1 fibers 
appear intermediate because of fading. (C) Patient with L221P (D) Patient 
with P332S. In biopsies from all three patients, type 1 fibres were uniformly 
smaller than type 2 fibres and there were no other abnormalities such as 
nemaline rods. Adapted from (Laing et al. 2004). 
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4.2.3 Loca t i on of D292V 
D292 (shown in Figure 4.2) is located on the surface of actin and is 
exposed in the actin polymer. 
(A) High Ca^* state (B) Low state 
Figure 4.2: Location of D292 and P332 in actin polymer 
D292 (white sphere) and P332 (brown sphere) both lie on the surface of actin 
and are close to tropomyosin (yellow) in both high and low states. 
Produced with MacPyMOL software Actin_Model.pdb file. 
D292 is also close to the long axis actin-actin interface and so may affect 
filament stability. The charge neutralisation due to D to G mutation likely has 
effects on regulation since D292 is in proximity of tropomyosin in both high 
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(Figure 4.2A) and low (Figure 4.2B) Ca^^ states. As its position relative to 
tropomyosin is reversed in the two states, this mutation has the potential to 
affect the transition between actin activity states. 
4.2.4 Isolation of F-Actin from A Patient Biopsy 
Extraction of F-actin from a D292V patient biopsy taken at age of 1 month 
and age-matched control human muscle sample was compared (Figure 4.3). 
Phalloidin induced full polymerisation in both actins. We saw no difference 
between the mutant and control actins in the amount of F-actin obtained. 
Ist unpoly standard 
, AC EX extract hs spin gcOn s/n F-actin actin 
homogenate pellet s/n p s/n _ +pha ' +Pha 0.02 0.05|j,g 
whole 
homogenise 
whole I 
muscle 
wash 6x 
-J\ in low [ 
salt buffer 
make acetone 
-N powder, extract 
G-actin with 
ACEX buffer 
polymerise with 
^ KCI/MgCl2 and 
sediment 
F-actin 
D292V 
Control 
Figure 4.3 Isolation of D292V F-actin from a patient biopsy 
Extraction of D292V actin and age-matched human control actin was 
compared in Western blots. There was no consistent difference between the 
mutant and control actins in the amount of F-actin obtained. 
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4.2.5 Exp ress i on Level o f Mutan t A c t i n 
The expression level of D292V actin in the biopsy sample was investigated 
using 2D electrophoresis. The mutant actin was found to be expressed at 
44% in whole homogenate and 40% in the isolated F-actin (Figure 4.4). 
WT D292V 
Homogenate 
44% 
F-actin 
40% 
Figure 4.4 2D electrophoresis on whole muscle and isolated 
F-actin from a CFTD patient with D292V actin mutation 
probed with 5C5 anti-actin antibody 
The predicted mutant actin was identified by its higher pi. 
4.2.6 In Vitro Mot i l i ty S tud ies of D292V A c t i n 
In vitro motility assay was performed on D292V actin isolated from biopsy 
samples taken at age of 1 month and 3 years. Each actin was compared with 
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an age-matched control human muscle sample. Actin fully polymerised in the 
presence of phalloidin was used in our experiments. The density and length 
distribution of the mutant actin filaments was similar to that of control actin. 
Motility study of D292V actin and reconstituted thin filament was carried out 
at 35°C instead of 28°C because of a low sliding speed of mutant and control 
actins at 28°C. At 35°C, D292V actin filaments had a 11.3% lower sliding 
speed than control actin, and this difference was highly significant in the 
paired t test. The percentage motility of actin filaments was similar for mutant 
and control actins (Table 4.1). Same results were obtained for actin extracted 
from biopsies taken at both age of 1 month (prep1&2) and 3 years (prep3&4). 
1 3.36±0.06 2.55+0.16 -24.1 50.3±16 47.8±5.8 -2.5 
2 3.32±0.18 
2.91±0.07 
3.28+0.05 
3.53±0.10 
3.47±0.18 
3.86±0.10 
2.52+0.05 
3.23±0.08 
3.27±0.05 
3.03+0.15 
3.33±0.04 
3.88±0.04 
-24.1 
10.8 
-0.3 
-14.2 
-4.0 
0.5 
84.4±5.6 
81.3±5.1 
84.2+3.9 
69.3±1.3 
78.0±8.0 
95.5±3.5 
72.5±7.0 
84.4±4.2 
82.5±5.9 
88.3±8.1 
94.6+2.5 
93.3±3.8 
-11.9 
3.1 
-1.7 
19.0 
16.6 
-2 2 
3 2.88±0.15 
3.59±0.12 
3.45±0.08 
4.54±0.16 
4.41±0.15 
2.47±0.15 
2.98±0.14 
2.97±0.32 
4.28±0.15 
3.71±0.08 
-14.2 
-17.0 
-13.9 
-5.7 
-15.9 
77.8±4.2 
88.8±4.8 
80.5±0.3 
85.5±2.6 
92.8+3.6 
72.3±4.5 
83.3±4.5 
95.0±3.5 
84.0±4.2 
86,3+4.2 
-5.5 
-5.5 
14.5 
-1.5 
-6.5 
4 4.64±0.11 
4.82±0.12 
4.79+0.21 
4.0±0.05 
4.28+0.14 
3.92±0.07 
- 1 & 8 
-11.2 
-18.2 
88.0±0.9 
90.0+3.5 
86.5±3.0 
88.8+1.8 
87.3+2.0 
80,5±3.9 
0.8 
-2.7 
-6.0 
Average 3.79±0.17 3.36±0.16 -11.0+2.5 82.2±2.8 82.7±3.0 0.5+2.3 
T Test 
P Value 
Paired =0.000301 
Unpaired =0.08036 
Paired = 
Unpaired = 
0.8235 
0.899 
Table 4.1: D292V mutation decreased filament sliding speed 
at 35°C 
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The low percentage motility of actins in Prep 1 (also the first set of data in 
Table 4.2) could be a consequence of unclean motility cells as the only 
difference between Prep 1 and the others was that the motility cells used for 
actins from the other preparations were kept in a desiccator cabinet. 
4.2.7 Tempera tu re -Dependency 
The lower sliding speed of D292V actin was observed at all the 
temperatures tested (20°C, 25°C, 28°C, 30°C and 35°C) as plotted in Figure 
4.5. There was no consistent difference seen in the percentage motility 
between mutant and control actin (Table 4.2). 
20 1.47+0.03 
1.39+0.03 
1.27±0.07 
1.43±0.03 
-13.6 
2.9 
32.8+10 
53.0+10 
7.8±2.0 
56.0±4.7 
-25.0 
3.0 
25 2.06±0.02 
1.84+0.04 
1.70±0.06 
1.75±0.03 
-17.5 
-4.9 
55.8±8.4 
87.0+3.6 
48.0+4.2 
73.0±3.0 
-7.8 
-14.0 
28 2.31±0.03 
1.90+0.07 
2.04±0.08 
1.98±0.02 
-11.7 
4.2 
69.5±7.1 
64.5+3.9 
69.2±5.0 
71.3±3.1 
-0.3 
6.8 
30 2.42±0.06 
2.29±0.18 
2.02+0.11 
2.21+0.02 
-16.5 
-3.5 
53.3±5.5 
73.0+7.4 
39.0±9.1 
69.5±6.0 
-14.3 
-3.5 
35 3.36±0.06 
3.32±0.18 
2.55±0.16 
2.52+0.05 
-24.1 
-24.1 
50.3+17 
84.4±5.6 
47.8±5.8 
72.5±7.0 
-2.5 
-11.9 
Table 4.2: Motility of D292V actin at different temperatures 
The sliding speed of D292V was lower than that of control actin at all five 
temperatures, whilst the percentage motility of D292V and control actins was 
very similar 
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Figure 4.5: Comparison of the effect of temperature on 
filament sliding speed for D292V and control actin 
D292V actin moved consistently slower than control actin at all the 
temperatures I tested. Lines are the means of two experiments. 
4.2.8 Ef fect of T r o p o m y o s i n on A c t i n Mot i l i ty 
When tropomyosin was added to D292V actin, motility was remarkably 
reduced (Table 4.3). A range of tropomyosin concentrations (5-30nM) was 
titrated, both the sliding speed and percentage motility of the mutant actin 
was notably decreased compared to that of control actin. Results from two 
experiments are plotted in Figure 4.6. 
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(A) Filament Sliding Speed 
1 3.28+0.05 3.27+0.04 2.30±0.10 1.45+0.08 
2 4.54+0.16 
2.88+0.15 
4.28+0.15 
2.47+0.15 
*M.44±0.13 
* 4.56±0.17 
** 4.54±0.29 
***4.16±0.13 
1.53±0.02 
2.73±0.64 
1.77±0.47 
1.82±0.29 
3 3.64+0.11 4.00+0.05 * 4.30±0.15 
**4.76±0.20 
***4.46±0.14 
1.47±0.03 
1.40±0.33 
1.56+0 
Average 3.59+0.35 3.51+0.41 4.19+0.28 1.72±0.15 
T test 
P value 
paired =0.667 
unpaired =0.8867 
paired <0.0001 
unpaired <0.0001 
(B) Filament Percentage Motility 
1 84.2±3.9 82.5±5.9 48.8±8.7 8.3+3.3 
2 85.5±2.6 
77.8±4.2 
84.0±4.2 
72.3±4.5 
** 90.3±6.2 
* 96.3±2.2 
** 85.0±3.5 
*** 92.8+3.4 
3.3+1.2 
16.8±6,3 
3.3+2.1 
7.0+2.7 
3 88.0±0.9 88.8±1.8 * 84.8+2.9 
** 82.0±2.9 
***69.8±7.5 
4.3+1.0 
3.0+2.7 
0.3+0,3 
Average 83.9±2.2 81.9±3.5 81.2+5.4 5.8+1.8 
T test 
P value 
paired =0.2273 
unpaired =0.6467 
paired <0.0001 
unpaired <0.0001 
Prep 1; with 20nM skeletal tropomyosin 
Prep 2 & 3: * with 5nM skeletal tropomyosin 
** with 10nM skeletal tropomyosin 
*** with 30nM skeletal tropomyosin 
Table 4.3: Effect of tropomyosin on motility of D292V and 
control actin 
(A) Filament sliding speed (B) Filament percentage motility. Tropomyosin 
abolished the motility of D292V actin. 
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(A) Filament Sliding Speed (B) Filament Percentage Motility 
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Figure 4.6: Effect of tropomyosin on motility of D292V and 
control actin 
(A) Filament sliding speed (B) Filament percentage motility. In the presence 
of tropomyosin, the motility of D292V actin w/as completely switched off. 
4.2.9 Effect of Tropomyosin-Toponin and Ca^^on 
Motility of D292V and Control Act in 
The switch off in filament motility was unchanged in the presence of 
troponin, even at the activating level of Ca "^" (pCa 5.4) (Table 4.4). Myosin 
subfragment-1 modified with N-ethylmalemide (NEM-S1), which has been 
proved to have the ability to switch on actin-tropomyosin filaments by acting 
as a rigor cross-bridge (Bing etal. 1998), was unable to reactivate 
reconstituted D292V thin filaments (Figure 4.7). In contrast, there was little 
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change in filament motility in the control actin with tropomyosin and full 
regulation with further addition of troponin. Moreover, NEM-S1 reversed the 
motility of control thin filaments at the low concentration of Ca^ (pCa 9) as 
expected (-NEM-S1: sliding speed = 3.95, percentage motility = 31.0; +NEM-
S1; sliding speed = 5.69, percentage motility = 95.0). 
(A) Filament Sliding Speed 
2 4.54+0.29 1.77+0.47 3.83+0.11 1.75+0.22 3.95+0.14 1.97±0.73 
3 4.76+0.20 1.40+0.33 4.35±0.14 
5.19±0.13 
1.47+0.04 
1.37+0.10 
1.44+0.05 
2.21±0.44 
1.39+0.14 
2.78+0.36 
Average 4.46±0.40 1.53+0.11 2.53±0.74 2.05+0.40 
(B) Filament Percentage Motilitv 
2 85.0+3.5 3.3+2.1 73.3+11.4 22.0+12.3 31.0+7.0 19.0+11.0 
3 82.0+2.9 3.0+2.7 82.0±1.5 
83.8±3.4 
3.3+2.4 
3.5+1.3 
5.3+0.8 
10.0+1.5 
2.0+1.4 
2.5+1.7 
Average 79.7±3.2 9.6+6.2 15.4±7.9 7.8+5.6 
Table 4.4: Effect of tropomyosin-troponin and Ca^^ on motility 
of D292V and control actin 
(A) Filament sliding speed (B) Filament percentage motility. The switch off In 
D292V filament motility persisted with tropomyosin-troponin (10nM) at the 
high Ca^^ concentration. 
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(A) Filament Sliding Speed (B) Filament Percentage Motility 
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Figure 4.7: Regulation of tropomyosin, troponin, and 
NEIVI-S1 on motility of D292V and control actin 
(A) Filament sliding speed (B) Filament percentage motility. Movement of 
D292V actin was abolished with tropomyosin and tropomyosin-troponin 
(10nM), or NEM-S1 (18nM) was unable to restore its motility. 
4.2.10 Force Assay 
The relative force of the interaction between actin and myosin using 
immobilised Z-line actin binding protein f-actinin to impose an internal load 
was measured. The more force produced by actin-myosin interaction, the 
more j-actinin needed to stop the movement. Figure 4.8 shows that the 
relative force was similar for D292V and control actin. 
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# — Control 
D292V 
S 60 = 60 
0.2 0.4 0.6 0. 
[alpha-actinin] (/vg/ml) 
0 0.2 0.4 0.6 0.1 
[alpha-actinin] (/vg/ml) 
Figure 4.8: D292V and control actin generated a similar level 
of force 
Results from two experiments were plotted in (A) and (B). 
4.2.11 Act in Binding Competit ion Assay for t -Actinin 
I also examined the relative affinity of D292V actin for f-actinin (see 
Methods 2.10). The biopsy sample we had was enough for only one 
experiment. 0, 10%, 20%, 60%, 80% and 100% of unlabelled rabbit skeletal 
actin was mixed with TRITC-phalloidin labelled D292V or control human 
actin. D292V actin (K=14.33±28.75) appeared to bind to f-actinin stronger 
than control actin (K=2.17±0.51) illustrated in Figure 4.9. 
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Figure 4.9: D292V actin bound to (p-actinin stronger than 
control actin 
(A) The actual numbers of labelled actin filaments were plotted. (B) Data was 
fitted to the (p-actlnln binding equation to produce K for each actin. In this 
experiment, the mutant actin had a 7-fold higher cp-actinin binding affinity 
than control actin. 
4.2.12 D i s c u s s i o n 
Actin from muscle biopsies of the CFTD patient identified with an ACTA1 
D292V mutation displayed similar polymerisation and stability to that of age-
matched control actin. The D to V mutation was expressed at approximately 
40% in both whole homogenate and the extracted F-actin, this value is 
similar to what Clarke 's group found in whole tissue (Clarke et al. 2007). 
Despite the lower sliding speed, D292V actin generated normal level of force 
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compared with control actin. In addition, it appeared to have a stronger 
binding affinity for f-actinin than control actin. 
The addition of skeletal tropomyosin abolished the motility of D292V actin 
filaments, but not control actin. Loss of filament motility persisted with 
troponin and at activating Ca^^ concentration, indicating that the troponin 
complex could not restore normal tropomyosin functioning, neither could 
NEM-S1 reactivate the thin filament motility. From D292 's closeness to 
tropomyosin strand in both high and low Ca "^" states, it is reasonable to 
predict that the loss of negative charge in D292V mutation may disrupt the 
normal Ca^^-mediated switching of tropomyosin and lead to a reduction in 
binding affinity of myosin, perhaps stabilising it in the "switched off" state. 
The impaired motility of D292V actin filaments is compatible with the 
hypocontractile phenotype of the patient. D292V is the first disease-related 
actin mutation to show such abnormality. Although the switching off of 
tropomyosin has been observed in few other actin and tropomyosin 
mutations, the effect was not to the same extent. E93K actin mutation 
expressed in Drosophila flight muscle largely decreased percentage motility 
of actin filaments when tropomyosin was present, but actin-tropomyosin 
filaments were reactivated by adding troponin at pCa5 or NEM-S1 (Bing et al. 
1998). Yeast actin mutation D56A/E57A was reported to weaken the actin-
myosin binding, and this reduction in actin-myosin affinity was exaggerated 
by the presence of tropomyosin and troponin (Korman et al. 2000). In 
addition, a recent research by Paul Robinson, University of Oxford, on two 
nemaline myopathy-causing mutations in ^-tropomyosin (E117K and Q147P) 
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revealed that both mutations bound to actin with a significantly reduced 
affinity. More importantly, E117K switched off ATPase with native actin 
similar to D292V switch off with native tropomyosin. 
Although this is a major effect of D292V mutation, Clarke 's group also 
investigated the tendency to aggregate or polymerise of D292V actin using 
C2C12 myoblasts, which was transfected with constructs of EGFP-tagged 
D292V or control actin. Transfection of C2C12 myoblasts with control actin-
EGFP displayed GFP-stained stress fibres or diffuse cytoplasmic staining. 
Rather differently, transfection of C2C12 myoblasts with D292V actin-EGFP 
resulted in the formation of actin aggregates in the cytoplasm in 10% of 
transfected cells. In comparison to those aggregates associated with 
nemaline myopathy actin mutations I163M and intranuclear rod myopathy 
actin mutation V163L, the less intense, nonuniform fluorescent aggregates 
seen within D292V-EGFP construct were unique (Clarke et at. 2007). 
In conclusion, D292V mutation appeared to act through a dominant-
negative mechanism. The impaired contractility and disruption of actin-
tropomyosin interactions were enough to cause the clinical phenotype of the 
patient. 
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4.3 P332S 
4.3.1 Phenotype and Histology 
The patient who carried the P332S actin mutation had facial weakness at 
the age of 10 months. At age of 3 years, she was bed bound, had no head 
control, could move only her distal limbs weakly and was continuously 
ventilated. The family had no history of muscle weakness (Laing et at. 2004). 
A muscle biopsy taken at 10 months showed a bimodal distribution of type 1 
muscle fibres being smaller than type 2 fibres but no nemaline rods (Figure 
4.1D). 
4.3.2 Location of P332 
Like D292, P332 is located on the surface of actin monomer at the 'hinge ' 
region between the two domains of actin, and will be exposed in the F-actin 
polymer. In addition, it is close to tropomyosin in both high and low 
states, suggesting the possible effect of this mutation on thin filament 
regulation (Figure 4.2A & B). 
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4.3.3 Isolation of P332S F-Actin from A Patient Biopsy 
A similar quantity of F-actin was extracted from P332S taken at age of 10 
months and age-matched control skeletal muscle biopsies. Polymerisation 
was the same for mutant and control actins (Figure 4.10). 
whole 1st AC EX extract hs spin unpoly F-actin standard 
homog- wast" pellet s/n p s/n acWn s/n - +pha actin 
enate s/n - +pha 0.02 0.05|ig 
^ P332S 
Control 
homogenise wash 6x make acetone polymerise with 
whole I—'y in low | — \ powder, | — y KCI/MgCb and 
muscle salt buffer extract G-actin sediment 
with ACEX F-actin 
Figure 4.10 Isolation of P332S F-actin from a patient biopsy 
Polymerisation of P332S mutant and age-matched control actins were 
indistinguishable. 
4.3.4 Expression Level of P332S Actin 
Because P332S mutation does not involve a charge change, 2D 
electrophoresis was unable to separate the mutant actin from wild-type actin. 
The mass difference of lODa between the mutant and wild-type peptide was 
used to determine the expression level of P332S actin in our sample with 
mass spectrometry performed by Clarke 's group. Samples of F-actin were 
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run in SDS-PAGE (t2.0<g in each band) and the actin bands were cut out for 
analysis. In Figure 4.11 each peptide was represented by a cluster of peaks 
due to variations in the CI 3 content of proteins, the areas under those peaks 
were summed. The ratio of total peaks representing mutant S332 and wild-
type P332 actin was 0.37:1. Therefore 25% to 30% of the F-actin I extracted 
was P332S mutant actin. 
Control 
\ 
A\.J'L.-V.A.A..A-A..A A A K /> A A AA A. 
\ \ \ 
Patient P332S 
792 796 
Mass (mk) 
Figure 4.11: Mass spectrometry analysis of F-actin extracted 
from a biopsy of patient with P332S mutation 
The tryptic peptide that was used contained residue 329-336 (IIAPPERK). 
WT (wild-type peptide) molecular weight (MW) =795.47 Da. M (mutant 
peptide) MW=785.45 Da. Peaks for the mutant peptide (M) were present in 
the patient sample but not in the control. The ratio of the sum of all peaks 
corresponding to wild-type and mutant peptides in the patient sample was 
0.3703, mutant protein was estimated to account for 25-30% of total (p-
skeletal actin in the sample. This was done by Valentina Valova, Children's 
Medical Research Institute, Sydney. 
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4.3.5 In Vitro Mot i l i ty S tudy of P332S A c t i n 
TRITC-phalloidin labelled P332S actin extracted from biopsies taken at age 
of 10 months was compared with control actin in in vitro motility assay. They 
were very similar in filament density and length distribution. Same as D292V, 
standard motility experiments were carried out at 35°C. The mutation 
elevated the filament sliding speed by 9% and percentage motility by 6%, but 
the difference was not statistically significant (Table 4.5). 
Filaments Sliding Speed 
(p,m/sec) 
Fi laments Percentage Motility 
I H 
1 3.07+0.12 3.53±0.14 15.0 50.8+3.3 77.7+3.8 26.9 
3.82±0.02 3.91±0.06 2.4 83.3±3.5 79.3±2.4 -4.0 
3.11±0.48 3.98+0.07 28.0 86.5+3.5 86.5±3.5 0 
4.24±0.04 4.07±0.03 -4.0 94.0±3.2 91.0±1.9 -3.0 
2 3.04±0.06 3.47±0.08 14.1 79.3±2.6 81.8±3.9 2.5 
3.06+0.06 3.66±0.13 19.6 82.3±1.3 87.8±4.3 5.5 
2.57+0.08 2.85±0.14 10.9 62.8±2.5 78.0+8.6 15.2 
3 3.94±0.16 3.56±0.18 - & 6 85.3±0.5 92.0±3.2 6.7 
4.16±0.15 5.17±0.11 25.7 74.5+2.3 88.3±3.5 1&8 
3.74±0.05 3.62±0.22 -3.2 86.3±3.8 89.0±1.0 2.7 
3.87+0.08 3.86±0.04 -0.3 80.8±2.5 81.8±1.9 1.0 
Average 3.51+0.17 3.79±0.17 9.0±3.8 78.7±3.7 84.8±1.6 6.6±3.0 
T T e s t Paired =0.06375 Paired = 0.05213 
P Value Unpaired =0.2577 Unpaired = =0.1419 
Table 4.5: P332S mutation increased filament sliding speed 
and percentage motility at 35°C 
Motility of the mutant and control actin was compared at temperatures in a 
range of 20-35°C. The increased sliding speed of D292V actin at 35°C was 
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observed only at 30°C, but the difference disappeared and eventually moved 
slower than control actin at lower temperatures as shown in Figure 4.12. 
Both actins displayed similar percentage motility against temperatures. The 
effect of temperature on the two actins is summarised in Table 4.6. 
20 2.50±0.04 2.06+0.06 -17.6 67.8±2.7 64.5±4.3 -3.3 
28 2.86±0.07 2.84±0.07 -0.7 85.0+2.3 71.5±3.7 -13.5 
30 2.92+0.10 3.12±0.06 6.8 79.3+3.5 81.0±2.0 1.7 
35 3.82±0.03 3.91±0.06 2.4 83.3±3.5 79.3±2.4 1 -4.0 1 
Table 4.6: Motility of P332S actin at different temperatures 
P332S mutation did not seem to affect the motility of actin filaments at any of 
the four temperatures tested. 
3.5 -
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0) 0) Q . 
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Figure 4.12: P332S actin had higher temperature-dependency 
than control actin 
It might suggest that something was happening at low temperatures, but not 
at high temperatures. 
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4.3.6 Ef fect of T r o p o m y o s i n o n A c t i n Mot i l i t y 
Tropomyosin decreased the motility of both actins. The higher sliding speed 
of mutant actin remained, and it had increased percentage motility compared 
to control actin, the difference was statistically significant (Table 4.7). Actin 
motility at different tropomyosin concentrations is shown in Figure 4.13. 
(A) Filament Sliding Speed 
M E a 
1 3.11±0.48 3.98+0.07 ** 3.19±0.09 3.99+0.12 
2 3.04±0.06 3.47+0.08 * 3.41+0.17 3.34±0.12 
* *3 .51±0 .13 3.28±0.09 
***2.48±0.24 2.45±0.24 
3 3.94±0.16 3.56+0.18 ** 3.47±0.17 4.40±0.03 
3.74±0.05 3.62±0.22 ** 3.46±0.14 4.27+0.09 
Average 3.46+0.23 3.66±0.11 3.25±0.16 3.62+0.30 
T t e s t paired =0.5266 paired =0.1496 
P value unpaired =0.4564 unpaired =0.307 
(B) Filament Percentage Motility 
m a 
1 86.5 +3.5 91.0+1.9 * *71 .0±5 .7 82.0±5.6 
2 79.3±2.6 81.8±3.9 * 49.0+7.0 
** 57.8+1.5 
*** 5.3±1.9 
53.0±1.0 
65.8±3.2 
18.0±8.5 
3 85.3±0.5 
86.3±3.8 
92.0±3.2 
89.0±1.0 
** 86.5+2.1 
** 74.3±3.7 
85.3±3.1 
85.3±2.3 
Average 84.4+1.7 88.5+2.3 57.3±11.7 64.9±10.7 
T t e s t 
P value 
paired = 
unpaired = 
0.02465 
0.2023 
paired =0.01702 
unpaired =0.6433 
* with 5nM 
skeletal Tm 
** with 10nM 
skeletal T m 
*** with 30nM 
skeletal T m 
Table 4.7: Effect of tropomyosin on motility of P332S and 
control actin 
(A) Filament sliding speed (B) Filament percentage motility. The mutant 
showed higher motility than control actin in the presence of tropomyosin. 
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(A) Filament Sliding Speed (B) Filament Percentage Motility 
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Figure 4.13: l\^otility ofP332S and control actin at different 
tropomyosin concentrations 
(A) Filament sliding speed (B) Filament percentage motility. Mutant actin 
seemed to have increased percentage motility compared to control actin in 
the presence of tropomyosin. Data plotted in this figure is summarised in 
Table 4.7 (Prep. 2). 
4.3,7 Effect of Tropomyosin-Toponin and Ca^'^on 
Motility of P332S and Control Actin 
P332S mutation did not appear to change regulation on actin with 
tropomyosin-troponin and Ca '^^ . Results from several experiments are 
summarised in Table 4.8, while the average values are plotted in Figure 4.14. 
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(A) Filament Sliding Speed 
1 3.19+0.09 3.99±0.12 4.57±0.11 5.03+0.15 1.44±0.04 1.64±0.08 
2 3.51+0.13 3.28±0.09 3,58±0.08 
3.81+0.08 
2.68+0.18 
2.50+0.10 
1.59+0.16 
1.50+0.08 
1.70+0.18 
1.93±0.09 
3 3.47+0.17 
3.46+0.14 
4.40+0.03 
4.27+0.09 
3.25+0.05 
4.16+0.20 
4.05+0.32 
4.21+0.15 
2.40+0.14 
2.37+0.30 
2.51+0.13 
1.73+0 
Average 3.41±0.07 3.99±0.25 3.87±0.23 3.69+0.48 1.86+0.22 1.90±0.16 
T test 
P value 
paired =0,1227 
unpaired =0.06857 
paired =0.6769 
unpaired =0.7442 
paired =0.8272 
unpaired =0.8795 
(B) Filament Percentage IViotility 
1 71.0+5.7 82.0+5.6 60.8±11.7 63.8+9.3 9.3±1.4 9.5±4.7 
2 57.8+1.5 65.8+3.2 57.8±3.7 
74.3+5.2 
44.0+5.8 
61.0+2.1 
5.5±3.5 
5.3+2.7 
9.3+4.6 
18.5±1.6 
3 86.5+2.1 
74.3±3.7 
85.3+3.1 
85.3±2.3 
65.0+1.0 
65.8+3.7 
69.5+6.4 
74.3+3.8 
21.0+6.8 
10.5+1.9 
25.7+1.5 
3.0±3.0 
Average 71.8±8.3 77.7±6.0 64.5±3.6 59.6±5.5 10.3+2.9 13.2±4.0 
T test 
P value 
paired = 
unpaired = 
0.2474 
0.5651 
paired =0.3997 
1 unpaired =0.4831 
paired = 
unpaired = 
0.4395 
0.5732 
Table 4.8: Effect of tropomyosin-troponin and Ca^^ on motility 
of P332S and control actin 
(A) Filament sliding speed (B) Filament percentage motility. There w/as no 
consistent difference between mutant and control actin on regulation with 
tropomyosin-troponin (10nM) and Ca^*. 
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(A) Filament Sliding Speed (B) Filament Percentage Motility 
£ 
S 
•D 0) Q) 
Q . (/) 
g 
CO 
Control 
• P332S 
Control 
• P332S 
Actin Actln+Tm Actin+Tm+Tn 
pCa5 pCa9 
Actin Actin+Tm Actin+Tm+Tn 
pCa5 pCa9 
,2+ Figure 4.14: Regulation of tropomyosin, troponin, and Ca 
on motility of P332S and control actin 
(A) Filament sliding speed (B) Filament percentage motility. Mutant and 
control actin displayed the same regulation with tropomyosin-troponin (10nM) 
and Ca 2+ 
4.3.8 Force Assay 
The relative force generated by actin and myosin interaction using 
immobilised Z-line actin binding protein f-actinin was measured on both 
mutant and control actin. The more force produced by actin-myosin 
interaction, the higher concentration of f-actinin needed to stop the 
movement. Figure 4.15 suggests that the relative force was similar for P332S 
and control actin. 
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(A) 
100 
(B) 
100 
= 60 •-
0 0.2 0.4 0.6 0. 
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(C) 
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Figure 4.15: Comparison of actin-myosin force generated by 
P332S and control actin 
Results from three experiments were plotted in (A-C). Mutant and control 
actin had very similar actin-myosin force in two of the experiments (B&C); 
while in the other experiment (A) P332S produced higher force than control 
actin. 
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4.3.9 A c t i n B i n d i n g Compe t i t i on A s s a y fo r j -Ac t i n in 
Actin binding competition assay was applied to study the relative affinity of 
P332S actin for j-actinin (see Methods 2.11). In each paired cell, TRITC-
phalloidin labelled human actin (P332S or control) competed with unlabelled 
rabbit skeletal actin for binding to j-actinin at a constant total actin 
concentration. Various ratio of unlabelled rabbit actin was mixed with labelled 
human actin. Figure 4.16 illustrates results from 3 separate experiments. In 
two out of the three experiments (A & C), P332S actin bound to j-actinin with 
a markedly higher affinity compared to control actin, but in the third 
experiment (C) it was reversed. The ratio of binding constant (K) for both 
actins and the difference between mutant and control actin are summarised 
in Table 4.9. 
A 0.87±0.11 4.64±2.96 5.33 
B 1.43±0.24 0.69±0.08 0.48 
C 0.40±0.08 1.31+0.44 3.28 
Table 4.9: Summary of relative ^-actinin binding affinity for 
P332S and control actin 
Experiment A-C correlate to those in Figure 4.16. Mutant actin bound to 0-
actinin stronger than control actin in two out of the three experiments 
performed. 
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Figure 4.16: Comparison of relative affinity of P332S and 
control actin for (p-actinin 
Data was fitted to the ^-actinin binding equation to produce K for each actin. 
In experiment (A&C) the mutant actin bound to cp-actinin stronger, whilst in 
the other experiment (B) it had a lower affinity for (p-actinin than control actin. 
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4.3.10 Discussion 
Even though mutant actin accounted for 25% to 30% of the total F-actin I 
studied, no significant effects was seen in any of the actin functions that were 
measured. There was a trend towards faster sliding at high temperatures, a 
steeper sliding speed vs. temperature curve and stronger j-actinin binding. 
Unfortunately there was not enough material to repeat those experiments to 
establish significance. 
This mutation had little effect showing no aggregates when transfected into 
C2C12 myoblasts (Clarke et al. 2007). Clarke's group also found that 
D292V and P332S mutation did not alter the ability of actin to polymerise and 
incorporate into long filaments in differentiating muscle fibres. This finding 
correlates to our result that both mutations had normal polymerisation. In 
addition, comparing with control samples, neither of the mutations changed 
the expression of other sarcomeric proteins including slow myosin, 
tropomyosin, troponin complex and f-actinin (Clarke et al. 2007). Supposing 
P332S actin is defective that it did not bind to phalloidin or HMM, in either 
case I would not see mutant filaments but only the wild-type filaments in the 
in vitro motility assay, therefore would not see any effects. P332S mutation is 
still, however, possible to cause other changes in parameters that were not 
assessed in our study, such as isometric tension or cross-bridge dynamics 
under load. 
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4.4 E205D 
4.4.1 Phenotype 
Another CFTD mutation I have studied is E205D. The patient had severe 
muscle weakness. Unusually for an inherited myopathy, the father also 
carries the mutation, but is clinically normal. Differences in penetrance like 
this are commonly found in HCM and are related to modifier genes. Given 
the small number of genotyped family members not enough information is 
present here. A biopsy was taken at age of 7 years and was provided by 
Professor Caroline Sewry, Hammersmith Hospital, London. 
4.4.2 Location of E205 
E205 is located in subdomain 4 (Figure 4.17A) facing into a space in 
between the two actin stands and is at the long axis interface of the actin 
polymer (Figure 4.17B) but is buried in the space filled model of actin. The 
residue is in the area where phalloidin binds and stabilises F-actin by forming 
hydrogen bonds with E72, T77, A114, R177, LI 78, D179, T194, S199, V247, 
E270, Y279 and K284 (Falcigno et al. 2001; Lorenz et at. 1993) in the 
experimental system. Hence E205D mutation has been hypothesised to 
affect actin polymerisation and phalloidin binding to actin. 
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(A) (B) 
Phalloidin 
binding site 
E205 
Figure 4.17: Location of E205 in the actin molecule 
{A) Ribbon representation of the actin monomer reveals the location of E205 
(brown sphere) in subdomain 4 and being close to phalloidin binding site 
(green spheres). (B) The residue is at the long axis interface of the actin 
polymer Produced with Chimera software using Actin 1J6Z.pdb (A) and 
Actin_l\/lodel.pdb file (B). 
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4.4.3 Isolation of E205D F-Actin from A Patient Biopsy 
Extraction of E205D and age-matched control human actin was compared. 
Phalloidin was added to induce full polymerisation. There was no difference 
observed in polymerisation between the mutant and control actin (Figure 
4.18). 
whole 1st AC EX extract hg spin unpoly F-actin 
homog- wash pellet s/n p s/n s/n _ +pha 
enate s/n - +pha 
standard 
actin 
0.02 O.OSfxg 
E205D 
Control 
homogenise wash 6x make acetone polymerise with 
whole I — \ in low i — \ powder, i — \ KCI/MgCIa and 
muscle salt buffer extract G-actin sediment 
with ACEX F-actin 
Figure 4.18: Isolation of E205D F-actin from a patient biopsy 
E205D mutation did not change the actin polymerisation compared to age-
matched control actin. 
Because the mutation E to D does not involve a charge change, the 
expression level of mutant actin in our sample could not be determined using 
2D electrophoresis. 
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4.4.4 In Vitro Motility Study of E205D Act in at 28°C 
Experiments were performed at 28°C. The density was the same for mutant 
and control actin. However, E205D filaments appeared to have 42% shorter 
length than control actin (Figure 4.19). The average filament length of E205D 
was 2.31+0.12, whereas that of control actin was 3.97±0.08 (n>100, 
p<0.0001). 
n Control 
• E205D 
^ 40 
E 3 
C 
C (1) 
L L 
2 4 6 
Length (jjm) 
Figure 4.19: Length distribution of E205D and control actin 
E205D actin filaments were 42% stiorter than control filaments, the 
difference w/as statistically significant. 
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E205D had a 12% increased sliding speed, and this difference was almost 
significant at the 95% confidence level (Table 4,10). The percentage motility 
of both actins decreased as the proteins got older, indicating a possible 
deterioration in the extracted actins. 
1 4.08+0.17 
4.59+0.07 
3.80+0.15 
3.11+0.08 
2.82+0.13 
2.78+0.23 
4.31+0.17 
2.54+0.17 
3.07+0.04 
4.15+0.04 
4.64±0.06 
3.91+0.05 
3.55±0.02 
3.01±0.06 
3.71±0.15 
4.48±0.13 
3.86±0.08 
2.95±0.09 
1.7 
1.1 
2.9 
14.1 
6.7 
33.5 
3.9 
52.0 
-3.9 
86.0+7.0 
89.8±6.5 
66.3+6.6 
38.5±4.5 
61.0+6.7 
34.3±5.0 
68.0±5.3 
25.3±3.2 
43.5±1.0 
93.0+1.7 
90.0±3.1 
75.3±5.6 
68.8+5.2 
52.3±2.4 
46.2±1.9 
78.3±3.6 
41.0±4.7 
41.3±1.5 
7.0 
0.2 
9.0 
30.3 
-8.7 
11.9 
10.3 
15.7 
-2.2 
Average 3.46+0.25 3.81±0.19 12.4±6.1 57.0±7.6 65.1+6.8 8,2+3.7 
T Test 
P Value 
Paired =0.05659 
Unpaired =0.2838 
Paired = 
Unpaired = 
0,06211 
•0.4366 
Table 4.10: E205D mutation increased the filament motility at 
28 °C 
4.4.5 Tempera tu re -Dependency 
The higher sliding speed of mutant actin persisted at lower temperatures 
(25°C); whilst at 35°C, E205D had decreased sliding speed compared to 
control actin. Therefore the sliding speed of mutant actin seemed to be less 
temperature-dependent than control actin (Figure 4.20). The percentage 
motility of the two actins was similar at all three temperatures tested (Table 
4.11). Due to small number of data, t tests were impossible. 
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20 2.81+0.14 3.17±0.08 12.8 86.5+4.4 91.3±0.5 4.8 
3.19±0.03 3.29±0.12 3.1 89.3+5.3 88.0±1.5 -1.3 
28 4.08±0.17 4.15±0.04 1.7 86.0±7.0 93.0±1.7 7.0 
4.59+0.07 4.64+0.06 1.1 89.8±6.5 90.0+3.1 0.2 
35 5.84±0.17 5.43+0.18 -7.0 94.0±6.0 90.5±4.6 -3.5 
5.55+0.15 5.01±0.14 -9.7 76.5±7.9 88.8+1.7 12.3 
Table 4.11: Motility of E205D and control actin at different 
temperatures 
5.5 -
o 0) (O 
E 
s 
T3 
CD m 
Q . 03 D) c y 
CO 
2.5 
• — Control 
E205D 
4.5 -
3.5 -
25 30 
Temperature (°C) 
Figure 4.20: Sliding speed of E205D actin appeared to be less 
temperature-dependent than control actin 
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4.4.6 Ef fec t of T r o p o m y o s i n on A c t i n iVlotiiity 
In the presence of tropomyosin, both sliding speed and percentage motility 
of E205D actin was notably higher than that of control actin, and the 
difference was statistically significant (Table 4.12). However, this could be a 
result of different degree of deterioration of the two actins (Table 4.10). Actin 
motility at three concentrations of tropomyosin (5nM, lOnM and 20nM) is 
shown in Figure 4.21. 
(A) Filament Sliding Speed 
1 3.80±0.15 3.91±0.05 * 3.92±0.11 4.27±0.11 
* *3 .71±0.13 4.09+0.24 
***2.64±0.40 3.84±0.10 
2.78+0.23 3.71±0.15 * 2.81+0.10 4.12±0.13 
2.54+0.17 3.86+0.08 * 2.52±0.08 2.72±0.13 
3.07±0.04 2.95±0.09 * 2.88±0.09 3.20+0.06 
Average 3.05+0.27 3.61±0.22 3.08+0.24 3.71±0.25 
T test paired =0.1972 paired =0.02621 
P value unpaired =0.1636 unpaired =0.1008 
(B) Filament Percentage Motility 
I M 
1 66.3±6.6 75.3±5.6 * 68.8±7.0 90,3+2.0 
** 56.7±2.7 76,0±13.7 
*** 18.3+9.5 68.3±5.6 
34.3±5.0 46.2+1.9 * 34.8±4.5 68.8±1.0 
25.3+3.2 41.0±4.7 * 51.0+3.6 42.5±6,8 
43,5±1.0 41.3+1.5 * 39.5±3.5 63,0±2,5 
Average 42.4±8.8 51.0±8.2 44.9±7.3 68.2±6.4 
T test paired = 0,1118 paired =0.03149 
P value unpaired = 0.5017 unpaired =0,03721 
* with 5nM 
skeletal Tm 
** with 10nM 
skeletal T m 
*** with 20nM 
skeletal T m 
Table 4.12: E205D actin had consistently higher motility than 
control actin in the presence of tropomyosin 
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(A) Filament Sliding Speed (B) Filament Percentage Motility 
Control 
E205D 
5 10 15 
[Tm] (nM) 
20 25 
# — Control 
E205D 
= 60 
5 10 15 20 
[Tm] (nM) 
Figure 4.21: Effect of tropomyosin on motility of E205D and 
control actin 
E205D actin had marl<edly higher (A) sliding speed and (B) percentage 
motility than control actin at all the concentrations of tropomyoisn tested. 
4.4.7 Effect of Tropomyosin-Troponin and Ca^^on 
E205D and Control Actin Motility 
The higher sliding speed and percentage motility of the mutant actin 
retained with troponin at pCa9 (Table 4.13), but with only two experiments 
from a single protein preparation performed, it is difficult to draw any 
conclusion. Data from these two experiments is shown in Figure 4.22. 
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(A) Filament Sliding Speed 
2.81+0.20 4.12±0,13 3.06-0.17 2.94-0.08 1.91 ±0.27 2.41±0.27 1 
1 2.88-0.09 3.20±0.06 2.73±0.07 2.55±0.11 0 1.73+0.1 1 
(B) Filament Percentage Motility 
34.8±4.5 68.8+1.0 48.0+4.0 44.0+6.4 6.5+2.9 17.3±4.2 
39.5±3.5 63.0+2.5 34.0+7.2 62.3+2.8 0 7.3±6.9 
Table 4.13: Regulation of troponin and Ca^* on motility of 
E205D and control actin 
(A) Filament Sliding Speed (B) Filament Percentage Motility 
Control 
• E205D 
• Control 
• E205D 
Actin Actin Actin+Tm+Tn 
+Tm pCa5 pCa5 pCa9 pCa9 
Actin Actin+Tm+Tn 
+Tm pCa5 pCaS pCa9 pCa9 
Figure 4.22: E205D mutation did not seem to affect troponin 
regulation and Ca^"^-sensitivity 
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4.4.8 A c t i n B i n d i n g Compe t i t i on A s s a y fo r f - A c t i n i n 
Actin binding competition assay for f - a c t i n i n was also done on E205D 
actin, which bound to j-actinin with a almost equal affinity to that of control 
actin (Figure 4.23). K for E205D and control actin was 3.86+0.68 and 
3.64±1.11 respectively. 
Control 
• E205D 
-S 400 
E 200 
0 0.2 0.4 0.6 0.8 1 
Fraction of unlabelled actin 
0 0.2 0.4 0.6 0.8 
Fraction of labelled actin 
Figure 4.23: E205D and control actin bound to ^-actinin with 
an equal affinity 
(A) The actual numbers of labelled actin filaments were plotted. (B) Data was 
fitted to the cp-actinin binding equation to produce K for each actln. The 
mutation did not change the actin binding affinity for ^-actinin. 
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4.4.9 Discussion 
In comparison to control actin, E205D had same polymerisation, stability, 
labelling, density, troponin and Ca "^" regulation and binding affinity for f -
actinin. The average filament length of mutant was 42% shorter than control 
actin. It moved faster at high temperatures and showed higher motility with 
tropomyosin than control actin. Among them, the difference in length 
distribution and higher motility with tropomyosin was statistically significant. 
The predicted effects of this mutation on actin polymerisation and phalloidin 
binding were not seen. Since the expression level of mutant actin in the 
sample I investigated was unknown, there is possibility that it was not 
incorporated into the sacomere or little was extracted. The mutation may as 
well alter other actin properties that were not measured. Another explanation 
could be that as Prof. Sewry suspected, this is not the disease-causing 
mutation, just a polymorphism. The curious temperature-dependency may 
indicate two effects with, again the possibility that mutant actin did not appear 
in in vitro motility assay. 
4.5 General Discussion of CFTD mutations 
D292V, P332S and E205D are all novel missense actin mutations found in 
children with typical phenotype of CFTD. All three patients had very similar 
presentations and clinical courses. The lack of family history in patients with 
D292V and P332S suggests that these two mutations arose de novo] whilst 
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the father of patient with E205D also carries the mutation, but shows no 
clinical phenotype, such difference in penetrance is a common feature of 
HCM mutations, or there is a possibility that this mutations might not be 
disease-causing. 
The three mutations do not cluster closely, but two of them (D292V and 
P332S) are located on the surface and will be exposed in the F-actin 
polymer. 
For at least two of the mutations (D292V and P332S), the mutant actin was 
incorporated into sarcomeric structures in significant amounts. In addition, 
Clarke's investigation on the incorporation level of GFP-tagged and FLAG-
tagged D292V and P332S actin into stress fibres and insoluble actins found 
that the two mutant actins had normal ability to fold, polymerise and integrate 
into large filamentous structures in cells without disrupting muscle 
architecture (Clarke et al. 2007). 
D292V showed the most distinct molecular features among the three CFTD 
mutations. Expression of EGFP-tagged D292V actin construct resulted in 
formation of abnormal aggregates in C2C12 myoblasts. Moreover, the almost 
complete suppression of tropomyosin, and Ca^"'-activated troponin with 
D292V actin is the most extreme molecular phenotype yet observed with any 
myopathic mutation. 
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Both P332S and E205D mutation resulted in higher percentage motility in 
the presence of tropomyosin than control actin, such difference was 
statistically significant, and is the opposite effect of D292V mutation. 
Although P332S and E205D mutation have not been seen to have any major 
changes in motility that could cause a pathogenic effect, they might alter 
properties of actins that have not been determined. Those three are the first 
CFTD-associated mutations that were functionally studied in detail. The 
finding that D292V mutation likely disrupts actin-tropomyosin interactions is 
the first case where a major pathogenic mechanism has been identified. 
Given the similar disease phenotype of these three mutations it is perhaps 
surprising that only one exhibits a phenotype at the molecular level. Clarke 
has hypothesised that the absence of nemaline rods in CFTD implies that 
mutant actin assembles correctly into the sarcomere and mass spectrometry 
showed that P332S was present in the purified actin we examined. 
The possibility that mutant P332S and E205D filaments were not seen in in 
vitro motility assay has to be considered, particularly since E205D mutation is 
thought to affect binding of the phalloidin which both stabilises the filaments 
and renders them visible, whilst P332 is close to putative tropomyosin and 
myosin binding site. If the P332S filaments did not bind tightly to the surface 
as active actin they might be washed away during preparation of the cell. The 
small quantities of biopsy samples available have limited the possibility to 
investigate these questions further. 
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5. Functional Characterisation of A 
Nemaline Myopathy Mutation (K336E) and 
An Intranuclear Rod Myopathy Mutation 
(V163M) 
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5.1 Investigation of K336E Actin Mutation That 
Causes Nemaline Myopathy and Hypertrophic 
Cardiomyopathy (HCM) 
5.1.1 Phenotype of K336E 
Professor Enrico Bertini 's group from the University of Florence reported 
on a sporadic case of nemaline myopathy in a male baby. At 2 months of age 
a heart murmur was detected. Unlike the other cases this child was initially 
referred for a cardiac problem. His echocardiography showed an asymmetric 
non-obstructive hypertrophic cardiomyopathy (HCM). At 6 months he was 
admitted to hospital for further diagnostic investigations. The 
echocardiography (Figure 5.1) confirmed the diagnosis of HCM with a 
maximal wall thickness (MWT) at the interventricular septum (IVS) of 6.7 mm 
(Z-score + 2.4) and normal thickness of the posterior wall (4.6 mm), with an 
interventricular septum; posterior wall thickness ratio of 1.46 (normal < 1.3)"'^ . 
No signs of cardiac failure such as sweating, tachypnoea, dyspnea, or 
tachycardia were detected. The child had normal cognitive development. 
Levels of serum CK were always in the normal range. At 2.5 years of age, 
the boy was able to sit unsupported and to raise his arms. Extensive cardiac 
investigations including echocardiography and Holter electrocardiography 
showed a persistent non-obstructive asymmetric HCM (MWT 9.2 mm; Z-
score +4.3) without arrrythmias and no signs of cardiac failure. The child died 
6 months later at 3 years of age (D ' Amico et al. 2006). Postmortem details 
were not available but it is presumed that this was a sudden cardiac death. 
207 
NMand HCMMutation K336E 
Figure 5.1: Echocardiographic evaluation of the patient at the 
age of 6 months. 
Parasternal long axis cut shows asymmetric left ventricular hypertrophy with 
maximal wall thickness at anterior interventricular septum [line with double 
arrow] (aIVS) of 9.2 mm. (estimated normal forage and height= 4.7mm). 
LV= left ventricle; LA= left atrium; Ao= aorta. Kindly provided by Giuseppe 
Paclleo, Seconda University, Italy. 
The clinical examination at the 6 months showed generalised skeletal 
muscle hypotonia predominantly involving axial and shoulder girdle muscles. 
He also had moderate reduced facial mimicry and had frequent episodes of 
bronchopneumonia. These symptoms suggested a skeletal muscle 
myopathy. The muscle biopsy of this patient showed clear changes for 
nemaline myopathy. Variability of muscle fibre size with numerous 
hypoplastic muscle fibres and multiple nemaline rods were present in most 
fibres (Figure 5.2 A). Oxidative enzyme staining did not show any myofibrillar 
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abnormalities or cores. The ultrastructural examination confirmed the 
presence of both cytoplasmic and intranuclear rods (Figure 5.2C and D). A 
diagnosis of nemaline myopathy was made. 
5 ' ' 
4 ' 
f ' i ' 
^ 
^ 
0 
Figure 5.2: Histology of a patient skeletal muscle biopsy 
(A) Gomori trichrome stain displayed numerous cytoplasmatic nemaline-rods. 
(B) Staining with rhodamine-phalloidin revealed accumulation ofactin 
filaments in most fibres which probably related to areas of abundant rods. 
(C) Electron microscopy confirmed the presence of nemaline rods. (D) An 
intranuclear rod in a hypotrophic muscle fibre. Kindly provided by Enrico 
Bertini, University of Florence and Adele D'Amico, Gesu Children's Research 
Hospital, Rome. 
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5.1.2 Identification of ACTA 1 K336E Mutation 
The genomic sequencing of the ACTA1 gene showed a "de novo" 
missense heterozygous mutation a>g in exon 7 changing a lysine to 
glutamate at position 336 (K336E). This was the first report of a HCM 
associated with nemaline myopathy and ACTA1 mutation. We were kindly 
supplied with a skeletal muscle biopsy sample from this patient taken at 6 
months of age. 
5.1.3 Location of K336 
K336 (shown in Figure 5.3) is located on the surface of actin at the junction 
between the inner (subdomains 3 and 4) and outer (subdomains 1 and 2) 
domains (the 'hinge ' region) of actin. 
K336 
Figure 5.3: Location of K336 in actin monomer 
K336 (brown sphere) is close to the nucleotide binding sequences (purple) 
and is part of the 'hinge' region (yellow). Two 4)-actinin binding sequences 
are represented in pink. Produced with Chimera software using Actin 
UdZ.pdb file. 
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In addition K336 is within the nucleotide binding site in a cleft between the 
two domains of actin and the amino group is hydrogen-bonded to the 
adenosine ring of MgADP. ATP is critical in stabilising actin in its polymeric 
form, therefore this charge reversal mutation may have effects on actin 
polymerisation. 
5.1.4 Isolation of F-Actin from A Patient Biopsy 
With the actin isolation method well established, F-actin was extracted from 
25x30^m cryosections of patient and age-matched control human muscle 
biopsies as described in Methods 2.3.1. I polymerised monomeric actin half 
with KCI/MgCb and half with 150nM phalloidin + KCI/MgCl2. In the absence 
of phalloidin, approximately 30% of the actin in both control and patient 
samples did not polymerise, whereas with phalloidin, all actin was 
polymerised (Figure 5.4). K336E and control muscle were indistinguishable. 
Thus there appeared to be no instability of mutant actin or polymerisation 
defect. 
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Figure 5.4 Isolation of K336E F-actin from a patient biopsy 
Extraction of K336E actin and age-matched human control actin was 
compared. There was no consistant difference between the mutant and 
control actin. The figure shows Western blots of fractions taken at various 
stages of the preparation (see Methods 2.3.1). 
5.1.5 Exp ress ion Level o f Mutant A c t i n 
2D electrophoresis was applied to investigate the expression level of 
mutant actin in whole muscle, myofibril fraction and extracted F-actin(see 
Methods 2.7). The values were 29%, 28% and 45% respectively (Figure 
5.5), indicating the mutated actin was incorporated into the sarcomere and 
was retained throughout the isolation process. 
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K336E WT 
1 I 
Whole 29% 
homogenate * 
Myofibril • # 28% 
fraction 
^ _ 45% 
F-actm 
Control 
Figure 5.5 2D electrophresis gel of K336E actin in patient 
muscle samples 
The mutant actin i/i/as present at a similar level in the whole muscle and 
myofril fraction demonstrating that the mutant actin was incorporated into the 
sacomere. In the F-actin I extracted, E336 actin was detected as two 
interlinked segments, which could be consequent upon the presence of an 
air bubble. 
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5.1.6 In Vitro Mot i l i ty S tud ies of K336E A c t i n 
5.1.6.1 Length Comparison 
Functional charactensation of K336E human actin was studied in 
comparison with actin from an age-matched (6 months) control human 
muscle sample. Actin fully polymerised in the presence of phalloidin was 
used in our experiments. The density of mutant and control actin filaments 
was similar whereas the average length of the mutant actin filament 
(1.0+0.07|xm) was significantly shorter than control actin (2.2+0.15|xm) 
(Figure 5.6). 
(1) 
3 
C 
C 0) 
C 2 0 -
• K336E 
H Control 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 
Length (^m) 
Figure 5.6: Comparison of length distribution of K336E and 
control actin 
K336E actin filaments were more than 50% shorter compared to control. 
Average was taken from over 100 filaments for each actin. 
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5.1.6.2 Sliding Speed of K336E Actin at 28°C 
When I investigated the effect of the mutation on actin functions using in 
vitro motility assay, K336E actin had a consistently 13.4% lower sliding 
speed than control actin at 28°C. This difference was statistically significant 
when doing paired t test. The percentage motility of filaments was similar 
between K336E and control actin (Table 5.1) 
1 2.79±0.05 
5.11±0.12 
3.63+0.03 
4.59±0.16 
4.19±0.08 
4.19±0.04 
2.40+0.02 
2.52±0.03 
2.46+0.09 
4.38+0.18 
3,79±0.06 
3.65±0.33 
3.68±0.02 
3.81±0.12 
1.95±0,01 
2.10+0.06 
-11.8 
-14,3 
4.4 
-20,5 
-12.2 
-9.1 
-18.8 
-16.7 
98.3±1.4 
95.3+0.8 
98.8±0,8 
75.3±3.8 
99.8±0.3 
82,5±16 
94,5±1.0 
96.0±2.2 
97.8+1,6 
94.8±2.8 
97.8±1.7 
71,3±5,9 
99,5+0,3 
100±0 
96.5+0.9 
93.5±2,5 
-0,5 
-0,5 
-1.0 
-4,0 
-0,3 
17,5 
2,0 
-2,5 
2 2.51±0.11 
1.82+0.02 
1.91±0.20 
2.0±0.01 
2.74+0.05 
1.85+0.15 
1.47±0.06 
1.98+0.21 
1.49+0.08 
2.34±0.12 
- 2 & 3 
-19.2 
3.7 
-25,5 
-14,6 
90.0±2.0 
79.5+0,9 
64.0±8.0 
85,8+1.3 
88.3+0.5 
70.8±9.3 
85.3±2.7 
91.7±1.8 
74,7±4.1 
79.3±7.3 
-19.2 
5,8 
27 7 
-11.1 
-9.0 
3 2.70+0.15 
3.29±0.09 
2.91+0.07 
2.47±0.07 
2.80+0.13 
2.63+0.21 
-8 5 
-14,9 
-9 6 
69.5±6.3 
68.5±5.0 
74.0+5,3 
77,0±7.8 
81.5+2.6 
87.0±13 
7.5 
13.0 
13.0 
Average 3.08+0.25 2.68+0.23 -13.4±2 85.0±3.0 87.4±2.6 2.4±2.9 
T Test 
P Value 
paired <0,0001 
unpaired =0.2414 
paired = 
unpaired = 
0.4199 
0,5439 
Table 5.1: K336E mutation decreased filament sliding speed 
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5.1.6.3 Temperature-Dependency 
The motility of K336E and control actin was studied at four different 
temperatures (20°C, 25°C, 28°C and 35°C). At all three temperatures, K336E 
had a decreased sliding speed compared to control actin (Figure 5.7). 
Because of the small number of data at 20°C, 25°C and 35°C, t tests were 
not possible. Again the percentage motility was not different between mutant 
and control actin (Table 5.2). 
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20 2.37+0.01 1.91±0.06 -19.4 96.8+1.9 86.5±2.3 -11.3 
25 2.55+0.02 2.20±0.02 -13.7 95.3±1.4 97.8±1.9 2.5 
28 2.79+0.05 2.46±0.09 -11.8 98.3+1.4 97.8+1.6 -0.5 
35 4.40+0.11 3.58±0.13 -18.6 97.3±2.1 97.5±2.2 0.2 
Table 5.2: Motility of K336E actin at different temperatures 
The sliding speed of K336E i/i/as lower than that of control actin at all four 
temperatures, whilst the percentage motility of K336E and control actin was 
indistinguishable. 
• — Control 
• — K336E 
25 30 
Temperature (°C) 
Figure 5.7: Comparison of the effect of temperature on 
filament sliding speed for K336E and control actin 
K336E actin moved consistently slower than age-matched control actin at all 
temperatures I tested. 
217 
NM and HCM Mutation K336E 
5.1.6.4 Regulation with Tropomyosin (Tm), Troponin (Tn) and 
Ca^^ 
Tropomyosin, tropomyosin-troponin regulation and Ca^^-sensitivlty of 
K336E actin was also investigated. Tropomyosin tended to lower the sliding 
speed of actin filaments; actin-tropomyosin sliding speed was more variable 
than actin sliding speed, and there was no evidence of a reduced sliding 
speed due to the mutation (Table 5.3A), speed variability was possibly a 
result of using different tropomyosin concentrations and isoforms. In many 
experiments NTG actin-tropomyosin motility was quite low, and with such low 
percentage motility, filament sliding speed was hard to be measured 
accurately. On average the percentage motility for actin-tropomyosin was 
30.9% greater with K336E actin, and this difference was statistically 
significant with paired ttest (p=0.001773) (Table 5.3B). K336E and control 
actin were very similar in cardiac thin filament regulation and Ca^^ sensitivity. 
In one experiment, in the presence of skeletal tropomyosin-troponin, mutant 
actin showed increased sliding speed and much higher percentage motility 
compared to control actin at both high (pCa5) and low (pCa9) 
concentration (Table 5.4). The effect of tropomyosin and tropomyosin-
troponin on K336E actin motility is summarised in Figure 5.8. There were too 
few experiments to make any conclusions about the effect of the K336E 
mutation on Ca^^ regulation. 
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1 3.63+0.03 
4.19±0.04 
3.33+0.02 
3.79±0,06 
3.68+0.02 
3.45±0.11 
3.13+0.05 
4.29±0.12 
3.01+0.11 
3.02±0.12 
4.39+0.14 
2.47+0.16 
2 2.51±0.11 
2.0+0.01 
1.85±0.15 
1.49+0.08 
* 1.75±0.06 
** 1.14±0.04 
***1.11+0.1 
* 2.52+0.08 
** 1.78+0.12 
***2.15+0.1 
1.44±0.13 
1.40±0.13 
0.83+0.07 
2.67+0.20 
2.0+0.23 
2.21±0.15 
3 2.70±0.15 
2.91+0.07 
2.47+0.07 
2.63+0.21 
* 2.73+0.11 
**3.39±0.07 
***2.4+0.04 
"'2.33+0.10 
2.50+0.10 
2.83±0.16 
2.83±0.13 
2.30+0.22 
Average 3.04±0.28 2.77±0.34 2.44±0.25 2.38±0.25 
Ttest 
Rvalue 
paired =0.06352 
unpaired =0.5478 
paired =0.4621 
unpaired =0.8549 
1 98.8+0.8 
82.5+16 
91.3+1.4 
97.8±1.7 
100±0 
96.0±3.1 
93.5±1.9 
100±0 
65.0±5.3 
93.5+5.8 
97.8+2.3 
66.8±5.3 
2 90.0+2.0 
85.8+1.3 
70.8±9.3 
74.7+4.1 
* 71.5±3,9 
** 14.8±2.3 
***9.5+2.9 
* 79.0±3.3 
** 43.0+8.3 
***56.5+4 
70.0+8.4 
46.8+7.6 
20.5±7.3 
85.8+5.5 
79.0+3.3 
82.3+3,3 
3 69.5+6.3 
74.0+5.3 
77.0+7.8 
87.0+13 
* 61.5+4.0 
** 59.3+7.8 
***29.8+5 
** 45.0+4.6 
77.3+3.7 
79.0+3.5 
80.5+4.9 
63.5±11 
Average 84.6±3.8 86.2±4.6 56.0±7.6 73.3+5.7 
T test 
P value 
paired =0.7532 
unpaired =0.7897 
paired =0.001773 
unpaired =0.08216 
(A) Filament 
Sliding Speed 
Prep 1: 
60nM cardiac Tm 
Prep 2 & 3: 
* 5nM skeletal Tm 
** 10nM skeletal Tm 
*** 20nlVI skeletal Tm 
(B) Filament 
Percentage Motility 
Table 5.3: Effect of tropomyosin on motility of K336E and 
control actin 
(A) Filament sliding speed (B) Filament percentage motility. K336E and 
control actin showed no consistent difference in sliding speed with 
tropomyosin. In the presence of tropomyosin K336E actin had consistently 
higher percentage motility than control actin. 
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(A) Filament Sliding Speed 
3.01-0.11 2.47±0.16 4.41±0.08 3.46+0.22 0.89+0.77 0 n 
1 2 2.33+0.10 2.30+0.22 2.57+0.15 2.99±0.20 1.35+0.22 1.51+0.16 1 
(B) Filament Percentage Motility 
Filament % Motility 
Actin-Tm 
Filament % Motility 
at pCa5.4 
Filament % Motility 
at pCa9 
n 65.0±5.3 66.8±5.3 66.7+4.5 57.3+2.1 2.3+2.1 2 45.0±4.6 63.5+10.5 18.5+3.2 62.8+6.2 2.0+0.7 35.0+10.8 1 
Prep 1; with 60nM cardiac tropomyosin + 40nM cardiac troponin 
Prep 2: witii 10nM st<eletal tropomyosin + 40nlVI sl<eletal troponin 
Table 5.4: Effect of tropomyosin-troponin and Ca^* on motility 
of K336E and control actin 
(A) Filament sliding speed (B) Filament percentage motility. K336E and 
control actin showed little difference in cardiac thin filament regulation and 
Ca^^-sensitivity. However, in the presence of skeletal Tm and Tm-Tn, mutant 
actin had distinctly increased percentage motility compared to control actin. 
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• K336E 
• Control 
(A) Cardiac on Sliding Speed (B) Cardiac on % IVIotiiity 
= 60 
ISSD 
Actin Actin+Tm Actin+Tm+Tn 
pCa5 pCa9 
Actin Actin+Tm Actin+Tm+Tn 
pCa5 pCa9 
(C) Skeletal on Sliding Speed (D) Skeletal on % Motility 
Actin Actin+Tm Actin+Tm+Tn 
pCa5 pCa9 
Actin Actin+Tm Actin+Tm+Tn 
pCa5 pCa9 
Figure 5.8: Thin filament regulation and Ca^* sensitivity of 
K336E and control actin. 
Average values of motility of actin only in Table 5.3 and individual values in 
Table 5.4 were used to plot effect of (A) cardiac thin filament on sliding 
speed, (B) cardiac thin filament on percentage motility, (C) skeletal thin 
filament on sliding speed (D) skeletal thin filament on percentage motility of 
K336E and control actin. Addition of skeletal Tm and Tm-Tn resulted in 
significantly higher filament percentage motility of K336E than control actin. 
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5.1.6.5 Force Assay 
The relative force of K336E actin-myosin interaction was assessed. The 
drag due to j-actinin cross-linking to the thin filaments reduced thin filament 
motility. The more force produced by actin-myosin interaction, the more t -
actinin needed to stop the movement. Our result illustrated in Figure 5.9 
suggested that K336E mutation elevated actin-myosin force than control 
actin. However, as the curve of both actins never reaches 0, no firm 
conclusion can be made. 
100 
Control 
K336E 
0.1 0.2 0.3 0.4 
[alpha-actinin] (/vg/ml) 
0.5 
Figure 5.9: Comparison of actin-myosin force generated by 
K336E and control actin 
Actin-myosin force generated by K336E mutant was greater tiian that 
generated by control actin. 
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5.1.6.6 Actin Binding Competition Assay for t -Actinin 
The relative affinity of K336E actin for t-actinin was studied by applying the 
actin binding competition assay. In each paired cell, TRITC-phalloidin 
labelled human actin (K336E or control) competed with unlabelled rabbit 
skeletal actin for binding to f-actinin at a constant total actin concentration. 
Various ratio of unlabelled rabbit actin in the mixture with labelled human 
actin were examined. Figure 5.10 shows results from 3 separate experiments 
I performed. In all 3 experiments, K336E actin bound to f-actinin with a 
remarkably reduced affinity compared to control actin. The K value for both 
actins and the difference between mutant and control actin are summarised 
in Table 5.5. 
A 7.25±7.58 0.31±0.03 0.043 
B 1.97±1.55 0.34±0.04 0.173 
C 1.28±0.29 0.85±0.20 0.664 
Table 5.5: Summary of relative (p-actinin binding affinity for 
K336E and control actin 
Experiment A-C correlate to those in Figure 5.10. In all 3 experiments 
performed mutant actin had a significantly lower K value than control actin. 
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Figure 5.10: Comparison of relative affinity of K336E and 
control actin for ^-actinin 
Data was fitted to the ^-actinin binding equation to produce K for each actin. 
In all 3 experiments (A-C) I performed, the mutant actin bound to (p-actinin 
with a lower affinity than control actin. 
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5.1.7 Discussion 
5.1.7.1 Characterisation of K336E Actin 
K336 is located close to the bound nucleotide, which is in the 'hinge ' 
region of actin and the j-amino group is hydrogen-bounded to the adenosine 
ring of MgATP. The conformational change induced by the hydrolysis of 
ATP-actin to ADP-actin locks F-actin into its stable state after subunit 
assembly. However, the polymerisation and stability of the mutant actin 
extracted from the patient biopsy appeared to be indistinguishable from 
control actin. The mutant actin was present at 28% in skeletal whole muscle 
and myofibrils, and it copolymerised with wild-type actin at 45% in F-actin. 
The ratio at 28% is unusual (normally 50%), one possible reason for this is 
degradation of K336E actin in the muscle. 
K336E exerted a dominant negative effect on skeletal actin functions. The 
shorter length of K336E actin reflected either a greater ratio of nucleation to 
elongation rates or (more likely) premature termination of elongation due to 
defective actin structure or extrinsic capping proteins, suggesting a poison 
peptide. The observed slower cross-bridge turnover rate and weaker binding 
to f-actinin, which anchors actin filaments to the Z-line, could result in 
impaired force transmission in both skeletal and cardiac muscle. This is 
compatible with patient's symptoms of muscle weakness and 
cardiomyopathy. Although K336E actin appeared to produce greater actin-
myosin force generation, with only one experiment done, it is unclear 
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whether this is truly what was happening in our mutant sample. The distinctly 
higher percentage motility of mutant actin filaments in the presence of 
skeletal tropomyosin implies possible abnormal contractility. These direct and 
indirect effects could be skeletal disease-causing. 
5.1.7.2 Unique Features of K336E Mutation 
Despite the presence of 20% skeletal muscle actin in the adult heart 
muscle, the cardiac muscle is generally spared in nemaline myopathy, 
perhaps because the expression level of t-skeletal actin in cardiac muscle is 
not sufficient enough to affect its function as suggested by llkovski et al. 
(2005) that t-cardiac actin was shown to be the predominant sarcomeric 
actin isoform. An association of NM with HCM has been reported only twice 
previously before molecular diagnosis was available (Skyllouriotis et al. 1999; 
Van Antwerpen et al. 1988). K336E seems to be the first in which a primary 
diagnosis of HCM has been linked to nemaline myopathy and a mutation in 
the ACTA1 gene. Another mutation in K336 to isoleucine was reported to 
cause intranuclear rod myopathy (Sparrow et al. 2003), but a 
cardiomyopathy was not found in the patient. 
Recently Kaindl et al. (2004) reported two related patients who carried a 
missense E334A actin mutation; HCM was observed in association with a 
dominant congenital myopathy with only cores and no rods. K336 and E334 
both lie within the 'hinge ' region and form a part of the nucleotide binding 
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pocket. The 'hinge ' region has been proposed to play a role in the 
transition between actin confirmations that may be linked to the regulation of 
thin filament interaction with myosin (Costa et al. 2004; Egelman 2001). 
The slower sliding speed and weaker binding to Z-line protein j-actinin 
corresponded to those observed in previous studies of mutations in 
tropomyosin and troponin T that cause dilated cardiomyopathy (DCM), 
whereas HCM mutations in thin filament proteins are commonly associated 
with faster cross-bridge turnover (Robinson etal. 2002). Similar to K336E, a 
HCM actin mutation E99K in transgenic mouse, however also exhibited a 7% 
lower sliding speed and higher Ca^'^-sensitivity. It may be that this child had a 
compensated hypertrophy in reaction to the mutation that would 
subsequently develop decompensated DCM. 
5.1.7.3 Other Skeletal Muscle Disease-Causing Mutations 
with Cardiac Involvement 
In contrast to ACTA1 mutations, most mutations that are expressed in 
skeletal and cardiac muscle show phenotypes in both tissues. 
5.1.7.3.1 Dystrophin Mutations 
Dystrophin is a cytoskeletal protein found in both skeletal and cardiac 
muscle. It anchors actin to the dystrophin-associated glycoprotein complex in 
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the plasma membrane of muscle cells (Ahn & Kunkel 1993). Mutations in the 
dystrophin gene lead to X-linked muscle diseases Duchenne and Becker 
muscular dystrophy which often involves dilated cardiomyopathy. 
Cardiomyopathy can be severe in patients with Duchenne and Becker 
muscular dystrophy (Beggs et al. 1991; Nigro et al. 1990). Female carriers of 
Duchenne and Becker muscular dystrophy may show combination of dilated 
cardiomyopathy with skeletal myopathy or in some cases cardiomyopathy 
alone as the clinical symptom (Mirabella et al. 1993). 
5.1.7.3.2 Desmin Mutations 
Myofibrillar myopathy consists of a heterogenous skeletal myopathies 
mostly accompanied by cardiomyopathy. One distinct subtype is termed 
"desmin myopathy" caused by mutations in the gene encoding desmin, a 
major cytoskeletal component of the myocytes critical for the structural 
integrity of myofibrils (Bar et al. 2007). Dalakas et al. (2000) reported 22 
patients from 8 families with dominantly Inherited myofibrillar myopathy and 2 
sporadic cases. Six missense mutations were identified in the desmin gene. 
7 of the 12 patients with mutations had cardiomyopathy. In transfected cells, 
the mutant desmin was unable to form filamentous network. Those mutations 
cluster in the C-terminus of the central t-helical rod domain of the desmin 
gene, which plays an important role in filament assembly. It is therefore 
reasonable to predict disrupted interactions between desmin and various 
cytoskeletal protein resulting in altered biomechanical properties of individual 
myocytes and eventually severe dysfunction of skeletal and cardiac muscle. 
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5.1.7.3.3 Lamin and Emerin Mutations 
Emery-dreifuss muscular dystrophy (EDMD) is an inherited muscular 
disorder clinically characterised by slowly progressive weakness in humero-
peroneal muscles, early joint contractures and adult onset cardiomyopathy 
with conduction defect (Funakoshi et at. 1999). Mutations in Lamin A/C gene 
have been associated with autosomal EDMD, other muscular dystrophy and 
cardiomyopathy (Hayashi 2005). The gene responsible for X-linked EDMD 
encodes an integral protein of the inner nuclear membrane of muscle cells-
emerin. It interacts with nucleoplasms and lamins thereby maintaining the 
mechanical stability of the nuclear membrane of skeletal and cardiac muscle 
cells. Positive staining of emerin at the cardiac demosomes and fasciae 
adherentes implies a possible physiological function of this protein in cardiac 
conduction. 
What these mutations have in common is that they are components of the 
cytoskeleton. It is well established that myofibrillar protein expression is very 
highly controlled (Kumar et al. 2004), for instance MyBP-C truncation 
mutations are excluded from heart muscle in patients with HCM (Moolman et 
al. 2000; Rottbauer et al. 1997). Ilkovski et al. (2005) has proposed that it is 
likely to happen with most ACTA1 mutations, which can readily be 
compensated for by upregulation of the unmutated allele or of ACTC. K336E, 
however, seemed to act as a classic poison peptide, implying that the 
mutation was present in heart muscle. Unfortunately there were no heart 
muscle samples available from this patient. It therefore remains a mystery as 
to why K336E and perhaps also E334A are the only congenital myopathy 
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mutations in ACTA1 out of over 140 that were expressed in heart muscle and 
produced a cardiac phenotype. 
5.1.7.4 Conclusion 
I was able to extract pure F-actin from the patient biopsy. Compared to 
control actin, K336E mutant actin showed distinct properties which could 
explain the phenotype of the patient. Over 140 ACTA1 mutations have been 
found in patients with congenital skeletal myopathies but do not affect 
cardiac function sufficiently to cause cardiomyopathy. K336E is the first 
ACTA1 mutation associated with severe cardiomyopathy to be fully 
characterised. 
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5.2 Investigation of the Intranuclear Rod 
Myopathy (IRM) Mutation V163M 
We obtained biopsy samples from a patient with severe nemaline myopathy 
combined with intranuclear rods. 
5.2.1 Phenotype of V163M IVIutation 
The patient required nasogastric feeding due to difficulties with swallowing 
soon after birth. At age 3.5 years she was able to walk and swallow. Now at 
age 6, she is unable to lift heavy items, hop or skip, and has a tall face and 
thin musculature. Her mother and grandfather also carried the mutation and 
had mild facial and limb muscle weakness. When examined by Gomori 
trichrome staining and electron microscopy, the patient muscle biopsy 
revealed numerous intranuclear rods and filamentous accumulations (Figure 
5.11), both of which were observed in the grandfather as well. However, only 
filamentous accumulations were seen in the mother (llkovski etal. 2004). 
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(A) (B) 
(C) Figure 5.11 Muscle histology 
of a patient with V163M. 
(A) Gomori trichrome staining of 
frozen muscle sections revealed 
intranuclear rods (arrow). (B) EM 
confirms the presence of nemaline 
rods. (C) EM showed filamentous 
accumulations (short arrow) with 
higher magnified image of long 
filaments with partial striations. 
Adapted from (Hkovskiet ai 2004). 
5.2.2 Location of V163 
Molecular modelling of actin shows that V163 is in adjacent to one of the 
two nuclear export signal (NES) sequences of actin (Figure 5.12), which 
have been demonstrated to govern actin transport in mammalian cells (Wada 
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et al. 1998). Hence V163M mutation may possibly interfere with normal actin 
localisation resulting in aggregation of actin in the nucleus. 
V163 
Figure 5.12: Location of V163 in actin monomer 
Molecular modelling of actin monomer produced with Chimers software using 
Actin USZ.pdb file shows the proximity between V163 residue (brown 
sphere) and NES (in black) of actin. 
5.2.3 Isolation of V163M Actin from A Patient Biopsy 
We were supplied with a biopsy taken at 5 months by Dr. Nigel Clarke, 
University of Western Australia. The extraction of V163M and age-matched 
control actin was similar (Figure 5.13). There was no mutant F-actin 
extracted in the absence of phalloidin. 
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Figure 5.13: Isolation of V163M actin from a patient biopsy 
The figure shows Western blots effractions taken at various stages of the 
preparation of V163M and control actin. The mutation appeared to cause 
reduced polymerisation in the absence of phalloidin. 
5.2.4 Expression Level of V163M Mutant Actin 
There is no charge change in V to M mutation, thus we were unable to 
investigate the expression level of mutant actin using 2D electrophoresis. 
Domazetovska et al. (2007) determined that V163M actin was present at 
20% of the total actin in the whole muscle from the same biopsy sample as 
we had (Figure 5.14). However, the expression level of mutant actin in our 
extracted F-actin was not measured due to insufficient amount of protein. 
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Figure 5.14: Mass Spectrometry analysis of peptides from a 
patient with W63M mutation and a control subject 
A peak corresponding to the wild-type (WT) peptide (MW=3,196.6Da) was 
present in both the control and patient samples. An additional peak i/vas 
present only in the patient samples, corresponding to the mutant peptide 
(MW=3,228.6Da). A 32Da shift from V to M allowed the relative expression 
level of V163M to WT peptide to be determined by summing the area of the 
peak clusters representing each peptide. Adapted from (Domazetovska et al. 
200%L 
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5.2.5 In Vitro Mot i l i ty Study of V163M Ac t i n 
As a result of the small size of the sample, only a limited number of assays 
were carried out on V163M actin. 
5.2.5.1 Density Comparison 
V163M actin was compared with age-matched control human actin in our 
functional studies. TRITC-phalloidin labelled mutant actin was as bright as 
the control. They had similar filament length, but filament density of the 
mutant was 50% lower than control actin. The average of filament density for 
V163M and control actin was 53.9±4.3 and 109.0+9.2 respectively, with P 
value <0.0001 in the significance t test. 
5.2.5.2 Temperature-Dependency 
The motility of V163M actin was examined at 20°C, 25°C, 28°C and 30°C. 
The mutant was not consistently different from control actin in either filament 
sliding speed or percentage motility (Table 5.6). Effect of temperature on 
filament sliding speed V163M is plotted in Figure 5.15. 
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20 1.75±0.11 1.61±0.02 -8.0 69.3+1.1 61.5+10 -7.8 
1.54+0.04 1.82+0.08 182 61.0±9.5 60.3+11 -0.7 
25 2.18±0.07 2.05+0.09 -6.0 57.5+11 81.6±10 24.1 
28 2.39+0.01 2.24+0.14 -6.3 93.0+2.7 65.5+12 -27.5 
2.44±0.03 2.40±0.09 -1.6 71.3±5.8 68.3±10 -3.0 
1.81±0.11 2.19±0.02 21.0 60.8±19 90.3±5.1 29.5 
30 1.94±0.04 2.39±0.09 2^2 56.3±3.9 92.5±3.8 36 2 
Table 5.6: Motility of V163M actin at different temperatures 
There was no consistent difference in fiiament sliding speed or percentage 
motility between the mutant and control actin at any of the temperatures I 
tested. 
• — Control 
V163M 
25 
Temperature ("C) 
Figure 5.15: Comparison of the effect of temperature on 
filament sliding speed for V163M and control actin 
The mutant actin was not different from control actin In temperature-
dependency. 
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5.2.6 Discussion 
The patient is from a family in which three generations were affected by 
IRM due to a single point mutation V163M in ACTA1. This is the first report of 
dominantly inherited IRM. Very recently published work by Domazetovska et 
at. (2007) explored the molecular mechanism by which the mutation altered 
normal actin functions in patient muscle biopsies, tissue culture and 
Drosophila. 
They demonstrated that despite the grossly intact sarcomere structure, 
those intranuclear rods found in the patient muscle fibres contained in 
addition to I-skeletal actin, Z-line proteins including f-actinin, f-filamin and 
myotilin. These proteins all play specific roles within the nucleus, but there 
has no evidence that any of them is localised to the nucleus. Hence the 
sequestration of these proteins within the nucleus might have impact on 
nuclear structure and activity. Proteins that are considered responsible for 
muscle regeneration were shown to be overexpressed in patient muscle 
fibres, which may explain the relatively normal sarcomere structure. 
Moreover, mass spectroscopy was applied to determine the expression 
level of V163M mutant actin in samples from all three generations from the 
family. 20% of the total actin in the child was M163 mutant, whereas the 
mother expressed the mutant actin at a level of 3 to 6%. Surprisingly, there 
was no mutant actin detected in the grandfather, suggesting the tendency of 
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degradation of the mutant actin. This finding may be the reason behind the 
remarkably reduced density of V163M actin observed in our experiments. 
The accumulation of filamentous actin displayed in the muscle fibres of the 
patient with V163M mutation are very similar to those previously described in 
three nemaline myopathy patients who carried ACTA1 mutations (Goebel et 
at. 1997; Nowakefa/. 1999). 
In order to assess the localisation of mutant actin and its potential effect on 
localisation of wild-type actin within the cytoskeleton, EGFP-tagged V163M 
construct and wild-type construct cotransfected with untagged V163M actin 
were transfected into C2C12 myoblasts. Intranuclear actin aggregates were 
observed with this mutation and another mutation on the same residue 
V163L as well. The intranuclear actin aggregates resemble those found in 
muscle samples from other intranuclear myopathy patients (llkovski et al. 
2004). Interestingly, this mutation led to accumulations of not only the mutant 
actin but also wild-type actin within the intranuclear aggregates. The two 
nuclear export signal sequences of actin are thought to facilitate the active 
transport of actin from nucleus to cytoplasm in mammalian cells (Wada et al. 
1998). VI63 residue lying in vicinity of NES1 suggests the hypothesis that 
mutations on this residue may induce conformational changes of NES, which 
in turn possibly contribute to nuclear retention and aggregation of the mutant 
actin as well as wild-type actin. 
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Furthermore, they inserted the mutation into Drosophila flight muscle-
specific Act88F actin gene. In the absence of regeneration and 
compensation by other actin isoforms as seen in human muscle, the 
sarcomeric and Z-line structure in heterozygous flies was disorganised. 
In conclusion, V163M mutation appeared to have a range of various 
detrimental effects on sarcomeric structure and function, protein aggregation 
and dynamics of different actin isoforms, all of which can be related to the 
clinical phenotype of muscle weakness in the patients. Our work does not 
suggest any significant role for alterations in contractile properties of this 
actin mutation. 
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6. Visualisation and Analysis of Actin 
Polymerisation 
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6.1 Introduction 
Up to now I have studied the effects of actin mutations on the actin-myosin 
contractile interaction and its regulation. In several cases, notably D286G 
(see Chapter 3) and P332S (see Chapter 4.2), I did not find any consistent 
differences from wild-type control actin, therefore it is possible that the 
mutations affect some other functions. In the studies of nemaline myopathy 
actin mutations using a cellular expression system, Costa et al. (2004) 
produced evidence that some mutations could alter actin polymerisation. 
Hence I have investigated techniques for measuring actin polymerisation at 
the single filament level. 
The functional form of actin in cells appears to be the filaments (F-actin). 
Actin monomers form polymers by the process of polymerisation. It involves 
two steps; slow formation of nuclei, followed by rapid elongation of actin 
filaments (Figure 6.1). 
Elongation 
^ Nuclestfon 
J B a t e d Pointed 
Figure 6.1: Schematic representation of the mechanism of 
actin polymerisation 
Adapted from www, cooperlab. wustl. edu/Reviews/ReviewARCB Ms. html 
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The rate of actin monomers being added to the actin polymer (konC) (units 
/sec) depends on the concentration of the actin monomers available (C) 
(units M), where kon is a second order process (/M/sec). The rate of actin 
dissociation from the polymer is constant given as koff. The net rate of 
assembly at one end is konC - koff. The critical concentration is the 
concentration of the actin monomers (Co) when they are at equilibrium with 
no net assembly in the actin polymer, where konCc = koff, Cc (units M) equals 
to kon/koff, and represents the dissociation constant of an actin monomer. 
Elongation can be measured at a range of monomer concentrations to give a 
plot as the one in Figure 6.2. 
• Elongation rate at barbed end 
• Elongation rate at the pointed end 
Barbed end S l o p e = K o n 
Pointed end 
K Off 
0.2 0,4 0.6 0.8 1 
G-actin concentration (/;M) 
Figure 6.2: A plot of elongation rate vs. G-actin concentration 
produces a critical concentration 
The slop of the plot equals to Kon, while Kon is the intercept on Y axis. The 
critical concentration which is the intercept on X axis is different at the barbed 
and the pointed end. Polymerisation is predominantly at the barbed end. 
Plotted using data from (Pollard 1986). 
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The different rates of monomer exchange at the pointed and barbed end of a 
single actin filament result in a difference between the critical concentrations 
at the two opposite ends of the same filament. The rate is about 20-fold 
faster at the barbed end than at the pointer end (Pollard 1986). The critical 
concentration at the barbed end is about 0.12|iM and that at the pointed end 
is around 0.6piM under physiological conditions (Pollard 1986). 
To date, most of physiochemical studies of actin polymerisation have been 
done in solution. In order to understand the mechanism of mutant actin 
polymerisation, an assay which can monitor real time polymerisation 
dynamics at individual filament level is required. In collaboration with Prof. 
Ferenczi and Dr. Dmitry Ushakov (Biophysical Science, Imperial College 
London), we visualised actin polymerisation in real time using total internal 
reflectance microscopy (TIRF) in the presence of TRITC-phalloidin. 
The nucleation and growth of actin filaments can be studied at the single 
filament level if the actin filaments are visualised by fluorescent microscopy. 
In preliminary experiments a modified method of Ishiwata (Ishiwata et al. 
2001) was applied to measure the rate of polymerisation at the single 
filament level in the presence of 150nm TRITC-phalloidin. TRITC-phalloidin 
is highly fluorescent and is incorporated into actin filaments as they 
polymerise on the cover glass surface. It also inhibits the depolymerisation of 
actin, therefore only net elongation rate is measured. However, since 
fluorescent filaments and TRITC-phalloidin in solution are not distinguished 
by conventional epi-fluorescent microscopy, the process had to be halted at 
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different times by washing out the G-actin and TRITC-phalloidin to measure 
the length of the actin filaments. The polymerisation process could be 
observed in real time by using total internal reflectance microscopy (TIRF) 
(Amann & Pollard 2001). 
6.2 Study of Actin Polymerisation in Solution 
Actin polymerisation is usually measured in the micromolar {\iM) 
concentration range using light scatter or fluorescence of a pyrene label on 
actin to monitor polymer formation. In our light scattering assay, rabbit 
skeletal actin polymerisation was initiated by 50mM KCI, 2mM MgCl2 at 
25°C, the light scatter correlating to the formation of actin polymer was 
measured at 360nm for 25 minutes. 1-10|iM G-actin was tested, there 
seemed no polymerisation with 1|iM actin. Figure 6.3A suggests that 
polymerisation curve of higher G-actin concentration involved two phases- a 
linear phase followed by a flatter phase. This could be a consequence of two 
actin populations in the solution or it may be (more likely) due to depletion of 
monomeric actin. Another possible reason was that the assay was not 
specific, many factors might interfere with the light scatter. Only the slope of 
the initial linear phase of each curve was used to calculate the rate of 
polymerisation. The initial rate of polymerisation increased linearly with actin 
concentration (Figure 6.3B) with a critical concentration of 1.3|^M. 
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Figure 6.3: Effect of G-actin concentration on polymerisation 
measured by light scattering assay 
(A) Polymerisation with higher G-actin concentrations w/as a two-phase 
process. (B) Linear fitting of the data revealed a linear relationship between 
G-actin concentration and the initial rate of polymerisation with a critical 
concentration of 1.3fAM. 
To investigate the role of phalloidin in actin polymerisation, 1, 2 and 3|iM G-
actin was polymerised with V M phalloidin. Our results clearly indicated that 
the addition of phalloidin elevated the rate of polymerisation, even with 1 |iM 
actin, where there was obvious polymerisation process taking place. 
In conclusion, light scattering assay can be applied to monitor the process 
of actin polymerisation. In the absence of phalloidin, IpiM G-actin did not 
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appear to grow. Rate of polymerisation increased linearly with increasing 
actin concentration. A critical concentration of I.SfxM was yielded, which was 
31% lower than that at the barbed end in the ADP state (1,9^M), but much 
higher than the value in the ATP state (0.12nM) obtained by Pollard (1986) 
using electron microscopy. The difference may be explained by possible 
breakdown of ATP in our sample or the presence of inactive G-actin. Whilst 
in the presence of phalloidin, the shape of polymerisation curves was 
consistent with those without phallloidin. For the same actin concentration, 
phalloidin induced faster polymerisation, which was expected as it blocks 
depolymerisation. 
6.3 Preliminary Test to Establish the Reaction 
Conditions for TIRF Experiments 
Before visualising actin polymerisation using TIRF, a conventional epi-
fluorescent microscope was utilised to detect actin polymerisation in order to 
determine the suitable concentration of anchors and G-actin that give 
polymerisation reasonable for measurement and analysis. 2 ! l i M anchors were 
made by cross-linking HMM and F-actin (see Methods 2.9.1). 100x diluted 
anchors were sonicated for 4 minutes. 10Ojil of sonicated anchors was 
infused into a flow cell and incubated for 4 minutes, then the cell was washed 
with 2x250^1 a buffer B (50mM KCI, 25mM Imidazole-HCI pH7.4, 4mlVI 
MgCl2, 1mM EDTA, 5mM DTT, 0.5mg/ml BSA). G-actin was infused into the 
cell immediately after mixing with buffer B and 120nM TRITC-phalloidin. The 
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cell was then stored in a humidity box for a certain time, followed by a wash 
of 100|xl buffer B and 50^1 buffer C (0.5mg/ml BSA, 0.1mg/ml glucose 
oxidase, 0.02mg/ml catalase, 3mg/ml glucose and 0.5% methylcellulose). 
Polymerisation of 0.5 and actin at 0 ,5 ,15 and 30 minutes was 
examined under an epi-fluorescent microscope. Both actins were 
overcrowded at early time, making the analysis impossible. To obtain a 
reasonable filament density, 500x diluted anchors was used next. 
Polymerisation of 0.5 and 1.4^iM actin at 0, 5, 30, 45 and 60 minutes was 
tested. Nothing was observed at 0 time with both actin concentrations. At all 
the other time points, the cell was overcrowded with 1.4|iM G-actin, whereas 
0.5^M G-actin had clear elongation between 0-15 minutes. However, after 15 
minutes, there seemed to be an increase in filament density rather than in 
length. Likely the absence of ATP in actin resulted in unstable actin. Some 
actin filaments did not elongate, then degraded, which destabilised those 
polymerising filaments, and subsequently might also stopped the whole 
polymerisation process from going any further. 
In our next experiment, lOOnM ATP was introduced to G-actin just before 
infusing into the cell. The filaments grew continuously, but were too crowded 
to be analysed with 500x diluted anchors and 0.5|j,M actin, suggesting ATP 
indeed stabilised actin, therefore facilitated polymerisation to happen. Then 
2000x and 5000x diluted anchors were tried. SOOOx dilution was more 
suitable for our assay. The concentration of G-actin was reduced to 0. V M . 
Polymerisation of 0. V M actin was visualised at 0, 15, 30 and 45 minutes. At 
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the same time point, filaments were much longer with ATP than those without 
ATP as expected, this may as well explain the higher density of filaments 
using the same concentration of anchors compared to previous experiment. 
6.4 Visualisation of Rabbit Actin Polymerisation 
6.4.1 Polymerisation of Rabbit Act in with A Single 
Concentration (0.1nM) 
A TILL Photonics TIRF system (provided by Prof. Mike Ferenczi and Dr. 
Dmitry Ushakov, Biophysical Science, Imperial College London) based on a 
Zeiss inverted microscope with a 100x NA 1.45 lens and a 514nm laser (see 
Figure 2.17) was used to observe the polymerisation process. Fluorescent 
filaments can be seen in the presence of TRITC-phalloidin by using TIRF 
because TIRF illumination excites only a few nm at the surface (Figure 6.4). 
it allows analysis of nucleation and elongation with picomolar quantities of 
actin. This is especially useful for the study of actin from rare sources such 
as muscle biopsies. 
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0 Actin monomer 
0 polymerised actin-TRiTC-
phalloidin 
Figure 6.4: Schematic illustration of the mechanism of total 
internal reflectance microscopy 
TIRF illumination excites only a few nm at the surface allowing fluorescent 
filaments to be seen in the presence of TRITC-phalloidin. 
The polymerisation of actin was visualised by adding G-actin to pre-formed 
nuclei ("anchors") that were coated on a microscope cover glass (Figure 
6.5). To make anchors, equimolar F-actin and HMM were cross-linked with 
EDAC and sonicated to provide nuclei for actin to grow on (see Methods 
2.9.1). Preliminary experiments were done to determine the most suitable 
concentration for anchors and actin, which appeared to vary for different 
protein preparations (see Methods 2.9.2.1). 
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Figure 6.5: Schematic representation of initiation of actin 
polymerisation on pre-formed anchors 
In our very first attempt, 2^M anchors were diluted 5000x in motility buffer 
B. lOO^il of diluted anchors were infused to a motility flow cell first to coat the 
cover glass, followed by 2x250[il washes with buffer B to remove free 
anchors. 0.1 piM G-actin was mixed with; SOmM KCI/1mM MgC^, 120nM 
TRITC-phalloidin, lOOnM ATP, 1mg/ml BSA, glucose oxidase, catalase and 
glucose to initiate polymerisation and infused into the flow cell. 
Methylcellulose was not added due to the possible interference with 
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polymerisation process. The cell was immediately put under a TIRF 
microscope. The surface of the cover glass was observed with a 
PCO SensiCam CCD camera. 
Focussing was very difficult because of the tiny depth of the evanescent 
field. Various pre-focus strategies were tried. Initially TRITC-phalloidin 
labelled F-actin was infused into the other half of the flow cell for much easier 
focusing. Once the focus was obtained, the lens was moved to the half that 
contained G-actin. The time to first observation was reduced, but it was still 
at least 3 minutes. With epi-fluorescent microscopy, it was impossible to 
visualise G-actin growth as there was plenty of free TRITC-phalloidin in the 
background of the cell. Whereas with TIRF, individual growing actin filaments 
were seen proving that TIRF indeed only picks up the objects on the surface 
of the cell. 
Digital images were acquired as a series of TIFF files every 0.6 seconds for 
30 minutes. Although actin filaments were anchored on the cell surface at 
one end, in the absence of methylcellulose, the filaments moved fastly in and 
out of the illuminated surface therefore different filaments were observed 
from frame to frame, which made the tracking and analysis of single 
filaments impossible. Another issue was that the filaments stayed in the 
focus for less than a minute, so the focus had to be adjusted constantly 
during the recording. 
252 
Actin Polymerisation 
6.4.2 Effect of Methylcellulose 
In our next actin polymerisation experiment, 0.5% methycellulose was 
added to 0.1 fxM G-actin in order to prevent G-actin from diffusing away from 
the cell surface. By doing this, actin grew along the surface of the cell. The 
polymerisation of G-actin was recorded in real time from 10 to 40 minutes 
after it was initiated. Focus had to be adjusted constantly during the 
recording. 
Actin filaments showed rapid bending and translational movements due to 
Brownian motion but the presence of the methylcellulose polymer network 
constrained lateral movement away from the surface. Both the length and the 
number of filaments increased with time, some filaments did not change 
length at all and some filaments joined up end-to-end (annealing). We did not 
see any decrease in filament length or filament breakage. 
6.4.3 Quantitative Analysis of Single Filament 
Polymerisation 
The sequence of digital images was converted to Quicktime movie format 
for quantitative analysis with Dynamic Image Analysis Software (DIAS). A 
CD containing the whole movie (Movie 6.1) and as well examples of 
filaments annealing (Movie 6.2A-C) is attached in this thesis. Frames were 
selected every 3 minutes. To determine the length of individual filaments, a 
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defined central field of view in each frame was selected, and the length of 
each filament in that field (even it grew out of the field) was measured 
manually using the "arbitrary length" function (Figure 6.6). 
Figure 6.6: IVIanual length analysis of a population of 
filaments in a selected field in a frame (0.1 M rabbit G-actin at 
16m in) 
Contour lengtfi of filaments was drawn in the movie frame (red line) and 
DIAS calculated length in pixels (red), white box indicates the area counted. 
Then I needed to consider how to analyse this data. One way was to track 
elongation of single filaments over time. However, most of the filaments 
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shifted from frame to frame, and moved in and out of the surface of the cell 
due to Brownian motion. In addition, the two ends of some filaments could 
not be determined because of filament overlap. As a result, only few 
filaments were able to be tracked over time. Figure 6.7 illustrates three 
examples of singe filaments tracking. Another limitation of this approach was 
that it did not account for the number change of actin filaments over time. 
20 30 
Time (min) 
Figure 6.7: Comparison of elongation rate ofttiree individual 
filaments and mean filament length 
The elongation rates (slope of the curves) of individual filaments (F1-F3) and 
the average elongation rates of all filaments and short filament population 
were fairly similar 
After tracking single filaments, polymerisation of a population of filaments 
(similar to that used in in vitro motility assay) was analysed. For each time 
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point, length of individual filaments was measured and shown as frequency 
histograms. Filament number was plotted vs. filament length (^m). 
10 min 
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Figure 6.8: Frames from movie of actin (0.1 M) polymerisation 
and histograms of filament length distribution. 
Short and long population is represented in blue and orange respectively. 
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Figure 6.8 indicates that both the length and the number of filaments 
increased with time, suggesting that nucleation was taking place on the 
surface of the cell. After 20 minutes, there were two populations of the 
filaments. Both the populations increased in length with time. The longer 
population continuously increased in number whilst the number of the short 
population remained constant after 25 minutes (Figure 6.9). The longer 
filaments were approximately twice the length of the short population, and 
elongated 2x as fast as the short ones. 
Short population 
# — Long population 
10 20 30 40 
Time (min) 
Figure 6.9 Increase in length and number of the short and 
long filament populations with time. 
Reading from histograms in Figure 6.8, length and number of the two 
filament populations was plotted over time. The numbers written under each 
point was the number of filaments at each time point. 
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The long filaments were formed by the end-to-end annealing of two or more 
filaments. This was frequently observed and joined-up filaments constituted 
up to 30% of all filaments after 35 minutes. The picture sequence in Figure 
6.10 shows an example of filaments joining up. To watch annealing events in 
real time, see Movie 6.2A-C in the complementary CD. 
18.86 min 19.06 min 19.20 min 19.33 min 
Figure 6.10: An example of end-to-end annealing of two actin 
filaments. 
These joning-up events of actin filaments led to the formation of long 
filaments, which emerged at later stage of polymerisation process. The time 
at which this event occurred Is Indicated. 
The average elongation rate of all filaments was similar to the elongation 
rate of individual filaments (Figure 6.7). These two approaches were both 
tried at the beginning, then the population approach was chosen as more 
efficient and accurate for subsequent quantitative analysis. 
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6.4.4 Polymerisation of Rabbit Act in over A Range of 
Concentrations 
We studied the polymerisation of actin over a range of concentrations with 
this established method. To enable us to obtain the focus of the cell as 
quickly as possible, a different technique was tried. Instead of using 
fluorescently labelled F-actin as a marker, the coverglass texture on the cell 
containing G-actin was focussed directly (Figure 6.11), then the subsequent 
cells were visualised without moving the lens, so it was already close to the 
correct focus point. 
Figure 6.11: Coverglass texture of the cell visualised by TIRF 
The unique surface texture of the cell (note the black the dots) used in our 
TIRF polymerisation assay enabled us to focus directly on the cell containing 
G-actin. 
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This reduced the time to first observation down to less than 1 minute. It was 
particularly important when G-actin concentration was high, and 
polymerisations took place within 5 minutes of initialisation. Digital images 
were acquired as a series of TIFF files every 0.6 seconds for 4-60 minutes 
stopping when the field became too crowded to be able to distinguish 
individual filaments. Up to ten frames were selected at 0.5-6 minute intervals 
depending on the rate of actin polymerisation. 
In the first experiment, polymerisation was observed at 8 G-actin 
concentrations in the range of 0.05-0.75^M. For each concentration, we 
measured the filament length and filament number at ten time points. 
Filament length, filament number and total polymerisation (given by length x 
number of filaments) with different G-actin concentrations are plotted in 
Figure 6.12 (A-C respectively). The delay before the first measurement was 
due to the focussing time. The recording was stopped when the filaments 
were growing too long and it was no longer possible to distinguish the two 
ends of each filament. 
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Figure 6.12: Polymerisation of rabbit actin with a range of 
different G-actin concentrations 
(A) Filament length (B) Filament number (C) Total polymerisation. The order 
of those experiment performed is stated in (D). Those experiments marked 
with * are plotted in Figure 6.13 to yield a critical concentration. 
Polymerisation rate seemed to be more time-dependent than concentration-
dependent. 
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There was clearly difference in rate of elongation and increase in number 
among different actin concentrations. However, the rate of polymerisation 
seemed to be time-dependent, which was probably even more significant 
than concentration-dependent. The later it was tested, the faster it 
polymerised. There was a 3-4 times increase in polymerisation rate with the 
same G-actin concentration tested at a later time (The elongation rate of 
0.25SM actin which was tested first and 0.2<M actin which was tested about 
Shours later was 0.48 and 2,16<m/min respectively.). This was found with 
both length and number of filaments. The only plausible explaination was that 
the temperature rose as time went by, because the laser was on all the time 
throughout experiments lasting for over 4 hours. The lens was in direct 
thermal contact with the observation cell and so its temperature would 
determine the temperature in the cell. 
All polymerisation features observed previously were seen again, including 
the second population at later stage of polymerisation and annealing events 
of two actin filaments. 
The rate of elongation calculated from the slope of initial linear phase of the 
curve of mean filament length against time (Figure 6.12A), against G-actin 
concentration was plotted using just the data of initial four experiments 
(marked by *) to minimise the temperature effect. They fitted into a straight 
line giving a critical concentration, which is the intercept on X axis, of 
0.022<M (Figure 6.13), and a slope, which is equivalent to Kon of 
5.6<m/min/<M. 
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Figure 6.13: Initial elongation rate increased linearly with G-
actin concentration 
Due to the potential effect of time or temperature on actin polymerisation, 
only the first four experiments (0.25, 0.5, 0.1 and 0.75\iM G-actinj were 
plotted. Linear fitting of those points generated a critical concentration of 
0.022pM. 
6.4.5 Polymerisation of Rabbit Actin over A Range of 
Concentrations at A Constant Temperature 
Polymerisation of rabbit actin over a range of concentrations (0.025-0. V M ) 
was then studied using 4000x diluted anchors at a constant temperature. 
During observation, the motility cells were kept on a motorised MS2000 
stage (Applied Scientific Instrumentation, Eugene, OR) equipped with an 
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objective regulatory system (Bioptechs, Butler, PA) at 25°C. The objective 
regulatory system consists of an objective regulator as presented in Figure 
6.14 and a controller on which the temperature could be set. 
Figure 6.14: An objective regulator used in TIRF 
polymerisation assay 
The TIRF polymerisation assay could be temperature-controlled with an 
objective regulatory system, which contains an objective regulator (shown) 
and a controller Adapted from 
http://www.biODtechs.com/Products/OBJ HTR/obi htrhtml 
Again, two populations at a later stage of polymerisation and filaments end-
to-end annealing were seen. The long population did not always occur at the 
same time, but at a certain degree of polymerisation for different G-actin 
concentrations. Length of individual filaments for each G-actin concentration 
was analysed and plotted as histograms (filament number vs. filament 
length) at different time points. Figure 6.15 and 6.16 show length distribution 
of 0.05, 0.075<M and 0.025, 0.1 <M G-actin at four different time points as 
examples. 
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Figure 6.15: Length distribution of 0.05 and 0.075ij[\/l G-actin 
at different time points 
Two filament populations are colour coded (short-blue, long-orange). 
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Figure 6.16: Length distribution of 0.025 and 0.1fjl\^ G-actin at 
different time points 
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The rate of elongation and total polymerisation increased almost uniformly 
with increasing G-actin concentration (Figure 6.17). 
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Figure 6.17: Polymerisation of rabbit actin with a range of 
different G-actin concentrations at a constant temperature 
(A) Filament length (B) Filament number (C) Total polymerisation. (D) shows 
how I selected the part of plot (C) to use forgetting the rate of total 
polymerisation (slope) by curve fitting. Elongation and total polymerisation 
increased uniformly with increasing G-actin concentration. 
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Thus with higher G-actin concentrations, the total recording time and time 
intervals between each measurement was reduced. 
Because polymerisation was very fast at high concentrations of actin, a 
lower range of G-actin concentrations was used than before and the 
measurement made over a longer time, which was more reliable. The rapid 
polymerisation made the analysis rather difficult, especially with higher 
concentrations (0.09 & 0.1 <M) of G-actin. Initial rates of elongation obtained 
by linear fitting of the initial part of each curve and total polymerisation (as 
illustrated in Figure 6.17D) were plotted against actin concentration. The 
elongation rate increased linearly with actin concentration and the X-axis 
intercept gave a critical concentration of 0.017^M actin (Figure 6.18A), which 
is similar to our previous measurement (0.022<M). Elongation rate constant 
(Kon) of 5.6|im/min/^iM (the slope of the plot) was the same as our previously 
measured value. Calculated from this was a second order rate constant of 
2072/min/^iM G-actin (34.5/sec/fxM) assuming 370 actin monomers per [im of 
filament. This is about 4 times faster than previously published values (7.5 
and 7.4/sec/|a,M by Amann & Pollard 2001 and Ishiwata etai. 2001 
respectively). The plot of total polymerisation rate vs. actin concentration 
yielded a critical concentration near zero (0.012<M), as expected in the 
presence of phalloidin (Figure 6.18B). 
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Figure 6.18: Initial elongation and total polymerisation rates 
increased linearly with G-actin concentration 
The critical concentration obtained from initial elongation plot (A) was 
0.01 YPM, which is very similar to our previous result of 0. 022ijM (Figure 
6.13). Data was linear fitted. (B) Plot of total polymerisation rate. 
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6.5 Study of Polymerisation of D286G (D1) 
Mouse Actin 
6.5.1 Preparation of Mouse G-actin for Polymerisation 
Assays 
F-actin extracted from biopsy samples was too dilute to be used in our 
polymerisation assay. Nemaline myopathy associated actin mutation D286G 
(see chapter 3) expressed in transgenic mouse (D1) and dilated 
cardiomyopathy mutation E361G (described later in this chapter 6.7.1) in 
transgenic mouse hearts appeared to be the only suitable candidates for 
polymerisation study. Initially F-actin was extracted from 150mg D1 and age-
matched non-transgenic (NTG) mouse leg muscle and then was 
depolymerised. The concentration of both F-actins was around SOfxM 
determined by Lowry assay (see Methods 2.4.1). When tested in preliminary 
experiments, aggregates of filaments were observed in both D1 and NTG 
actins. Under a TIRF microscope, it seemed that increasing number of pre-
formed filament aggregates landed onto the cell surface without elongating. 
The formation of those aggregates could be a result of protein impurities or 
denatured proteins. 
In order to find out whether the aggregates were caused by protein 
impurities, a DNasel column was combined with a DEAE column to purify 
and concentrate mouse G-actin as described by Cook eta/. (1991). G-actin 
bound to DNase 1 (1ml) and was eluted with 2 volumes of G-buffer (10mM 
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TRIS, pH 7.5, 0.2mM CaCl2, 0.2mM ATP, 1% Tween 20, 1% Triton) plus 
50% formamide. G-actin was concentrated and neutralised by flowing directly 
onto DEAE sepharose (0.5ml) equilibrated with G-buffer. G-actin was then 
eluted with G-buffer plus 0.4M KCI. Flow through and column fractions were 
run on a Coomassie Blue stained gel, protein impurities were eluted in the 
flow through, whereas a single band of actin was seen in three column 
fractions. The concentration of eluted G-actin was obtained using Western 
blotting. It was extremely low (0.18<M), suggesting possible loss of protein 
during the purification process. In addition, when G-actin was re-polymerised, 
labelled with TRIRC-phalloidin and examined in motility assay. Neither D1 
nor NTG F-actin was motile. 
We then moved on to using S300 gel filtration column to purify mouse G-
actin similar to the standard purification of rabbit G-actin (see Methods 
2.3.4.3). The purified actin was still not concentrated enough (2.7^M) for the 
polymerisation assay though it was 14x more concentrated than that was 
yielded from DNase1-DEAE column. Hence next I focussed on ways of 
further increasing the concentration. Firstly I used freeze-drying in 5% 
sucrose and 1% dextran (Allison et al. 2000), which did improve the actin 
concentration but the yield of G-actin was low from the freeze-dried pellet. 
Then dialysis against polyethylene glycol (65g in 450ml buffer) was tried, but 
a low level of actin was recovered. Possibly because many actin stuck onto 
the wall of the dialysis tube. 2mg/ml BSA was introduced to G-actin just prior 
to dialysis to improve the recovery rate. Since 55kDa BSA was much more 
abundant than 43kDa actin, its band would easily cover the actin band on 
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SDS-PAGE. To overcome this problem, a different concentration approach 
which required only 0.2mg/ml BSA was attempted. Purified G-actin was 
concentrated with centrifugal filters (see Methods 2.3.4.4). As the 
concentration of actin was low (as low as ISfxM), and also because BSA 
would interfere with the absorbance measurement in Lowry assay, I 
developed dot blot actin assay for actin concentration determination 
(Guttenberger et al. 1991) (see Methods 2.4.3). Several preparations of actin 
were extracted, depolymerised, purified through S300 gel filtration column, 
concentrated with centrifugal filters and lastly tested in dot blot assay. 
Comparing the G-actin concentration before and after filter treatment, 
typically the volume was reduced at least 90%, and 11.5-83% of actin was 
recovered, in other words a 3-5 fold increase in actin concentration was 
achieved, which was suitable for use in the polymerisation assay. 
6.5.2 Polymerisation of iVIouse G-actin 
Once the protocol for isolation, purification and concentration was 
established and optimised, polymerisation of D1 and standard rabbit actin 
was examined again. Despite the rise in filament length and number, many 
long filaments were seen in both actins at zero time, indicating that this was 
not a result of different species, neither of the mutation. 
Those pre-formed filaments were not present in previous rabbit 
polymerisation experiments. The only difference between the preparations of 
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rabbit actin used before and used in this experiment was the additional 
concentration step, which might cause the formation of actin filaments or 
even aggregates. To avoid this step, 400mg instead of 150mg mouse muscle 
tissue was used to extract F-actin. However, the concentration of the yield 
was still too low for the polymerisation assay, hence a concentration step 
was still necessary. Polymerisation of D1 and NTG actin ranging from 0.01 to 
0.09|xM was measured using TIRF. As before, there were filaments formed 
prior to the initiation of actin polymerisation. Both actins displayed an 
abnormal polymerisation pattern that increased in number rather than in 
length. Throughout the process, more and more short filaments emerged, 
there was hardly any elongation taking place (Figure 6.19). 
Following a new supply of D1 and NTG leg muscles from Dr. Nowak, I 
isolated F-actin starting with 1.2g tissue and also reduced the volume of 
ACEX in which isolated F-actin was resuspended by 50% in order to 
maximise actin concentration. F-actin was depolymerised, purified through a 
S300 gel filtration column. Column fractions were checked on a Coomassie 
Blue stained gel. Concentrations of G-actin were determined, and were 
2.3^l\/l and 4.0p.lVI for D1 and NTG respectively. The concentration step was 
omitted since both actins were concentrated enough to be used in the 
polymerisation assay. Probably a consequence of damage to the tissue 
sample from which NTG F-actin was extracted, NTG G-actin did not 
polymerise at all. In contrast, D1 mutant actin grew in length as well as in 
number. Thus a satisfactory preparation of mouse G-actin could, in principle, 
be obtained by avoiding the concentration step. 
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Figure 6.19: Polymerisation of D1 and NTG mouse actin 
concentrated with centrifugal filters 
Both actins increased in number, but not in length. 
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Analysis of polymerisation for three different concentrations of D1 G-actin 
(0.5, 0.75 and 1<M) is shown in Figure 6.20. Filament number and total 
polymerisation increased with G-actin concentration. 
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Figure 6.20: Polymerisation of D286G actin with different G-
actin concentrations 
(A) Filament length (B) Filament number (C) Total polymerisation. 
Polymerisation increased with increasing G-actin concentration. 
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Because the points in the plot of initial elongation rate vs. G-actin 
concentration (Figure 6.21A) were scattered, the critical concentration 
yielded from Figure 6.21 B was included to give an approximate Kon of 
0.49<m/min/<M (the slope of the plot), which is 11-fold lower compared to 
5.6<m/min/<M for rabbit actin. In contrast, the rate of total polymerisation 
displayed a linear relationship with G-actin concentration (Figure 6.21 B) 
producing a critical concentration of 0.088<M, which is 7.3-fold higher that of 
rabbit actin (0.012<M Figure 6.18B). 
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Figure 6.21: Effect of G-actin concentration on D286G actin 
rate of initial elongation and total polymerisation 
(A) Plot of initial elongation rate (B) Plot of total polymerisation rate. Among 
the three concentrations of G-actin, 0.75/v/W actin had the highest intial 
elongation rate, while the rate of total polymerisation increased linearly with 
G-actin concentration producing a critical concentration of0.088pM. 
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6.5.3 Comparison of Polymerisation between D1 and 
NTG Actin 
A pair of D1 and NTG G-actins was prepared freshly from 1.2g mouse 
tissue samples, and was visualised with TIRF. 0.6, 0.8 and 1jiM G-actin were 
examined. There were no pre-formed filaments seen in either of the actins 
(Figure 6.22). Polymerisation was recorded up to 25 minutes. 
D1 NTG 
Si: 
Figure 6.22: Frame of 1IJM D1 and NTG actin at Iminute 
polymerisation showing no pre-formed filaments 
Maybe because they were not labelled properly with TRITC-phalloidin, the 
filaments were very dim with rather poor contrast. Analysis with DIAS 
programme was impossible, as I could not see the two ends of a filament 
clearly, either a result of poor labelling, or filaments not sitting on the cell 
surface. Hence the length of individual filaments was analysed by an 
alternative manual approach. Polymerisation movies were played using 
QuickTime Player. For each time point the movie was played backward and 
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forward in a range of 10 frames to identify the two ends of each individual 
filament. Then the contour of each filament was tracked on an acetate film 
stuck on the computer screen as illustrated in Figure 6.23. 
^ \ 
Figure 6.23: Tracking of the contour of individual filaments 
on an acetate film 
For polymerisation of each single concentration, 3 time points at 8, 16 and 24 
minutes were selected for analysis. After converting the distance on the 
acetate film (cm) to the distance in the movie (pim) the actual length of 
filaments was calculated. As the two filament ends were visible for only some 
of the filaments, the number of filaments used in length analysis was smaller 
than that used in number analysis, which counted all the filaments in the 
frame including those with undefined ends. The results of 0.6, 0.8 and 1<M 
279 
Actin Polymerisation 
actin polymerisation are shown in Figure 6.24, 6.25 and 6.26 respectively. D1 
actin appeared to have a lower elongation and total polymerisation rate, 
otherwise a similar polymerisation pattern compared to NTG actin. 
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Figure 6.24: Polymerisation analysis of 0.6IJM D286G (D1) and 
NTG actin 
(A) Filament length (B) Filament number (C) Total polymerisation. Mutant 
actin polymerised much slower than NTG actin. 
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Figure 6.25: Polymerisation analysis of O.SfjM D286G (D1) and 
NTG actin 
(A) Filament length (B) Filament number (C) Total polymerisation. At this 
concentration, mutant and NTG actin displayed comparable elongation and 
polymerisation. 
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Figure 6.26: Polymerisation analysis oflfjM D286G (D1) and 
NTG actin 
(A) Filament length (B) Filament number (C) Total polymerisation. D1 actin 
seemed to elongate and polymerise slightly slower than NTG actin. The two 
actins showed a very similar polymerisation pattern. 
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Elongation and total polymerisation rate vs. G-actin concentration were also 
plotted for D1 and NTG actin (Figure 6.27). At all three G-actin 
concentrations, mutant had a consistently reduced elongation and 
polymerisation rate than NTG actin. 
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Figure 6.27: D286G had consistent slower initial elongation 
and total polymerisation than NTG actin 
(A) Plot of initial elongation rate (B) Plot of total polymerisation rate. This 
difference remained at all three G-actin concentrations tested. 
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6.6 Other TIRF Polymerisation Experiments 
6.6.1 Polymerisation of DCM Mutant Actin E361G 
Extracted from Transgenic Mouse Hearts 
E361G is a DCM-associated actin mutation studied by Emma Dyer in our 
group. When isolating E361G F-actin from transgenic mouse hearts, most of 
the monomeric mutant actin appeared to be unable to polymerise. Therefore 
polymerisation assay on E361G actin was thought to be valuable to detect 
the difference in polymerisation between E361G and NTG actin if there was 
any. F-actin was extracted directly from thin filaments (see Methods 2.3.3) 
from four transgenic and four NTG mouse hearts (approximately 200mg for 
each sample), purified though a S300 gel filtration column (see Methods 
2.3.4.3) and concentrated using centrifugal filters (see Methods 2.3.4.4). 
Concentration for E361G and NTG actin was 6.25 and 1.53fxM respectively. 
Polymerisation of 1|xM mutant and NTG actin was compared with 4000x 
diluted anchors. Both actins had poor contrast making the analysis difficult. 
This was likely due to the concentration step as found with D286G actin. 
E361G seemed to elongate and polymerise slower than NTG actin (Figure 
6.28). Only the initial part of each curve was linear fitted to give the initial 
elongation rate for mutant and NTG actin which was 0.40 and 0,44<m/min 
respectively, and the total polymerisation rate which was 11 .Onumber x 
<m/min for E361G and 35.5number x <m/min for NTG actin. These values 
are comparable with those for D286G and NTG actin (Figure 6.26). 
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Figure 6.28: Polymerisation analysis of IjjM E361G and NTG 
actin from mouse tiearts 
(A) Filament length (B) Filament number (C) Total polymerisation. Mutant 
had a lower polymerisation rate compared to NTG actin. Black lines indicate 
how I selected the part the each curve for obtaining the rate of initial 
elongation and total polymerisation, which was similar to that for D286G and 
NTG actin shown in Figure 6.26. 
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6.6.2 Polymerisation of Actlns Purified from 
Baculovirus 
Four actin mutations were expressed in baculovirus by Dr. Kay Beckman, 
University of Sydney. I examined the polymerisation of these mutant actins. 
In preliminary experiments using a conventional epi-fluorescent microscope, 
control actin was short with long dim filaments in the background; D286G 
and G182D showed short bright filaments with many short dim filaments in 
the background; 1136V and Ml32V actin had dotty filaments with few 
background. These bright filaments were considered to be insect actin 
whereas the dim ones could be human actin. When tested in TIRF 
polymerisation assay, control actin polymerised till 4 minutes, then stopped 
growing any longer and a number of filamentous aggregates were observed. 
The most plausible explanation is that the actin polymerised rapidly at a very 
early time causing no more anchor being available for further elongation. 
6.7 Discussion 
6.7.1 Single Filament Assays for Actin Polymerisation 
Two different approaches have been employed to study actin 
polymerisation at the single filament level. Ishiwata et al. (2001) analysed 
polymerisation of TRITC-phalloidin labelled actin in solution with conventional 
fluorescent microscopy. To overcome violent Brownian motion, they cross-
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linked HMM and F-actin to anchor short actin filaments onto a collodion 
(nitrocellulose)-coated glass surface, and observed elongation of the same 
filaments. This simple technique can be used with unmodified actin, and any 
actin, even mutants, which we are interested in. Because in the presence of 
phalloidin the critical concentration for actin polymerisation is very low (we 
found it is between 0.015 and 0.025<M) compared to 1.3<M for unmodified 
actin (Figure 6.18), low actin concentrations can be used, so polymerisation 
is slow taking up to 60 minutes. This technique however, only measures rate 
of polymerisation, Kon as phalloidin suppresses depolymerlsation. 
The other approach visualised polymerisation of actin labelled on Cys374 
with Oregon green rather than TRITC-phalloidin by TIRF (Kuhn & Pollard 
2005). Both polymerisation and depolymerisation rates were measured 
giving a true critical concentration, but this method has limitations. Firstly it 
requires modified actin, which makes it impossible to be applied to mutant 
samples present in small quantities. Secondly the fluorescent tag on actin 
inhibits polymerisation, so 10-50% mixture with native actin has to be used, 
which may alter the rate of polymerisation and / or depolymerisation. 
In order to examine polymerisation of mutant actins at low concentrations, 
Ishiwata 's method was the only one suitable. 
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6.7.2 Polymerisation of Rabbit Act in 
TIRF enables us to study actin polymerisation over a range of G-actin 
concentrations at a single filament level in real time. We analysed actin 
polymerisation process both as a population and as individual filaments, then 
the population approach was chosen as more efficient and accurate for 
quantitative analysis. 
The plot of elongation rate, which was calculated from the slope of the 
length vs. time plot, against G-actin concentration yielded a critical 
concentration of around 0.02|.iM (Figure 6.18A). It also produced a specific 
rate of adding molecules to a filament, 34molecules/sec/|iM (assuming 370 
actin monomers/^im of filament). This value is in the same range as our 
previous measurement (Figure 6.13), and is much faster than other 
published ones by Amann & Pollard (2001) and Ishiwata etal. (2001) (7.5 
and 7.4/sec/[iM respectively). This could be a result of differences between 
our protocol and theirs. We added TRITC-phalloidin to the actin just before 
initiating polymerisation, whereas Amann & Pollard covalently labelled the 
actin with Oregon Green overnight prior to polymerisation, allowing the label 
to be fully incorporated covalently. It is noted that the labelling does stop 
polymerisation and so it is generally used at a low concentration but possibly 
still reduces the rate. Although Ishiwata 's group labelled actin the same way 
as we did, they did not introduce methylcellulose in the solution, which may 
play a role in assisting actin elongation if the surface catalyses 
polymerisation and the filaments are confined to the surface. This method is 
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now sufficiently developed to enable us to make comparable measurements 
of wild-type and mutant actin polymerisation. 
During polymerisation we frequently observed annealing of two or more 
filaments end-to-end, leading to the formation of long filaments, which was 
supported by the occurrence of two populations of filaments at a later stage 
of polymerisation process in our analysis. Annealing of actin filaments was 
first reported by Murphy etai (1988) using electron microscopy and 
afterwards by Andrianantoandro et al. (2001) with fluorescent microscopy, 
but has never been observed in real time. Our data suggested that this event 
was more concentration-dependent rather than time-dependent as it 
occurred at different times with different G-actin concentrations (Figure 6.15, 
6.16). For 0.1 <M G-actin, annealed filaments constituted the same proportion 
(around 25%) of total filaments at 26-30minutes in two separate experiments 
(Figure 6.9, 6.16), which was significant in forming long filaments. There was 
no filament breakage seen. 
Our results showed that the number of actin filament increased with time 
during the polymerisation process, no other group has noted this. No filament 
was seen in the absence of anchors containing cross-linked actin and HMM 
in most of our experiments, thus anchors are required for actin to grow. 
Anchors are cross-linked HMM and F-actin, this may make a proportion of 
the bad nuclei which had a low probability of starting filaments, ie. will start 
later than the good ones. There are several possible reasons for this 
increase in number, some filaments may be diffusing away from the surface 
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with one end still attached and are being counted when they came back to 
the surface. This is however, less likely as methylcellulose was added to the 
solution to hold the filament onto the surface, and if this is the case, filaments 
would be expected to also diffuse away from the surface giving the 
appearance of shortening which we never saw. Another reason could be a 
decreased affinity of actin for anchors due to the cross-linking of the anchors 
or delayed capping protein dissociation from the actin anchors may also be 
responsible, as a result filaments started polymerising at a later stage. The 
glass surface itself may induce nucleation as other groups did not use a 
silicon surface. If nucleation in situ was what was happening, then new 
filaments should emerge short as visualised in our movies, elongate at the 
same rate and be similarly affected by temperature as original filaments. This 
behaviour was proved by our result that the for the same G-actin 
concentration tested Shours apart, the level of increase in filament number 
and length was the same. 
6.7.3 Use of TIRF to Study Effects of Act in Mutations 
on Polymerisation 
We demonstrated that TIRF can be used to study polymerisation of mutant 
actins in small quantities. The main obstacle was obtaining enough fully 
purified and active actin from transgenic mouse muscle. I adapted the 
procedure for actin isolation, depolymerisation, purification and concentration 
determination, which was essentially a scaled down normal actin preparation, 
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involving S300 chromatography to purify G-actin. Functional G-actin was 
produced at a concentration suitable for the polymerisation assay. Elongation 
of rabbit and NTG mouse actin made this way was slower than that of 
standard rabbit actin by up to 15-fold and sometimes did not label well with 
phalloidin. When the actin was not properly labelled, an alternative manual 
approach was applied to analyse the length of individual filaments. Using 
this, D286G and E361G mutants were shown to elongate and polymerise 
slightly slower than NTG actin. There was no significant difference observed 
in the polymerisation pattern between mutants and NTG actin. Our result is 
consistent with Costa et al. (2004) 's finding. They tested the ability of 
D286G actin to co-polymerise with wild-type actin. ^®S-labeiled mutant was 
expressed and co-polymerised with wild-type rabbit skeletal actin. Mutant 
actin incorporation into filaments was measured by quantifying levels in 
fractions containing aggregates, G-actin or F-actin. About 50% of D286G 
actin polymerised compared to 60% of wild-type actin, the difference was 
within the error margins of their assay, the mutant was therefore considered 
to be similar to wild-type actin. The two mutants we looked at are ones that 
appeared to form filament easily, in both cases the reduced initial elongation 
and polymerisation rate is unlikely to be relevant to the clinical phenotype of 
the mutations. However, it needs to be taken into account that only 
polymerisation not depolymerisation was studied. 
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7. General Discussion 
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7.1 Genotype-Phenotype Correlations in ACTA1 
Mutations That Cause Congenital Myopathies 
Mutations in the t-sl<eletal muscle actin gene, ACTA1 cause various 
congenital myopathies with different severities. Since their discovery in 1999, 
141 ACTA1 mutations have been identified in patients with nemaline 
myopathy (NM), intranuclear rod myopathy (IRIVI), actin myopathy (AM), 
congenital fibre type disproportion (CFTD) and central core disease (CCD). 
Majority of them are NM mutations. Few result in more than one clinical 
phenotype. Much is now know about the clinical aspects of the myopathies, 
but only a limited number of these mutations have been characterised at the 
molecular level. Here I discuss the findings of 30 congenital myopathy-
causing ACTA1 mutations that were functionally studied by several groups 
using a range of biochemical and in vitro approaches. Six of these are the 
subjects of this thesis. They showed diverse molecular defects, and there is 
no obvious pattern seen in mutations resulting in the same disease. 
7.1.1 Location of the Mutated Residues 
3-dimensional crystal structure of the actin molecule was used to map the 
mutated residues in actin monomer as shown in Figure 7.1. Predictions on 
the possible effects of each mutation were made based largely on its 
structural location and our knowledge of actin structure-function 
relationships. In the absence of reliable functional data these predictions 
remain speculative. The object of this thesis was to apply direct tests to such 
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models. The 30 mutations on 27 resides are located throughout the four 
subdomains of the actin molecule and do not cluster. 
K336 
R183 
G182 
N115 
L221 - • 
M132 
N280 
1136 
V163 V370 D292 
Figure 7.1: Location of ACTA1 mutations that have been 
functionally studied 
Mutations (brown spheres) do not cluster on the 3D structure of actin. 
Mutations studied in this thesis are highlighted in purple. Produced with 
Chimera software using Actin UdZ.pdb file. 
G15 (Figure 1.26) and K336 (Figure 5.3) form a part of the nucleotide 
binding site in a cleft between the two domains of actin, the amino group of 
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K336 is hydrogen bounded to the adenosine ring of the MgADP. G15R and 
K336E will therefore interfere with nucleotide binding or exchange thereby 
destabilising F-actin structure as ATP is crucial in actin polymerisation. E72, 
H73, N115, G182, R183 are located on either side of the cleft, substitutions 
on these residues likely affect the opening/closure of the cleft. 
I136M, V163M, V163L, P332S, E334A and K336E are either close or within 
the 'h inge ' region connecting the two domains of actin molecule, 
suggesting possible impact on 'hinge ' flexibility, which has been 
hypothesised to be important in the transition between actin confirmations 
that might be linked to thin filament regulation with myosin (Costa et al. 2004; 
Egeiman 2001). 
H40, E205, D286 and D292 are involved in intermolecular contacts along 
the long axis of F-actin (Figure 1.4). D286 forms a salt bridge with R39 and 
E270 of different actin monomers. Hence H40Y, E205D, D286G and D292V 
may disrupt actin-actin interactions/polymerisation. Holmes et al. (1990) 
proposed that a 'plug ' from one actin monomer occupies a 'pocket ' 
formed between two monomers in the opposite F-actin strand. The apex of 
the 'plug ' in a monomer on one strand consists of 266-269, while the 
' pocket ' contains residues 166, 169, 171, 285 and 289 in one monomer 
and 40-45, 63 and 64 in another monomer in the opposing strand. Mutations 
H40Y, I64N, Q263L, G268C and G268R possibly affect the docking of the 
' p l u g ' into the 'pocket ' during polymerisation. 
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164, T66, G182 and R183 have been recently identified by Neiryncl< et al. 
(2006) to bind to prefoidin, whilst G268 binds to cytosolic chaperonin 
containing TCP-1 (CCT) (Figure 1.6). Both prefoidin and CCT are chaperone 
proteins which assist folding and prevent aggregation of actin in the cell. 
Mutations I64N, T66I, G182D, R183C, R183G, G268C, G268R and three 
other mutations L94P G259V and V370F that are in proximity to the binding 
site of prefoidin or CCT have the potential to cause abnormal folding or 
aggregation of actin. 
N115S, I357L and V370F sitting within Z-line protein f-actinin binding 
sequences (Figure 1.8) might alter interactions between actin and f-actinin, 
whereas D1Y and P332S could affect myosin binding to actin (Figure 1.15). 
VI63, G182 and L221 lie adjacent to one of the two nuclear export signal 
(NES) sequences of actin that govern actin transport in mammalian cells 
(Wada etal. 1998). Thus V163M, V163L, G182D and L221P are thought to 
impair actin localisation leading to aggregation of actin in the nucleus. Since 
E72, H73, N115, E205, G268, and N280 are close to the binding sites of 
phalloidin, which is used to stabilise and label F-actin, mutations on these 
residues may disrupt phalloidin binding, hence destabilise F-actin structure in 
experimental systems. Some mutated residues (R147, D292, K328, P332, 
E334, K336) may interact with tropomyosin in the high or low Ca^"'-states. 
Ml32 is completely buried, so Ml32V probably has effects on the internal 
packing of actin (Sparrow et al. 2003). 
296 
General Discussion 
7.1.2 Molecular Defects 
In order to find out how well the structural predictions correlate to the actual 
functions of the mutations, demonstrably molecular defects of the mutations 
were looked at. Table 7.1 (folding, polymerisation, formation of aggregates) 
and 7.2 (expression level, in vito motility, actin-myosin force, f-actinin 
binding) summarise all the available functional details on ACTA1 mutations 
causing congenital myopathies. 
7.1.2.1 Non-Folding Mutants 
Proper folding is a prerequisite for functional actin. In eukaryotic cells 
cytosolic chaperone proteins prefoldin and CCT facilitate the folding of actin 
(see Introduction 1.3.2). L94P and G259V were reported by Costa et al. 
(2004) to result in non-folding actin thus non-fucntional protein. They are both 
recessive missense mutations causing severe NM and are located close to 
prefoldin or CCT binding sites. Sparrow et al. (2003) predicted that when 
mixing with wild-type actin, these two mutant actins were benign, indicating 
the fully functional folding machinery with one copy of folding-defective actin. 
Seven other mutations (I64N, R183C, R183G, Q263L, G268C, G268R, 
V370F) that were predicted to affect folding produced fully folded and stable 
actins. 
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7.1.2.2 Mutants That Are Folded but with Folding Instability 
Cyclase-associated protein (CAP) binds to actin in the cleft between 
subdomain 1 and 3 (Rommelaere etal. 2003) and promotes rapid actin 
turnover in mammalian cells (Moriyama & Yahara 2002). CAP has a high 
affinity for actin in the nucleotide-free state, and the level of actin binding to 
CAP can suggest possible folding instability (Rommelaere et al. 2003). 
G15R, N115S, V163L and G182D residing either at or near the cleft that 
contains the nucleotide binding site were predicted to affect nucleotide 
binding or exchange by Sparrow et al. (2003). G15 is in direct contact with 
the t-phosphate of the nucleotide (Kabsch etal. 1990), N115, V163 and 
G183 although are not directly involved in nucleotide contacts, play a role in 
cleft structure. G15R, N115S, V163L and G182D likely alter or prevent 
nucleotide binding. These mutant actins bound to CAP with an increased 
affinity, one (G182D) remained bound to CAP even in the presence of ATP 
(Costa et al. 2004), indicating unstable actin, which might explain the 
aggregate structures observed in muscle fibres from patients with these 
mutations. 
7.1.2.3 Abnormal Polymerisation 
I64N, I163M, G182D, R183G, Q263L, G268C, G268R, N280K, I357L and 
V370F actin had a lower co-polymerisation capacity compared to wild-type 
actin, mostly polymerising to less than 25% in Costa et al. (2004) 's study. 
I64N, Q263L, G268C and G268R were proposed to alter polymerisation 
(Sparrow et al. 2003) as these residues interact with residues in another 
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monomer along or across the filament (see Introduction 1.2). The other 
mutations N115S, I136M, G182D, R183G, N280K, I357L and V370F are 
completely outside the intermoiecuiar contacts. N115S, G182D and R183G 
lie in proximity to the nucleotide binding cleft, which could have effects on 
ATP binding or exchange; whilst I163M may disrupt the flexibility of the 
' hinge ' region between the two actin domains, therefore will interfere with 
the opening and closure of the nucleotide binding cleft necessary for the 
ADP-ATP exchange. N115S and N280K are close to phalloidin binding site. 
Both ATP and phalloidin are important in stabilising actin in the polymeric 
form, it is not surprising that these mutants conferred abnormal 
polymerisation. Similarly, N115S , I357L and V370F might result in impaired 
t-actinin binding and thus in disordered sarcomere structure. Schultheiss et 
al. (1992) reported that expression of truncated f-actinin in myoblasts 
disrupted normal cross-linking of the thin filaments and induced formation of 
aggregates and nemaline rods. 
Several mutant actins (H40Y, M132V, V163L, R183C and D286G) also 
polymerised with a reduced capacity, but the difference was within the error 
margins of the assay (Costa et al. 2004). Additional information came from 
previous work in our laboratory that M132V actin extracted from a NM patient 
muscle biopsy required phalloidin for full polymerisation to occur while all the 
wild-type actin polymerised in the absence of phalloidin (Marston et al. 2004). 
On the other hand, D286G, which is in direct intermoiecuiar contact along the 
filament, displayed slower initial elongation and total polymerisation rate in 
ourTIRF polymerisation assay (Chapter 6.4). Moreover, considering some 
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congenital myopathy patients have excess thin filaments (Goebel et al. 
1997), mutant actins could even have elevated polymerisation, such as 
V163L (llkovski et al. 2004). 
Differentiated C2C12 myotubes were employed to explore the ability of 
mutant actins to polymerise with endogenous actin isoforms and to 
incorporate into cytoskeleton sarcomeric structures. R183G actin produced a 
reduced ability to incorporate into insoluble actin filaments (llkovski et al.. 
2004), which is consistent with what Costa et al. (2004) found that R183G 
mutant showed a lower polymerisation capacity. In contrast, V163L construct 
exhibited an enhanced capacity to form insoluble filamentous actins (llkovski 
et al. 2004), this is comparable with the presence of filamentous actin 
aggregates in muscle biopsies from the patient with this mutation. Most of the 
mutants showed better incorporation into actin cytoskeleton in differentiated 
myotubes than in undifferentiated myoblasts. The severe NM mutation 
D286G appeared delocalised in most of the myoblasts like other NM 
mutations I64N and N115S, but rather different, it did not integrate into the 
majority of differentiating myotubes, instead formed big, rod-shaped 
aggregates in the cytoplasm, which were similar to those in fibroblasts 
described by Costa et al. (2004). The appearance of aberrant stress fibres, 
that were not seen in myoblasts, were observed in all of the mutants 
examined (G15R, H40Y, N115S, V163L, G268R, D286G) by Bathe et al. 
(2007) in differentiated myotubes. The aberrant stress fibres vary in 
proportions in different mutants with the highest numbers for G15R, H40Y 
and V163L. The lack of those aberrant structures in undifferentiated cells 
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could be due to their later development after the initial integration of mutant 
actins into endogenous actin isoforms. 
Mutagenic analysis of H73 of yeast actin revealed that Hf R mutation gave 
a retarded rate of actin polymerisation, a tighter and more compact 
monomeric structure with a greater resistance to proteolysis and increase 
stability (Yao etal. 1999). H73, methylated in the vast majority of actins, is on 
the exterior of the protein in a cleft between the two domains of acitn. The 
potential interaction between H73 and adjacent residue D184 on the opposite 
side of the cleft may be important in determining the flexibility of the two 
domain relative to each other. Positive charge induced by H73R mutation 
hence stabilised its interaction with negatively charged D184, and produced 
a more protected and more compact actin monomer. 
In summary, 15 mutations were predicted to have polymerisation defects 
and were tested in the polymerisation assay, 10 of them confirmed the 
predictions, while 5 out of the 15 mutants with abnormal polymerisation were 
not predicted. 
7.1.2.4 Formation of Nemaline Rods and Other Aggregates 
Costa et al. (2004) investigated cellular behaviour often actins with NM, 
IRM or AM mutations in N-terminally Myc-tagged NIH3T3 fibroblasts. Seven 
of them (G15R, H40Y, I64N, V163L, G182D, D286G, 1357L) induced 
formation of aggregates and rods. Intranuclear rods with an appearance of 
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parallel bundles of filaments were revealed in patient samples with H40Y, 
V163L and I357L mutation (Goebel & Warlo 1997; llkovski et al. 2001; 
Nowak et al. 1999). In fibroblasts, H40Y and V163L actins formed similar 
rods and star-shaped structures in the nuclei, but different from its clinical 
phenotype, I357L actin showed cytoplasmic aggregates. Rods and 
aggregates induced by G15R, H40Y, V163L, G182D and D286G stained with 
phalloidin, indicating filamentous actin. 
Similar experiments were performed on T66I, E72K, N115S, I163M, 
V163M, V163L, R183G, G268C and I357L by llkovski et al. (2004) using 
C2C12 myoblasts. EGFP-tagged wild-type and mutant actins were 
transfected into C2C12 myoblasts. Numerous intranuclear actin aggregates 
in V163M and V163L transfected myoblasts resemble those observed in 
muscle samples from patients with IRM carrying these two mutations. Co-
transfection of wild-type construct with untagged V163M actin into C2C12 
myoblasts led to accumulations of not only the mutant but also wild-type actin 
within the nucleus (Domazetovska et al. 2007). Although R183G has not 
been linked to IRM, surprisingly intranuclear actin accumulations were seen 
as well in R183G transfected cells. Molecular modelling shows that residues 
VI63 and R183 are within the radius for bond formation with the actin 
nuclear export signal (NES). Hence V163M, V163L and R183G presumably 
change the localisation activity of NES, resulting in retention and aggregation 
of these mutant actins within the nucleus. In addition, the I136M-EGFP 
construct produced cytoplasmic accumulations only, which did not stain with 
phalloidin or DNase I, whereas the other mutant actin aggregates were 
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observed with phalloidin labelling. This result suggests that aggregates 
formed by different mutant actins are not identical, may involve differential 
mechanisms. The other mutations did not induce actin accumulations in 
C2C12 myoblasts. 
Three (H40Y, V163M, V163L) out of the four tested IRM mutantions led to 
formation of nuclear aggregates in cell cultures, but I357L produced 
cytoplasmic aggregates only. Nuclear aggregates were also seen with a NM 
mutant R183C and a CFTD mutant D292V. Only two of these mutations are 
located close to NES, hence were predicted to show accumulations of actin 
within the nucleus. 
Central core disease (CCD) and congenital fibre type disproportion (CFTD) 
are characterised by muscle weakness without the presence of nemaline 
rods. Expression studies in fibroblasts, myoblasts and myotubes were 
recently conducted on two CCD (D1Y, E334A), and three CFTD (L221P, 
D292V, P332S)-causing ACTA1 mutations (Vandamme et al. unpublished). 
All the mutants were correctly folded, stable and able to incorporate into actin 
filamentous structures, with the exception of P332S, which displayed a 
diffuse cytoplasmic localisation and was present in curved thick actin fibres. 
Unexpectedly, other two CFTD mutations L221P and D292V resulted in rod 
and aggregate formation in fibroblasts. Cytoplasmic aggregates were 
revealed in some fibroblasts transfected with L221P actin, while D292V 
induced formation of cytoplasmic aggregates as well as long thin rods in the 
majority of fibroblasts. Those rods were intranuclear or perinuclear in cell 
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extensions, which has not been previously described for NM-causing ACTA1 
mutations. Clarke et al. (2007) also saw cytoplasmic aggregates with ribbon-
like structures unlike nemaline rods in D292V-EGFP transfected C2C12 
myoblasts, but not in L221P constructs. It does not appear to be a correlation 
between the phenotype in patients and in cellular systems. The most striking 
histological abnormality in CFTD is hypotrophy of type 1 muscle fibers, but 
the cause of this has been unclear in most CFTD patients. It is also possible 
that relative type 1 hypotrophy represents a non-specific adaptation to 
chronic weakness because relative type 1 fiber hypotrophy is a common 
secondary abnormality in many forms of congenital myopathy (Clarke et al. 
2007). The observation that some CFTD ACTA1 mutations display similar 
histology to NM mutations promotes the reconsideration of the relationship 
between histology and disease phenotypes. 
Although cell cultures have been often used to characterise the cellular 
behaviour of mutant actins, all of the functional studies were performed on 
tagged actins (Table 7.1). It was reported that certain tags especially at the C 
terminus of actin might have impact on actin structure and function (Brault et 
al. 1999) (see Chapter 3.5.2). Furthermore, the overexpression of mutant 
actins in cell culture systems had the potential to cause phenotypes that 
were not seen in the patients, which may explain the intranuclear 
aggregations observed in myoblasts transfected with a NM mutant R183C. 
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Table 7.1: Summary of functional effects of congenital 
myopathy-causing ACTA1 mutations 
D1Y CCD myosin binding X - X 8 
G15R NM, AM nucleotide unstable X cytoplasmic 1, 3 
binding rods/aggregates 
H40Y severe NM, nuclear & 1,3 
IRM F-actin contact X X cytoplasmic 
I64N typical NM F-actin contact X T cytoplasmic 3 
folding rods/aggregates 
T66I NM, AM folding - - X 6 
E72K severe NM cleft, phalloidin - - X 6 
binding 
H73R intermediate cieft, phalloidin - T - 9 
NM binding 
L94P severe NM folding unfolded - - 3 
cleft, t-actinin. 1.3, 
N115S typical NM phalloidin unstable t X 6 
binding 
Ml 32 V mild NM buried X t X 3, 7 
I136M mild NM 'hinge' region X t cytoplasmic 3, 6 
V163M IRM 'hinge' region. - X nuclear & 5,6 
NES cytoplasmic 
V163L IRM. AM 'hinge' region. unstable t nuclear & 1,3, 
NES cytoplasmic 6 
G182D typical NM cleft, folding, unstable t cytoplasmic 3 
NES 
R183C severe NM cleft, folding X T - 3 
R183G severe, cleft, folding X T nuclear & 3,6 
typical NM cytoplasmic 
E205D CFTD F-actin contact - X - 10 
L221P CFTD NES X - cytoplasmic 2.8 
G259V severe NM folding unfolded - - 3 
Q263L severe NM folding, F-actin X - - 3 
contact 
G268C typical, mild F-actin contact X T X 3,6 
NM folding 
G168R severe NM F-actin contact X t X 1,3 
folding 
N280K severe NM phalloidin X T - 3 
binding 
D286G severe NM F-actin contact X t cytoplasmic 1,3 
D292V CFTD F-actin contact X X nuclear & 2, 8 
cytoplasmic 
P332S CFTD 'hinge' region. X X curved thick fibres 2,8 
myosin binding 
E334A CCD, HCM 'hinge' X - X 8 
K336E NM, HCM nucleotide - X - 5 
binding, 'hinge' 
I357L severe NM, t-actinin X T cytoplasmic 3,6 
IRM binding 
V370F severe NM folding, t - X t - 3 
actinin binding 
Notes: - not tested, x not affected, 1 
Ref: 1. Bathe etal. (2007) 
2. Clarke etal. (2007) 
3. Costa etal. (2004) 
4. D'Amico etal. (2006) 
5. Domazetovska etal. (2007) 
reduced, t increased; subjects of this thesis are highlighted. 
6. Ilkovski et al. (2004) 
7. Mars ton etal. (2004) 
8. Vandamme etal. unpublished 
9. Yao etal. (1999) 
10. Chapter 4.4 of this thesis 
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7.1.2.5 Expression Level of Mutant Actins in Muscle Samples 
from Patients 
The most important determinant of the effect of a mutation is the amount 
expressed. It is generally regarded that dominant negative mutations are 
expressed as poison peptides, however in most cases this has not been 
measured. 
Expression level of mutant actins could be determined by 2-dimensional gel 
electrophoresis if there is a charge change in the mutation or by mass 
spectrometry when a mutation does not involve a charge change. In the 
whole muscle samples from patients, E72K actin was expressed at a slightly 
reduced level compared to wild-type actin, whilst R183G was present at a 
roughly equal level to wild-type actin (llkovski et al. 2004). In our study, the 
expression level of K336E was 29% of the total actin in the muscle biopsy 
from a patient with NM as well as HCM (D'Amico et al. 2006). CFTD mutant 
D292V appeared to be present at 44% in the whole muscle and 40% in F-
actin, while 25-30% of our purified F-actin from P332S patient was mutant 
actin (Clarke et al. 2007). Hutchinson et al. (2006) reported the first dominant 
inheritance of IRM in a family which three generations carried a single 
ACTA1 mutation V163M. Application of mass spectrometry on samples from 
all three generations from the family revealed that 20% of the total actin in 
the child was mutant, whereas 3-6% in the mother, and surprisingly the 
absence of mutant actin in the grandfather, suggesting a possible tendency 
of degradation of the mutant actin (Domazetovska et al. 2007). Marston et al. 
(2004) used polymerase chain reaction (PCR) to identify messenger RNA of 
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M132V mutant and revealed that 61% of ACTA 1 transcripts in the patient 
carried the mutation. 
7.1,2.6 Expression of Other Sarcomeric Proteins in Patients 
Changes in expression of several sarcomeric proteins in NIVI patients with 
ACTA1 mutations were assessed. A general increase in levels of Z-line 
proteins f-actinin, |-filamin, myotilin and desmin was detected (llkovski et al. 
2004), which correlates to the presence of Z-line-derived nemaline rods in 
NM patient samples. The elevated level of Z-line proteins was also 
demonstrated in intranuclear rods found in muscle fibres from patient with the 
IRM mutation V163M (Domazetovska et al. 2007). Sequestration of these 
proteins within the nucleus might have impact on nuclear structure and 
activity. The relatively normal sarcomere structure in most of the congenital 
myopathy patients may be explained by the overexpression of proteins that 
are responsible for muscle regeneration as observed in V163M patient 
muscle fibres (Domazetovska et al. 2007). 
Clarke et al. (2007) assessed a total of 15 sarcomeric proteins by 
immunohistochemistry and Western blotting in muscle biopsies from patients 
carrying D292V or P332S mutation, all of the mutant samples showed the 
same pattern of protein expression as control samples. 
Nebulin immunostaining showed a very low level or even absence of 
nebulin in some NM patients with E72K patient exhibiting the most marked 
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abnormality (llkovski et at. 2004), although E72 is not near nebulin binding 
sites. The reason for nebulin abnormalities in NM ACTA1 patients is unclear, 
it could be related to defective binding to actin, or perhaps reflects a certain 
state of the disease in patients as it appears to be common in patients with 
severe clinical phenotype. 
7.1.2.7 Altered Motility and Contractility in In Vitro Motility 
Assays 
I have characterised two NM (D286G, K336E), three CFTD (D292V, 
P332S, E205D) and one IRM mutation V163M utilising various in vitro 
techniques (D 'Amico et al. 2006; Clarke et al. 2007), and another NM 
mutation M132V was previously studied in our laboratory by Dr. Mahmmoda 
Mirza (Marston et al. 2004). Each mutation was compared with an age-
matched control actin. All the mutants seemed to incorporate into myofibrils 
and to polymerise normally except M132V, which had partial polymerisation 
with KCI/MgCl2 in the absence of phalloidin. TRITC-phalloidin labelled 
mutants were as bright as the control. Compared to control, the majority of 
the mutants showed unchanged filament density and length distribution, but 
V163M actin had 50% lower filament density, while the average filament 
length of K336E and E205D was significantly shorter, which may reflect 
premature termination of elongation due to defective actin structure or 
extrinsic capping protein, suggesting a poison peptide. 
Motility of mutant actins was assayed over a bed of HMM. Three mutations 
(D286G, E205D, P332S) increased sliding speed by around 10%, whilst 
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K336E and D292V actin moved slower than control actin. Two CFTD 
mutants E205D and P332S elevated filament percentage motility by 8.2% 
and 6.6% respectively. P332 is close to myosin binding site, Pf S mutation 
possibly alter the structure of the binding site of myosin on actin, thus 
affecting the cross-bridge turnover rate. 
The temperature-dependency of filament sliding speed of mutant and 
control actin was also compared. M132V, V163M, D286G, D292V and 
K336E were indistinguishable from control. E205D actin appeared to be less 
temperature-dependent, P332S in contrast had higher temperature-
dependency. This difference might be explained by potential structural 
changes on actin caused by mutations. 
Tropomyosin-troponin confers Ca "^" regulation on filament movement. 
Addition of skeletal tropomyosin increased sliding speed but decreased 
percentage motility in our assay conditions. In the presence of tropomyosin 
alone, higher percentage motility was observed in K336E, E205D and P332S 
actin, but the mutants did not seem to have any effects on tropomyosin-
troponin regulation or Ca^'^-sensitivity. M132V plain actin was not different 
from control in sliding speed, but its reconstituted thin filament moved faster 
at pCa5. An extremely defective regulation was seen with D292V. The 
addition of skeletal tropomyosin abolished the movement of mutant filaments, 
and it could not be reactivated by Ca "^" or NEM-S1. The proximity of D292 
residue to tropomyosin in both high and low states suggests the 
hypothesis that the loss of negative charge in D j V mutation may interfere 
309 
General Discussion 
with transition between tropomyosin conformations, possibly stabilising it in 
the ' o f f ' state, and consequently disrupt the binding of myosin. The 
impaired motility of D292V actin correlates to the hypocontractile phenotype 
of the patient. But such correlations were not observed with the other 
mutations despite being present in the F-actin. D292V is the first disease-
causing ACTA1 mutation to exhibit this abnormality. 
f-actinin is the major Z-line protein cross-linking actin filaments at both 
ends of the Z-line. K336E actin bound to f-actinin with a remarkably reduced 
affinity. Unlike K336E, CFTD mutations D292V and P332S resulted in a 
higher binding affinity for f-actinin. The difference in binding affinity for f -
actinin seen in mutations could lead to altered force transmission in the 
muscle of the patients, thin filaments could be pulled out of Z-lines resulting 
in loss of force and the need for repair 
When the relative force of the interactions between mutant actin (M132V, 
D286G, D292V, P332S, K336E) and myosin was determined, two NM 
mutants M132V, and D286G appeared to generate greater actin-myosin 
force than control actin, whereas the two CFTD mutations D292V and P332S 
did not affect force generation, despite the fact that P332S sits at the myosin 
binding site. K336E also required more t-actinin to stop the movement, but 
this could be a consequence of the observed weaker binding to f-actinin 
even if the force was the same. 
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In summary, only in two out of seven mutations studied there was a clear 
defect in contractility. Some mutations with a common phenotype gave very 
different results at the single filament level. 
Ml 32 V mild NM buried 61% 
mRNA 
X X X t t -
V163M IRM 'hinge', 
NES 
20% X X X - - -
E205D CFTD F-actin 
contact 
- 42% t 12% T t T - X 
D286G severe 
NM 
F-actin 
contact 
30% X 10% t X X T X 
D292V CFTD F-actin 
contact 
44% X ^ % f X t X T 
P332S CFTD 
'hinge', 
myosin 
binding 
25-
30% X 9% T t T X t 
K336E NM, HCM 
nucleotide 
binding, 
'hinge' 
29% 50% t 1 3 % r X T T T 
Notes: - not tested, x not affected, t reduced, t increased 
Mutat Mutation, Clinical Pheno Clinical Phenotype, Expre Expression Level, 
Temp Dep Temperature Dependency, Regu Regulation 
Table 7.2: Summary of in vitro motility and mechanical 
studies of congenital myopathy-causing ACTA1 mutations 
7.1.3 Conc lus ion 
Although to date 141 ACTA1 mutations have been linked to various 
congenital myopathies, most investigations on these mutations have been 
restricted to genetics, pathophysiology and histology. Development of/n vitro 
assays and establishment of actin expression systems allowed properties of 
mutant actins to be characterised at the molecular level. Differentiated 
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myotubes and undifferentiated cells are suitable to study the ability of 
mutants to incorporate into endogenous actin structures, to co-polymerise or 
to form abnormal structures within the cell. Transgenic mouse models 
provide sufficient amount of proteins for extensive functional assessment. 
However, the system may not recapitulate disease in patients, as exemplified 
by D286G transgenic mice. I have proved the possibility of using actin 
extracted from patient biopsies in in vitro motility assays, but the small 
quantity of biopsy samples limits the number and range of experiments that 
can be carried out. 
Actin mutations that are associated with congenital myopathies are 
heterozygous both clinically and genetically. Most of them are dominantly 
inherited missense mutations. Investigations on molecular effects of 30 
disease-causing ACTA1 mutations demonstrate the diversity in defects due 
to the mutations. Any of the functions of actin can be altered. Mutations with 
the same clinical phenotype do not cause one common defect, but rather 
affect various functions. Although in a certain degree structural predictions 
are a good indicator of the likely molecular defects of actin mutations, for 
example 2/3 of the predicted polymerisation defect was confirmed in 
functional studies, in many cases there is disagreement between the 
structure and functions of mutants. Only 3 out of 11 predicted folding defect 
was confirmed, half the mutations that are close to the actin nuclear export 
signal resulted in cytoplasmic aggregates only, and none of the three 
mutants with altered binding affinity for t-actinin is directly involved in 
contacts between j-actinin and actin, A few mutations resulted in unfolded or 
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unstable actins, some led to reduced polymerisation capacity, formation of 
aggregates in cells, altered expression of other sarcomeric proteins, impaired 
motility and contractility. CFTD mutation D292V showed the most dramatic 
abnormality in tropomyosin regulation that the movement of mutant filament 
was completely switched off in the presence of tropomyosin, and could not 
be rescued by high concentration or NEM-S1. Many mutations however, 
did not seem to have any detrimental effects on actin functions within the 
range of measurement. 
The same mutation could be linked with more than one phenotype, for 
instance V163L was reported to cause IRM as well as AM. Co-existence of 
hallmark features of each phenotype (nemaline rods, intranuclear rods, actin 
aggregates, fibre-type predominance, cores) has been described in patient 
muscle fibres (Jungbluth et al. 2001), raising the question that to same 
extent, common underlying molecular mechanisms may be shared by 
different congenital myopathies, hence care needs to be taken when making 
diagnosis. 
Despite the expression of ACTA1 in the heart at up to 20%, cardiac 
involvement is generally not seen in congenital myopathy ACTA1 patients, 
possibly because of a low expression level of mutant ACTA1 gene in cardiac 
muscle, being compensated by wild-type |-cardiac muscle actin functions 
(llkovski et al. 2005). K336E is the first ACTA1 mutation to be found in the 
patient with both NM and HCM, and to be also functionally characterised. A 
mutation on residue E334, which is next to K336 in the 'hinge ' region, was 
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also identified in two related patients with central core disease (CCD) and 
HCM (Kaindl et al. 2004). The rarity of the connection between skeletal and 
cardiac myopathies may simply due to the comparative severity of skeletal 
myopathies and the infrequency of cardiological examination in patients from 
neuromuscular clinics. K336E is exceptional since the patient was referred 
for HCM before the discovery of skeletal myopathy. Other cases are likely to 
exist (Sampaolo et al. 2007). A genetic screening on ACTA1 as well as 
ACTC gene in patients with congenital myopathy might uncover more cardiac 
involvement, therefore should be considered in future genetic analysis. 
In conlcusion, enough evidence suggests that there are no genotype-
phenotype correlations in congenital myopathy-causing ACTA1 mutations, 
either because the wrong things are being correlated or because there 
simply is no single connection in most cases. 
7.2 Other Disease-Causing Actin IVIutations 
Mutations in cardiac actin encoding gene ACTC can lead to hypertrophic 
cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and atrial septal 
defect (ASP). Since these diseases are always studied in families and the 
phenotype is very well defined it is more likely that a connection can be made 
between genotype and phenotype. Mogensen et al. (2004) reported seven 
HCM mutations in ACTC gene: E99K, P164A, A230V, Y166C, A295S, 
M305L and A331P. Interestingly A230V in ACTA1 gene has been found to 
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cause NM (Laing eta!, unpublished), which merits further investigation. Only 
two ACTC mutations have been linked to DCM; R312H and E361G, which 
were suggested to affect force transmission from the sarcomere to the 
surrounding syncytium (Olson etal. 1998). Vang et al. (2005) studied the 
folding and stability of HCM and DCM mutants using a cell-free system, and 
also the ability of these mutants to incorporate into filaments in transfected 
cells. All the mutants were able to fold to the mature form but with variable 
efficiency, R312H exhibited the least efficient folding, this mutant also had 
the highest tendency to form aggregates. Three HCM mutations (E99K, 
P164A, M305L) and both DCM mutations (R312H, E361G) gave rise to a 
partially folded conformation with reduced resistance to proteolytic 
degradation, and lower ability of actin to incorporate into filaments. But there 
was no evidence that any of these mutations did not incorporate into actin 
filaments: in transgenic mice E99K and E361G certainly did. 
On-going functional investigations on E99K and E361G actin expressed in 
transgenic mouse hearts (provided by Prof. Dominic Wells, Charing Cross 
Hospital, London) by Emma Dyer in our laboratory implied altered muscle 
thin filament motility and contractility. E99K had a lower sliding speed for the 
pure actin and in reconstituted thin filaments 2.5-fold greater Ca^^-sensitivity, 
which resembles to the effects of other HCM thin filament mutations. This is 
also consistent with results from Bookwalter & Trybus (2006) that E99K 
mutation in baculovirus resulted in a decresed sliding speed, a reduced 
binding affinity for myosin S1 and lower actin-myoisn force than non-
transgenic (NTG) actin. E99 lies at initial 'weak ' myosin binding site on 
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actin, a charge reversal in Et K mutation is likely to change the charge 
pattern of the binding site, therefore impairing actin-myosin interactions and 
contractility, which may account for the phenotype in the patient. E361G also 
decreased filament sliding speed, but the main impact of this mutation was 
the lack of response of reconstituted thin filament containing mutant actin to 
the level of troponin I phosphorylation. A reduced binding affinity for f-actinin 
was also observed, which can consequently interfere with force transmission 
in cardiac muscle. Such an effect on interactions between actin and j-actinin 
is predictable from the location of E361 residue in the j-actinin binding site. 
Matsson etal. (2008) recently identified a mutation in ACTC gene, M123V, 
in patients with atrial septal defect (ASD), which is one of the most frequent 
congenital heart defects. The purified mutant actin from baculovirus had a 
reduced affinity for myosin without changing the cross-bridge turnover rate. 
Although this residue is not close to myosin binding site, it sits within one of 
the t-actinin binding sites, and might like E361G, affect force transmission 
and contractility. ASD can also be caused by mutations in MYH6 gene, which 
encodes t-myosin heavy chain, suggesting contractility is needed for the 
formation of the septum in heart development. 
Mutations in another actin gene have been reported to be disease-causing. 
Six point mutations in f-cytoplasmic actin gene have been associated with 
autosomal dominant deafness (Bryan et al. 2006). They engineered these six 
mutations (T89I, K18M, P264L, T278I, P332A, V370A) in yeast and found 
that K118M, T278I, P332A and V370A resulted in significant stunting of cell 
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growth, while V370A actin displayed accelerated polymerisation. In constrast, 
a NM mutation on the same residue (V370F) in ACTA1 gene was 
demonstrated to give a reduced polymerisation capacity (Costa et al. 2004). 
A CFTD ACTA1 mutation P332S did not show any abnormalities in 
polymerisation (Clarke et al. 2007). 
7.3 Future Work 
Functional investigations on actin mutations has been proven to be difficult 
as actin is a multi-functional protein which interacts with many sarcomeric 
proteins, the current available actin expression systems all have limitations 
on the range of measurement. The generation of transgenic animals are very 
expensive and time-consuming. Another problem is that as exemplified by 
the lack of clinical phenotypes in the D286G mouse (see Chapter 3.5.3), they 
may not recapitulate the human disease or show possible polymorphism as a 
result of gene regulation even though the extracted pure protein might still 
display biophysical differences. Thus at present further investigations of 
ACTA1 mutations would not be worthwhile unless a transgenic mouse model 
with a clear phenotype is available. 
Tropomyosin, on the other hand is a relatively simple thin filament 
regulatory protein interacting with actin and troponin. In human there are 
three muscle isoforms of tropomyosin, fast j-tropomyosin, encoded by 
TPM1, slow I-tropomyosin encoded by TPM3 and ^-tropomyosin encoded 
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by TPM2. To date six different disorders of striated muscle have been 
associated with mutations in all three genes, NM (TPM2 & TPM3) (Donner et 
al. 2002; Laing et al. 1995), distal arthrogryposis (TPM2) (Sung et al. 2003), 
cap disease (TPM2) (Lehtokari et al. 2007), CFTD (TPM3) (Clarke et al. 
2007 submitted for publication) and cardiomyopathies (TPM1) (Thierfelder et 
al. 1994). TPM3 mutations have been found in 20% of all CFTD cases, 
compared with a frequency of 13% for ACTA1, suggesting TPM3 mutation is 
a relatively common cause of CFTD. Since we have examined 3 out of 5 
known CFTD mutations in ACTA1, it should be possible to obtain a 
comprehensive analysis of this phenotype. Several other pieces of evidence 
indicate the potential for successful structure-function analysis. We provided 
the first functional analysis of CFTD ACTA1 mutations. All of the three 
mutations D292V, P332S and E205D altered tropomyosin regulation, 
although in different ways. Considering the fact that mutation in TPM3 gene 
is the most frequent cause of CFTD, actin-tropomyosin interactions may 
likely be affected by CFTD mutations. 
Other interesting information came from potential interactions between 
tropomyosin and actin based on their crystal structures. Brown et al. (2005) 
proposed that the closest contact would occur between residues 167, 169-
173 of tropomyosin and 329-334 of actin in both high and low Ca^^ states. 
Positively charged residues R147, K291, K326 and K328 of actin favoured 
electrostatic interactions with residues E173, E177, El 81 and El 84 of 
tropomyosin. Notably, many residues involved in actin-tropomyosin contacts 
are mutated in patients with cardiac and skeletal myopathies. Location of 
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actin residues that are involved in these contacts is illustrated in Figure 7.2, 
and the chemical basis of actin-tropomyosin interactions is shown in Figure 
7.3. For actin, CFTD mutations D292V, P332S and NM mutation K336E, 
which are either within or next to the contact sites, have been demonstrated 
to cause abnormal filament regulation with tropomyosin, E334A was linked 
with CCD as well as HCM (Kaindl et al. 2004), R147K was linked to AM and 
K328 deletion was found in NM patients. 
K336 
K328 
E334 
R147 
Figure 7.2: Location of actin residues involved in actin-
tropomyosin contacts 
Several congenital myopattiy-causing ACTA1 mutations (grey spheres) are 
located either at or close to the proposed actin-tropomyosin contacts (brown 
spheres). Produced with Chimera software using Actin UdZ.pdb file. 
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Whilst four HCM tropomyosin mutations I172T, L185R, D175N and E180G 
are close to the actin binding site. E180G tropomyosin was reported to have 
a weaker actin binding affinity and association of myosin S1 to E180G 
tropomyosin bound actin reduced the flexibility of the filament (Golitsina et al. 
1999). Newly discovered CFTD TPM3 mutations R168H, R168G, R168C, 
and K169E are also at the proposed contact region (Clarke et al. submitted 
for publication). 
.Ut in 
Figure 7.3: Molecular modelling showing the chemical basis 
of actin-tropomyosin interactions 
Residues involved in interactions between actin (blue) and tropomyosin 
(yellow) are indicated. The axial and rotational alignments are based on 
positioning apolar (black numbering), as well as oppositely charged (red, 
acid; blue, base) clusters of residues across from one another Adapted from 
(Brown et al. 2005). 
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In conclusion, all three CFTD ACTA1 mutations that were investigated 
affected tropomyosin effects, esp. D292V, two of them (D292V, P332S) are 
located under tropomyosin in actin structure, so are K336E and E334A, 
which just happen to be the two with cardiac involvement. The actin-
tropomyosin interface according to Brown et al. is close to all 4 mutated actin 
residues and many of the tropomyosin mutations are in corresponding 
positions. Bringing together all the evidence, we may ask whether altered 
actin-tropomyosin interactions and tropomyosin regulation is a common 
mechanism underlying myopathies such as CFTD? 
To answer the question, we are planning to explore the molecular 
properties of a number of disease-related tropomyosin mutations utilising a 
series of well-established in vitro motility techniques. We are kindly supplied 
with two NM mutants (E177K, Q149P) and six CFTD mutants (L100M, 
R168H, R168G. R168C, K169E, D245G) expressed in baculovirus by Dr. 
Kristen Nowak, University of Western Australia. This work will hopefully 
provide additional insights into the molecular mechanisms that account for 
the development of congenital myopathies, and contribute to a clearer picture 
of genotype-phenotype correlations of thin filament mutations leading us to 
better understanding of the cause and ultimately devising potential treatment 
for the diseases. 
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